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Damage to the small blood vessels has been implicated in cerebrovascular disease, 
particularly stroke, and dementia. Despite advances in neuroimaging, damage to the small 
vessels of the brain is difficult to observe in vivo, while quantification of brain atrophy 
remains an expensive, skill-intensive and time-consuming technique.  
The retina, as an extension of the brain, provides a unique window to observe subtle and early 
microvascular and neuronal damage in association with cerebrovascular disease and dementia. 
Retinal microvascular abnormalities have been previously linked to stroke, dementia, 
cognitive performance, as well as subclinical MRI markers of cerebral atrophy and small 
vessel disease. Retinal nerve defects have been also linked to mild cognitive impairment and 
Alzheimer’s disease (AD). Novel parameters quantifying the geometry of the microvascular 
network and the neuronal layers of the retina have been proposed as potential markers for 
early microvascular and neurodegenerative pathology in relation to stroke and dementia. 
In this thesis, advanced retinal imaging and analytic techniques for the quantitative 
assessment of the retinal microvascular network and neuronal layers will be applied in four 
epidemiological studies of varying designs to demonstrate the following: (1) Retinal vascular 
parameters are associated with acute ischemic stroke, and subclinical cerebral small vessel 
disease; (2) Retinal vascular parameters are associated with cognitive performance, 
preclinical dementia, AD and vascular dementia; (3) Thinning of the retinal neuronal layers 
are associated with cerebral atrophy, preclinical dementia, AD and vascular dementia. 
Two major findings from the work presented in this thesis are: (1) Retinal microvascular 
changes are associated with both cerebrovascular disease and cognitive impairment, providing 
evidence that microvascular pathology plays an important role in both cerebrovascular disease 
and dementia. (2) Retinal neuronal loss is correlated to neurodegenerative changes in early 
cognitive impairment, and dementia attributable to both AD and cerebrovascular disease. 





retinal imaging has enormous potential in unraveling mechanisms underlying cerebrovascular 
and neurodegenerative disease.
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CHAPTER I:  





1. INTRODUCTION  
1.1 Age-related Vascular and Neurodegenerative Brain Disease  
The world’s population over 60 years is set to increase to 22% by 2050.[1] Disease 
occurrence profiles are shifting towards non-communicable and chronic disease, leading to a 
rapid increase in the number developing age-related cerebrovascular and neurodegenerative 
disease. Cerebrovascular disease and dementia are currently within the top causes of mortality 
and disability worldwide.[2, 3] The prevalence of stroke in Singapore is higher compared to 
Caucasian populations, as well as Chinese and Indian populations outside of Singapore.[4] 
The prevalence of dementia here is currently estimated to be 2-6%,[5] and is expected to 
increase exponentially. Due to the high prevalence of cerebrovascular disease, vascular 
dementia forms a major proportion of dementia cases here.[5] Despite the increase in 
awareness of risk factors associated with stroke and dementia,[6, 7] it is still difficult to 
reliably predict which individuals will eventually develop them. 
Cerebrovascular disease and dementia are tightly intertwined with each other, sharing 
common risk factors such as hypertension, diabetes, and hypercholesterolemia.[7] A number 
of cerebral lesions on neuroimaging are common in both cerebrovascular disease and 
Alzheimer’s disease (AD), the major subtype of dementia.[8] Current evidence points toward 
a synergistic relationship between vascular disease and AD which is correlated with 
microvascular pathology, suggesting that cerebrovascular disease may be both a cause and 
catalyst for further neurodegeneration.[8] However, the specific role and importance of 
microvascular pathology in the cascade of events leading to neuronal loss and cognitive 
decline has not been clearly elucidated.  
Both cerebrovascular disease and dementia are major burdens not only in terms of economic 
cost, but also in how it adversely affects quality of life for the patient and their families. 
Appearance of overt clinical symptoms for cerebrovascular diseae and dementia usually 
indicates substantial and irreversible brain damage; highlighting the need for early markers of 




cerebrovascular and neurodegenerative pathology. Accessible and sensitive markers of early 
cerebrovascular and neurodegenerative damage will allow us to better identify persons-at-risk 
of developing stroke and dementia, as potential targets for prevention and early intervention 
strategies. Additionally, markers of subtle cerebrovascular and neurodegenerative pathology 
may also function as objective assessment tools for monitoring disease progression, providing 
information on prognosis and treatment efficacy. 
1.2 Non-invasive Imaging Biomarkers for Preclinical Signs of Cerebral Damage 
In the search for preclinical markers of cerebrovascular disease and cognitive impairment, 
much of the focus has been on developing non-invasive neuroimaging biomarkers using 
magnetic resonance imaging (MRI). A range of subclinical MRI structural imaging markers 
for increased risk of stroke and dementia have been identified, which can be classified into 
two major divisions – cerebral small vessel disease and cerebral atrophy (Figure I-1).[9-12]  
However current MRI technology is not sufficiently sensitive to subtle vascular and 
degenerative changes. As an expensive technique, MRI imaging cannot be feasibly applied to 
population-based studies or to community-at-large for screening purposes. Furthermore, MRI 
has several contraindications common in the elderly, including claustrophobia, poor 
compliance, cardiac pacemakers, and allergic reactions to contrast dyes. Hence, imaging 
modalities that allow us to non-invasively and directly observe subtle and early microvascular 
and neuronal changes in vivo are potentially powerful tools in aiding our understanding of 
microvascular and neurodegenerative mechanisms in cerebrovascular disease and dementia. 
1.3 The Retina as a Surrogate Marker for Cerebral Microvascular and Neuronal 
Damage 
As an extension of the diencephalon, the retina shares embryological origins with the brain, 
sharing many similarities in anatomical and physiological features while maintaining a direct 
link to the brain via the optic nerve.[13, 14] Compared to structural neuroimaging, retinal 





unique window to assess subtle microvascular and neurodegenerative changes directly and 
non-invasively in vivo, giving additional insight into vascular and neuronal pathological 
mechanisms in the brain.  
The retinal vessels share morphological and functional similarities with the cerebral 
microvessels. Vascular mechanisms that affect the cerebral microvasculature are likely to also 
affect the retinal vascular network. Microvascular abnormalities in the retina presenting as 
retinopathy lesions detected using digital retinal photography have been consistently 
associated with stroke and dementia.[15-17] As detection of these retinopathy lesions are 
observer-dependent, they are qualitative in nature. Furthermore, as they are also considered 
late stage manifestations of microvascular target organ damage, retinopathy lesions are 
limited as an early biomarker. A range of novel retinal vascular parameters assessed using 
computer-based methods have been developed to quantify early and subtler changes in the 
retinal vascular network. Compared to qualitative retinal signs, these quantitative parameters 
can be assessed objectively in all subjects even in the absence of visible pathology, and will 
provide additional insight into the role of microvascular pathology in both cerebrovascular 
disease and cognitive impairment. 
Besides the microvessels in the retina, retinal ganglion cells (RGC) also share structural and 
physiological features with the cerebral neurons, and are directly linked to the brain though 
the optic nerve and synaptic connections. Neuronal loss in the brain can directly affect the 
retinal neurons through transneuronal degeneration and vice versa. Reduction in the axons of 
the RGCs measured using optical coherence tomography has been observed in AD and mild 
cognitive impairment.[18-20] However, cerebrovascular disease in cognitive impairment has 
been neglected in these studies. Improvements in scan acquisition technology now allow 
assessment of RGC cell body and dendritic integrity, which may be more sensitive to 
neurodegenerative pathology.  
  




2. STUDY RATIONALE  
The retina has potential as a model to study cerebrovascular and neurodegenerative disease, 
particularly stroke and dementia. This thesis intends to explore how retinal markers of 
microvascular and neurodegenerative damage are associated with cerebrovascular 
disease and dementia, and with subclinical markers of cerebral vascular and 
neurodegenerative damage on MRI.  
Through the studies included in this thesis, my aim is to explore whether the retina can 
provide novel biomarkers for cerebrovascular and neurodegenerative diseases.  
3. SPECIFIC AIMS  
Based on the above, the overall objective of this thesis is to study how novel markers of 
retinal microvascular and neuronal damage are associated with cerebrovascular disease 
and dementia, using retinal imaging techniques. Based on this focus, the specific aims are:  
AIM 1: To examine whether retinal microvascular changes are related to cerebrovascular 
disease, cognitive impairment and dementia.  
 Sub-aim 1a: To examine whether retinal vascular parameters are related to acute 
ischemic stroke  
 Sub-aim 1b: To examine whether retinal vascular parameters are related to 
neuroimaging markers of cerebral small vessel disease (cerebral microbleeds, white 
matter lesions and lacunar infarcts). 
 Sub-aim 1c: To examine whether retinal vascular parameters are related to 
Alzheimer’s disease and vascular dementia 
 Sub-aim 1d: To examine whether vascular parameters are related to preclinical 





AIM 2: To examine whether retinal neuronal changes are related to cerebrovascular disease, 
cognitive impairment and dementia. 
 Sub-aim 2a: To examine whether retinal neuronal changes are related to Alzheimer’s 
disease and vascular dementia.  
 Sub-aim 2b: To examine whether retinal neuronal changes are related to preclinical 
stages of dementia (mild cognitive impairment). 
 Sub-aim 2c: To examine whether retinal neuronal changes are related to cerebral 
atrophy on MRI     




4. THESIS STRUCTURE 
This thesis consists of 11 chapters:  
In Chapter I (this chapter), I introduce the scope of study covered in this thesis, the rationale 
for conducting the study, and describes specific aims this thesis attempts to achieve.  
In Chapter II, literature related to stroke, cerebral small vessel disease, dementia and 
cognitive impairment is reviewed, and how the retina provides a unique window from which 
to study microvascular and neurodegenerative pathology in the brain is discussed in detail.  
In Chapter III, study methods are described in general. Study populations involved are 
described, with brief description of the study designs, and outcomes of interest examined in 
each study. Retinal imaging and assessment of retinal vascular and neuronal parameters 
common to the study populations are described in detail. Study specific inclusion and 
exclusion criteria, definition of study outcomes of interest, and data analysis are further 
detailed in each chapter.  
In Chapter IV, I examine whether retinal vascular parameters are associated with acute 
ischemic stroke and its subtypes. This is a case-control study deriving stroke cases from the 
Multi-Center Retinal Stroke (MCRS) study and controls from the Singapore Epidemiology of 
Eye Diseases (SEED) studies. 
In Chapter V, I examine whether retinal vascular parameters are associated with markers of 
cerebral small vessel disease. This is a cross-sectional study based on neuroimaging findings 
in the community-based Epidemiology of Dementia in Singapore (EDIS) study cohort.  
In Chapter VI, I examine whether retinal vascular parameters are associated with the two 
major subtypes of dementia – Alzheimer’s disease (AD) and vascular dementia. This is a 
case-control study deriving dementia cases from the Retinal Imaging in Dementia (RD) study 





In Chapter VII, I examine whether retinal vascular parameters are associated with preclinical 
stages of dementia. Correlations of retinal vascular parameters with varying severities of 
cognitive impairment and with domain-specific cognitive performance are examined in a 
cross-sectional study of participants from the EDIS cohort.  
In Chapter VIII, I examine whether thinning of the retinal neuronal layers is present in 
patients with mild cognitive impairment, and compares these changes with clinically 
diagnosed AD cases in a case-control study deriving cases from the RD study and controls 
from the SEED studies. 
In Chapter IX, I examine whether thinning of the retinal neuronal layers is associated with 
dementia in the presence of cerebrovascular disease – particularly vascular dementia and AD 
with cerebrovascular disease. This is a case-control study deriving dementia cases from the 
RD study and controls from the SEED studies.  
In Chapter X, I examine whether thinning of the retinal neuronal layers is associated with 
global and regional cerebral atrophy on MRI in a cross-sectional study of participants from 
the EDIS cohort. 
In Chapter XI, I summarize the main findings from chapters IV-X, and discuss their 
implications in cerebrovascular disease and dementia. Limitations of the studies and proposed 
future research directions will also be discussed.  
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CHAPTER I FIGURES 
Figure I-1. Cerebral MRI and retinal imaging  
Stroke and cerebral small vessel disease result from cerebrovascular disease, while dementia 
generally results from neurodegeneration in the brain. Vascular damage in the brain is also a 
major contributor to dementia. MRI markers of vascular damage in the brain include infarcts, 
lacunes, microbleeds, and white matter lesions; and neuronal damage is observed as atrophy 
on MRI. Similarly, vascular damage in the retina can be observed as retinopathy lesions, and 
through assessment of retinal vessel parameters from digital retinal photographs. 









CHAPTER II:  





1.  AGE-RELATED BRAIN DISEASE – CEREBROVASCULAR DISEASE & 
DEMENTIA 
Improvements in medical care over the past century have led to longer lifespans, resulting in 
the rapid aging of populations around the world.[1] As a result, the number of persons 
developing age-related cerebrovascular and neurogenerative diseases is expected to rise 
rapidly as well. Combined, stroke and dementia are major causes of mortality and disability 
worldwide.[2, 3] Age-related brain diseases of stroke and dementia are major economic and 
societal burdens, adversely affecting quality of life for the aged and their families.  The full 
burden is likely to be much higher, as caregiver burden adversely affects caregiver physical 
and emotional health, leading to additional unaccountable load.[4, 5]  
With multi-morbidity being more common in the elderly,[6] the amount of evidence showing 
that there is significant overlap in cerebrovascular disease (CeVD) and dementia is 
building.[7] Furthermore, appearance of overt clinical symptoms in cerebrovascular disease 
and dementia is a sign of significant cerebral damage; highlighting the need to better 
understand early and subtle signs of vascular and neurodegenerative damage in the brain. The 
development of better and more economical markers for predicting and monitoring disease 
progression is crucial to guiding focused prevention and better disease management. 
2. CEREBROVASCULAR DISEASE 
2.1 STROKE  
Stroke is characterized as a neurological deficit attributed to an acute focal injury of the 
central nervous system (CNS) by a vascular cause, including cerebral infarction and 
hemorrhage.[8] Cerebral infarction is characterized by focal ischemic injury in a defined 
vascular distribution in the brain caused by stenosis, occlusion or hemorrhage.[8] Current 
methods of confirming the vascular cause and region affected depends heavily on 
neuroimaging, usually by computed tomography (CT) or magnetic resonance imaging (MRI). 




A diagnosis of clinical stroke is given when evidence of infarction or hemorrhage is 
accompanied by symptoms of focal neurological dysfunction corresponding to the lesion.  
Ischemic stroke can be further classified into a few main subtypes by etiology:[9] 1) Large-
artery stroke is caused by atherosclerosis and stenosis of the extracranial or intracranial large 
arteries; 2) Cardioembolic stroke by occlusion of cerebral vessels by thromboembolism, and 
highly correlated with cardiovascular disease; 3) Lacunar stroke is caused by occlusion of the 
small vessels, usually a deep penetrating artery, resulting in relatively smaller lesions (size 
<1.5cm).  
2.2 CEREBRAL SMALL VESSEL DISEASE 
Cerebral small vessel disease refers to a group of pathological processes that affect the small 
arteries, arterioles, venules and capillaries of the brain. Cerebral small vessel disease is an 
important aspect of cerebrovascular disease, contributing to stroke, cognitive decline and 
dementia in the elderly.[10, 11] As the cerebral microvasculature cannot be directly 
visualized in vivo, brain parenchyma lesions that result from cerebral microvascular damage 
are being used as markers of cerebral small vessel disease. Hence, the term “cerebral small 
vessel disease” collectively refers to lesions such as lacunar infarcts (lacunes), while matter 
lesions (white matter hyperintensities or leukoaraiosis), and cerebral microbleeds.  
As these lesions are often asymptomatic, they are defined primarily by their characteristics on 
neuroimaging. Based on recommendations from STandards for ReportIng Vascular changes 
on nEuroimaging (STRIVE), neuroimaging markers of cerebral small vessel disease are 
defined as follows:[12]  
1. Lacunar infarct/ Lacune: A round ovoid, subcortical, fluid-filled cavity (with signal similar 
to cerebrospinal fluid) of between 3mm to 15mm in diameter, consistent with a previous acute 





2. White matter lesion/ white matter hyperintensity: Signal abnormality of variable size in the 
white matter showing the following characteristics: hyperintensity on T2-weighted images 
such as fluid-attenuated inversion recovery (FLAIR) sequences, without cavitation (signal 
different from cerebrospinal fluid).  
3. Cerebral microbleed: Small (generally 2-5mm in diameter, but up to 10mm) areas of signal 
void with associated blooming seen on T2*-weighted gradient-recalled echo (GRE) MRI or 
on sequences sensitive to susceptibility effects such as susceptibility weighted imaging (SWI). 
They are not seen on CT, FLAIR, T1-weighted or T2-weighted sequences.  
2.3 MICROVASCULAR PATHOLOGY IN CEREBROVASCULAR DISEASE 
Microvascular damage in the cerebral circulation has been implicated in ischemic stroke, and 
considered to be highly related to but not restricted to lacunar stroke.[10, 13-15] The primary 
modifiable risk factors for ischemic stroke are hypertension, smoking, and diabetes; all of 
which are known vascular risk factors also associated with cerebral small vessel disease.[16, 
17] The link between small vessel disease and stroke goes both ways: presence of cerebral 
small vessel disease increases the risk of stroke and vascular-related mortality,[18-20] while 
the presence of infarcts predicts progression of cerebral small vessel disease.[21-23]  
Histopathologically, damage in the small vessels of the brain has been attributed to processes 
such as atherosclerosis, lipohyalinosis, arteriosclerosis and fibrinoid necrosis. These processes 
lead to vessel stenosis, narrowing and occlusion, causing local ischemia.[10, 24] Blood-brain 
barrier failure resulting in leakage of blood and plasma components into the perivascular 
tissue causes microhemorrhages, edema and tissue damage.[25, 26] Cumulative tissue 
damage eventually leads to rarefaction and demyelination seen in white matter lesions.[27] 
These pathological changes damage the ability of cerebral arterioles to regulate local blood 
flow, increasing susceptibility of the brain regions served by these vessels to ischemic and 
hemorrhagic damage.  




However, despite advances in neuroimaging technology, the small vessels of the cerebral 
microvasculature cannot be visualized directly in vivo using conventional MRI (<3 Tesla). 
Lacunes, microbleeds and white matter lesions are in effect, parenchymal lesions. They are 
signs of significant microvascular damage in the brain, but not the microvasculature itself. 
Hence, in order to gain additional insight into the contribution of microvascular pathology to 
age-related brain disease, there is a need for an alternative in vivo window to observe and 
quantify early and subtle microvascular structural changes before the appearance of overt 
damage to the parenchyma.   
3. COGNITIVE IMPAIRMENT AND DEMENTIA 
3.1 DEMENTIA: ALZHEIMER’S DISEASE AND VASCULAR DEMENTIA 
Dementia 
Dementia is a chronic or progressive syndrome, characterized by deterioration of cognitive 
function beyond that expected of normal aging.[28] Although memory is usually the first to 
be affected, other functions such as language, attention, orientation, comprehension, judgment 
and perception can also be impaired.  
A clinical diagnosis of dementia is given when cognitive impairment is detected through a 
combination of history-taking from the patient and a knowledgeable informant, and through 
an objective cognitive assessment, either by a mental status examination or 
neuropsychological testing; and when the impairment represents significant decline from 
prior levels of functioning and performance; and must have cognitive or behavioral symptoms 
that interfere with the ability to function at work or at usual activities.[29, 30]  
With clinical presentation varying from individual to individual, combined with a lack of 
awareness and understanding coupled with the progressive nature and myriad of causes 






Alzheimer’s disease and vascular dementia 
Alzheimer’s disease (AD) is the most common cause of dementia affecting about 60% of 
those with dementia.[32] Clinically, AD is characterized by gradual onset of cognitive 
symptoms, clear history of progressive cognitive decline, with predominant impairment in 
memory and at least one other cognitive domain, and without evidence of substantial 
concomitant cerebrovascular disease causing impairment or other causes of neurological 
disease. The earliest pathological change in AD is abnormal Aβ peptide processing leading to 
amyloid plaque deposition, and subsequent neuronal dysfunction and degeneration, resulting 
in eventual neuronal loss.[33] 
Cerebrovascular disease is the next leading cause of dementia in the elderly, affecting about 
26% of cases with dementia. Vascular disease such as clinically overt stroke, silent brain 
infarction and even subclinical brain injury can result in neurodegeneration and dementia.[34-
38] Vascular dementia (VaD) is clinically characterized by either onset of cognitive 
symptoms corresponding to dementia within 3 months of a clinical stroke; or abrupt 
deterioration in cognitive function or fluctuating and stepwise progression of cognitive 
deficits correlated with evidence of cerebrovascular lesions on brain CT or MRI.[39] 
Cerebrovascular disease and Alzheimer’s disease are interconnected in dementia 
The clinical profiles of patients with AD and VaD have significant overlap,[40] and similar 
damage to brain structures are observed in both AD and cerebrovascular disease.[7, 41] There 
is an increasing amount of evidence showing that AD and cerebrovascular disease are tightly 
intertwined in the progression of cognitive decline. Autopsy studies show that AD is 
accompanied by the presence of cerebrovascular disease in about a quarter to a third of 
cases;[42] and conversely, about half of dementia patients with cerebrovascular disease also 
have features of AD on autopsy.[43] Hence, despite the clinical separation of these two major 
subtypes of dementia, it is likely that both syndromes have significant parallels in 
pathological mechanisms.  




3.2 MILD COGNITIVE IMPAIRMENT 
Pathological changes in dementia, especially AD, occur many years before the onset of any 
clinical symptoms. By the time cognitive deficiency and symptoms meet clinical criteria for 
dementia or AD, neuronal damage is already significant and irreversible. Hence, it is 
imperative to identify persons at risk of developing dementia early in order to target treatment 
at a stage where cognitive function can still be salvaged or preserved.  
Mild cognitive impairment (MCI) is generally considered the preclinical stage of dementia. 
MCI is characterized by evidence of concern about a change in cognitive performance, with 
objective impairment in one or more cognitive domains for the person’s age, but 
independence of function in daily life is essentially preserved.[44, 45] However, only a 
portion of MCI patients eventually converts to dementia,[46] hence biomarkers to better 
identify converters from non-converters is essential. Additionally, objective and early markers 
are needed for monitoring progress of preclinical disease in high-risk individuals to evaluate 
potential of various therapeutic interventions. 
3.3 MICROVASCULAR DAMAGE IN COGNITIVE IMPAIRMENT AND 
DEMENTIA 
Systemic vascular risk factors such as hypertension and diabetes are important risk factors in 
both vascular dementia and AD, mediating neuronal damage though microvascular 
damage.[47, 48] In addition to large cortical and strategic lesions, cerebral small vessel 
disease also has a major role in vascular cognitive impairment and dementia. White matter 
lesions have been consistently shown to predict dementia, with lesion load correlated to 
progression of cognitive decline.[24] Lacunar stroke, despite having relatively better 
prognostic outcomes compared to non-lacunar stroke, is associated with higher risk of 
cognitive impairment and dementia, as with the presence of silent lacunes.[49, 50] 
Microinfarcts, which are even smaller ischemic lesions compared to lacunes, have been 





dementia.[51, 52] Another relatively new marker, cerebral microbleeds, is also linked to 
cognitive impairment.[53-55] 
These lesions are not specific to vascular dementia but also prevalent in AD.[7] 
Cerebrovascular disease lowers the threshold of amyloid and tau pathology required to cause 
symptomatic disease in AD-mediated cognitive decline.[7, 47] Even amyloid-driven 
pathology in AD has a microvascular component. Amyloid plaque deposits not only in the 
brain parenchyma, but also in the cerebral vasculature, mainly in the leptomeningeal and 
cortical arteries. Vascular deposition of amyloid plaque in the cerebral small vessels, leads to 
cerebral amyloid angiopathy.[56] This disrupts vessel integrity, increasing the risk of 
hemorrhages and subsequent vascular events. Lobar cerebral microbleeds are a hallmark of 
cerebral amyloid angiopathy.[57] Cerebral amyloid angiopathy leads to vessel occlusion and 
reduction in microvessel density.[56, 58, 59]  
High variability and overlap in type and distribution of lesions associated with both AD and 
vascular cognitive impairment suggest that there is a microvascular component in both 
phenotypes. However, current neuroimaging techniques do not allow direct in vivo 
observation of structural changes in the cerebral small vessels. 
3.4 NEURODEGENERATION IN COGNITIVE DECLINE AND DEMENTIA  
Cerebral atrophy is directly correlated to cognitive function, and atrophy rates are strongly 
linked to the rate of cognitive decline. Although atrophy on structural MRI is generally 
considered a relatively late biomarker for AD, [60] it remains the most relevant and 
prominent marker of neurodegeneration. It is still the strongest predictor of MCI conversion 
to dementia,[61, 62] and the most functionally useful marker for tracking disease 
progression.[60, 63] Atrophy is a versatile biomarker that allows both temporal and 
anatomical tracking of progression. Computational segmentation techniques are increasingly 
being used to obtain quantitative volumetric measurements from whole-brain, regional and 
sub-regional areas of interest such as the hippocampus.[64] Although these methods may be 




considered generally straightforward, scans need to be normalized to a standardized template 
before measurement, which may result in loss of morphological information. Another 
drawback is that visual inspection and manual editing is usually required to correct for the 
orbits, the brainstem, and vascular lesions. These considerations make MRI data processing a 
long and tedious process, and requires highly trained research staff for image grading and 
analysis. 
Functional imaging biomarkers are also being explored to detect evidence of 
neurodegeneration earlier in vivo, to better identify processes in individuals who are at 
increased risk of converting to dementia.[61, 62, 65-67]  However, the availability and 
acceptability of these examinations are limited in the clinic due to its high cost and multiple 
contraindications, and are unlikely to be used for routine screening of high-risk individuals 
for AD and dementia. A simpler, faster, objective and more cost-effective method is needed 
to identify the presence of neuronal and microvascular damage in persons at-risk of 
developing AD or vascular dementia.  
4. THE BRAIN AND THE RETINA  
4.1 MICROVASCULAR SIMILARITES IN THE BRAIN AND RETINA 
The retinal vessels measuring 100-300µm in width are highly similar to the cerebral small 
vessels. Both vascular systems have a distinct blood-tissue-barrier, undergo autoregulation 
through local myogenic and metabolic control, and are relatively low-flow and high oxygen 
extraction systems.[68, 69] Aging results in reduction of cerebral and retinal blood flow rates 
and vessel density that corresponds to reduction in metabolic demand.[70-73] Systemic 
diseases such as hypertension and diabetes, and hereditary small vessel diseases such as 
cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CARDASIL) and hereditary endotheliopathy with retinopathy, nephropathy and stroke 





These overlaps in structure and function strongly suggest that microvascular changes in the 
brain can also be observed in the retina. Retinopathy lesions are a major manifestation of 
microvascular target organ damage in hypertension and diabetes in the eye. Generalized and 
focal retinal arteriolar narrowing, and arteriovenous nicking is the result of intimal thickening, 
media wall hyperplasia, hyaline degeneration, vessel wall necrosis from elevated blood 
pressure.[74, 75] Both hypertension and diabetes can cause endothelial dysfunction and 
blood-retinal barrier breakdown due to damage from shear stress and inflammation.[76] 
Weakened vessel walls are susceptible to microaneurysms, while compromised endothelial 
walls allow the exudation of blood resulting in hemorrhages, and exudation of lipids result in 
hard and soft exudates.[77] Focal ischemia in the retinal layers present as cotton wool 
spots,[77] while narrowing and occlusion in the small arterioles lead to vessel collapse and 
reduced network density.[78] This suggests that pathological changes that adversely affect 
perfusion and vessel wall function in the cerebral small vessels are likely to be reflected as 
similar changes in the retinal vessels. 
4.2 RETINAL MICROVASCULAR CHANGES ON RETINAL FUNDUS 
PHOTOGRAPHY 
Unlike the cerebral microvasculature, the retinal microvasculature can be observed directly 
using relatively simple imaging techniques such as digital retinal fundus photography. Retinal 
microvascular abnormalities in the form of qualitative retinopathy signs can be detected and 
graded from digital retinal fundus photographs.[79] These qualitative markers include 
“classical” retinopathy signs such as microaneurysms, retinal hemorrhages (flame and blot-
shaped), cotton wool spots (soft exudates) and hard exudates; and hypertension-specific 
arteriolar signs of arteriovenous nicking, enhanced arteriolar light reflex, focal arteriolar 
narrowing, and generalized arteriolar narrowing.[80, 81]  
However, these retinopathy lesions only reflect focal changes that represent a relatively 
severe stage of target organ damage in the retina. It is imperative to shift our focus from 




qualitative markers of microvascular damage to quantitative markers which may be able to 
detect early changes in the retinal microcirculation preceding these lesions. With the 
introduction of image processing software such as the ARIC grid, and Retinal Analysis 
grading systems into a number of prolific population-based studies in the last decade, retinal 
vascular calibers have emerged as a potential early quantitative marker.[82-86]  
Early studies in vessel calibers mainly focused on arteriovenous ratio (AVR), a dimensionless 
construct that does not require correction for magnification effect from the camera and ocular 
refractive media.[87] However, relatively recent studies have shown that arteriolar and 
venular calibers, calculated as central retinal arteriolar equivalent (CRAE) and central retinal 
venular equivalent (CRVE) respectively, are affected by different pathological mechanisms 
despite being highly correlated to each other, and should be evaluated and analyzed 
separately.[87, 88] Arteriolar caliber changes are mainly associated with past, present and 
future blood pressure, hypertension, and reflect vasoconstriction and vasodilatory auto-
regulative function; while venular caliber changes are more closely related to blood glucose 
levels, diabetes, dyslipidemia, smoking, endothelial dysfunction, and inflammation.[87] 
Another caveat of caliber measurement is that arteriolar and venular caliber across the pulse 
period can vary by 6-17% and 2-11% respectively [89]. Measurements from a single time 
point have significant variability due to pulse cycles, highlighting the need to explore 
parameters that are less time-variable. Novel retinal vascular parameters designed to better 
capture the complex structure of the retinal microcirculation have been developed, such as 
fractal dimensions, vessel tortuosity, and branching parameters.[90] Fractal dimensions are a 
global measure of vascular network complexity, capturing the optimality and efficiency of 
blood distribution; while vessel tortuosity quantifies the curvature of the vessel path, 
reflecting vessel integrity and barrier dysfunction.[91, 92] 






Numerous studies have shown that qualitative retinopathy signs are associated with 
cerebrovascular pathology in the brain (Table II-1 and Table II-3). Large-population based 
studies such as the Atherosclerosis Risk in Communities (ARIC) Study, the Beaver Dam Eye 
Study (BDES), the Blue Mountains Eye Study (BMES) and the Cardiovascular Health Study 
(CHS), have examined community-based cohorts of middle-aged and elderly subjects and 
showed that retinopathy signs are associated not only with incident stroke, but also subclinical 
MRI-defined markers of cerebrovascular disease, including cerebral infarction, white matter 
lesions and cerebral microbleeds.  
Qualitative retinopathy signs in stroke and cerebral small vessel disease  
The relationship between qualitative retinopathy signs with incident stroke has been 
extensively studied in a number of large population-based studies, presenting compelling 
evidence that the presence of retinopathy signs is predictive of stroke, and related to MRI-
defined cerebral infarcts, both symptomatic and silent lacunar infarcts (see Table II-1), and 
subsequent vascular events in acute stroke patients.[93] These associations were independent 
of traditional cardiovascular risk factors, suggesting that these retinal signs may provide 
additional information for stroke risk stratification.  
A smaller number of population-based studies have examined the link between retinal 
vascular changes and cerebral small vessel disease. Data from established studies in middle-
aged and elderly cohorts such as the ARIC study and the AGES-Reykjavik study have 
reported that persons with retinopathy signs are more likely to have lacunar infarcts (see 
Table II-1), multiple cerebral microbleeds and relatively greater progression of WML (see 
Table II-3).  
Quantitative retinal vascular parameters in stroke and cerebral small vessel disease  
Both studies using AVR and direct vessel width measurements have provided consistent 
evidence that narrower arterioles but wider venules are associated with stroke risk, 
independent of cardiovascular risk factors (see Table II-2). These associations were 




consistent even with markers of cerebrovascular disease, with narrower arterioles and wider 
venules also associated with incidence of lacunar infarcts and white matter lesion 
progression.[94-96] These findings reinforce the notion that arteriolar and venular changes 
may reflect different mechanisms of systemic microvascular damage and must be evaluated 
separately.  
Early studies in the new parameters of vessel tortuosity and branching angles, have not 
produced significant associations with stroke risk,[97] and studies examining fractal 
dimensions and branching in different subtypes of stroke have produced conflicting 
results.[98-101] Studies in hereditary small vessel disease such HERNS, CADASIL, and 
hereditary retinal arteriolar tortuosity provide additional evidence that reduction in retinal 
vascular fractal dimensions and increased arteriolar tortuosity coexist with microvascular 
pathology in the brain, such as microbleeds and white matter lesions.[102, 103]  
However, no studies have systematically quantified an extensive range of retinal vascular 
parameters (including arteriolar and venular caliber, fractal dimension, tortuosity, and others) 
over a comparable region on the retina in a single interface in studying cerebrovascular 
disease. Hence, the full potential of these retinal vascular parameters still needs to be 
determined in the field of stroke (such as ischemic stroke subtypes), and subclinical markers 
of cerebral small vessel disease. 
4.4 RETINAL MICROVASCULAR CHANGES IN DEMENTIA AND 
COGNITIVE IMPAIRMENT  
Qualitative retinopathy signs in dementia and cognitive impairment 
A number of population-based studies in the elderly have demonstrated that retinopathy is 
associated with dementia, and both Alzheimer’s disease and vascular dementia (see Table II-
4); particularly in specific high-risk populations such as hypertensives.[104] Retinopathy has 





Large population-based and community-based studies have also studied the link between 
retinal microvascular changes and cognitive impairment (Table II-5). In the ARIC study,[107] 
retinopathy signs were clearly associated with cognitive impairment. However, findings from 
other studies, including the Los Angeles Latino Eye Study (LALES), the CHS, the BMES, 
and the AGES-Reykjavik Study, have been less clear.[104, 108-110] For example, in the 
BMES,[110] these associations were only present among subjects with hypertension, whereas 
in the AGES-Reykjavik Study,[108] retinopathy combined with the presence of cerebral 
microbleeds was associated with cognition. These discrepancies could partly be due to 
different cognitive tests used, such as the Mini Mental State Examination, or the Abbreviated 
Mental Test,[104, 110, 111] but also differences in the specific cognitive domains tested such 
as psychomotor speed, executive function, and verbal memory.[104, 107]  
Quantitative retinal vascular parameters in dementia and cognitive impairment 
With respect to quantitative retinal vascular parameters, the Rotterdam study has shown that 
wider venules and narrower arterioles are associated with risk of incident dementia, especially 
vascular dementia.[112] However, a small clinical study suggested that venular narrowing 
and reduced retinal blood flow was associated with AD.[113] Reduced retinal vascular fractal 
dimensions, or a sparser retinal vascular network, was associated with cognitive impairment 
and AD in the Singapore Malay Eye Study (SiMES) and the Australian Imaging, Biomarker 
& Lifestyle Flagship Study of Ageing (AIBL) studies.[114-116] There is also early evidence 
suggesting that alterations in the retinal microvascular network can be detected even in non-
impaired persons with significant amyloid plaque burden.[116] 
However, it remains unknown whether these quantitative retinal vascular parameters are 
associated with particular subtypes of dementia, early cognitive impairment, or if they are 
directly correlated with global cognitive function across various cognitive domains, or related 
only to specific domains more susceptible to vascular damage. 
 




4.5  NEURONAL DAMAGE IN THE BRAIN IS REFLECTED IN THE RETINA  
The retina is directly linked to the brain via the optic nerve, which is formed by the axonal 
processes of retinal ganglion cells. The retinal ganglion cells receive information from 
photoreceptors via intermediate neuronal cells such as the bipolar, amacrine and horizontal 
cells. The retinal ganglion cells share structural morphology with cerebral neurons in having a 
cell body, dendrites and an axon that is myelinated as it exits the eye. The axonal processes 
form the optic nerve, relaying visual information directly from the retina to the visual cortex 
in the occipital lobe, forming a direct connection to the brain. Like cerebral neurons, damage 
to the retinal ganglion cells leads to retrograde and anterograde degeneration, with limited 
axonal regeneration capability.[117] Both types of neurons also respond similarly to 
neurotoxic and neurotrophic stimuli.[117] Hence, neurodegeneration in the brain may be 
reflected as retinal ganglion cell damage in the retina.  
Histological studies have demonstrated that AD is associated with loss of retinal ganglion 
cells (RGC) and optic nerve axons.[118-121] Clinical studies have also reported changes in 
the optic nerve head, such as increased cup-to-disc ratio, using ophthalmoscopy and retinal 
fundus photography in AD,[122, 123] However, optic nerve head evaluation is not highly 
reproducible or reliable, as it is subject to high inter-observer variability.[123]  
4.6 RETINAL NEURONAL DAMAGE ON OPTICAL COHERENCE 
TOMOGRAPHY 
Optical coherence tomography (OCT) is a non-invasive in vivo optical imaging technology 
capable of penetrating tissue to provide high-resolution, biopsy-like cross-sectional images of 
the retinal layers. OCT imaging is widely used clinically in glaucoma and retinal disease, 
such as macular edema and age-related macular degeneration.[124] Ocular neuronal damage 
is assessed primarily by measuring the thickness of the peripapillary retinal nerve fiber layer 
(RNFL), the most hyper-reflective layer on the interior surface of the retina. Compared to 





improvements in spectral domain-OCT (SD-OCT) technology now allows measurement of 
the ganglion cell-inner plexiform layer (GC-IPL), another neuronal layer directly posterior 
and exterior to the RNFL.[125, 126]  
The RNFL contains the unmyelinated axons of the retinal ganglion cells, and is thickest at the 
peripapillary area around the optic nerve. The GC-IPL contains the dendrites and cell bodies 
of same retinal ganglion cells, and is thickest at the macular region around the fovea. 
Thinning of the RNFL is an indicator of axonal damage and loss, while thinning of the GC-
IPL reflects loss of dendritic and cell body integrity. As cell bodies are much larger compared 
to axonal width, and loss of dendritic complexity and area occurs prior to ganglion cell 
death,[127-129] is likely that GC-IPL changes may be more sensitive to neuronal damage 
than RNFL.  
4.7 RETINAL NEURONAL CHANGES IN DEMENTIA AND COGNITIVE 
IMPAIRMENT 
Earlier clinical studies using scanning laser ophthalmoscopy did not find any significant 
differences in RNFL thickness in AD patients, while studies using time domain-OCT 
technology showed that peripapillary RNFL thinning is associated with both mild cognitive 
impairment and AD (Table II-6). However, studies examining papillary RNFL in AD using 
SD-OCT have not been as consistent (Table II-6).[130] Furthermore, cohort studies looking 
at the association between RNFL thickness and general cognitive ability have mixed 
results.[131, 132] 
Studies using SD-OCT have additionally shown that RNFL thickness at the macular region, 
and full macular thickness (which includes both the RNFL and GC-IPL) is reduced in patients 
with AD (Table II-6).[130, 133-135] Currently, there is no clear evidence if the GC-IPL is 
also reduced in MCI and AD, independent of RNFL thickness changes. Furthermore, as these 
have been small clinical studies, cerebrovascular disease and systemic vascular risk factors 
have neither been adjusted nor accounted for.  




Recent reports have used SD-OCT to assess retinal ganglion cell changes in other 
neurodegenerative disease such as multiple sclerosis and Parkinson’s disease,[136-139]  
suggesting that GC-IPL thinning is likely to be also present in cognitive decline. While there 
have been small retrospective case studies showing that hemianopia associated with stroke 
results in corresponding thinning of the ganglion cell layer,[140, 141] there have barely been 
any studies examining neuronal damage using OCT in cerebrovascular disease and 
particularly vascular dementia.  
5. RETINAL IMAGING IN CEREBROVASCULAR DISEASE AND DEMENTIA 
The retina and the brain share many similarities in microvascular and neuronal structure and 
function, providing us a unique “window” from which we can potentially study brain 
microvascular and neuronal pathological changes non-invasively in vivo. Advances in image 
acquisition and analysis have now equipped us with powerful tools to quantify subtle changes 
in the retinal microvascular network and neuronal layers, relatively impossible to obtain 
directly from the brain through current neuroimaging techniques.  
Using retinal photography to detect microvascular damage through the identification of 
retinopathy lesions and vessel narrowing/widening has been well-tested in population-based 
studies. However, because retinopathy lesions are not common in the general population, and 
indicate a relatively late stage of microvascular damage, the usefulness of using retinopathy to 
evaluate stroke and dementia risk is limited. New quantitative measures aimed at better 
characterizing the retinal vascular network have been developed, but their relationship to 
cerebrovascular disease, especially stroke and cerebral small vessel disease, needs to be 
examined. And because vascular disease is a major contributor to cognitive decline and 
dementia, these retinal vascular measures need to be examined for associations with major 
subtypes of dementia, and early cognitive impairment. It is also unknown whether retinal 
microvascular changes are correlated with global cognitive performance across various 





Although a number of clinical studies have studied retinal neuronal thinning in dementia 
using OCT, these studies have been primarily focused on AD. It remains unknown whether 
dementia associated with cerebrovascular disease is also similarly affected, and whether these 
changes are also observed in mild cognitive impairment. Also, it is unclear if thinning in the 
retinal neuronal layers is directly associated with global atrophy or only in regions directly 
associated with the eye.  
Hence, the main focus of this thesis is to study how markers of retinal microvascular and 
neuronal damage are associated with cerebrovascular disease, dementia, and cognitive 
impairment using novel techniques in structural retinal imaging. 
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CHAPTER II TABLES 
Table II-1: Associations of qualitative retinopathy signs with stroke, arranged by type of retinal signs 
Author and References 
(study) 
Study Type and population Retinal signs Outcome Associations (95% CI) 
Wong et al [142] 
(ARIC) 
Prospective cohort study; n=10358, age 
51-70 years, mean follow-up=3.5 years 
Retinopathy signs* Incident stroke (110) HR 2.58 (1.59-4.20) 
Wong et al [143] 
(ARIC) 
Prospective cohort study; n=1684, age 
51-72 years, median follow-up=4.7 
years 
Retinopathy signs* Incident stroke (32) HR 3.7 (1.2-11.8) 
Mitchell et al [144] 
(BMES) 
Prospective cohort study; n=3583, 
age>49 years, 7-year follow-up 
Retinopathy signs* Incident stroke or TIA (132) 
Cerebrovascular death 
OR 2.4 (1.1-5.4) 
OR 1.6 (1.0-2.7) 
Yatsuya el al [94] 
(ARIC) 
Prospective cohort study; n=10496, age 
45-64 years, median follow-up=11.2 
years 
Retinopathy signs* Incident thrombotic (192) and 
cardioembolic stroke (80) 
HR 2.41 (1.47-3.95) 
HR 2.25 (1.09-4.65) 
Cheung et al [145] 
(ARIC Brain MRI 
Study) 
Population-based prospective study; 
n=810, age≥55 years, median follow-
up=10.5 years 
Retinopathy signs* Incident silent cerebral infarct 
(164) 
Incident lacunar infarct 
(131)Retinopathy* 
OR 2.81 (1.42-5.60) 
OR 3.19 (1.56-6.50) 
Cheung et al [146] 
(ARIC) 
Prospective cohort study; n=1617 
diabetics, age 51-70 years, mean 
follow-up=7.8 years 
Diabetic retinopathy Incident ischemic stroke (75) HR 2.34 (1.13-4.86) 
Kwon et al [147] Cross-sectional cohort study, n-550 
hypertensive subjects 
Hypertensive retinopathy grade 2† Silent brain infarcts (61) OR 2.98 (1.20-7.42) 
Wong et al [142] 
(ARIC) 
Prospective cohort study; n=10358, age 
51-70 years, mean follow-up=3.5 years 
Arteriovenous (AV) nicking Incident stroke (110) HR 1.60 (1.03-2.47) 
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1285, age>65 years, 5-year follow-
up 
AV nicking Incident stroke (356) HR 1.84 (1.15-2.94) 
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. †Hypertensive retinopathy grade 2 defined as modest to severe narrowing of retinal 
arterioles (focal or generalized), with an arteriovenous ratio < 1:2 or arteriovenous nicking 
ARIC: Atherosclerosis Risk in Communities Study; BDES: Beaver Dam Eye Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study, MCRS: Multi-
center Retinal Stroke Study 
Table II-1 (continued): Associations of qualitative retinal signs with stroke, arranged by type of retinal signs 




Author and References 
(study) 
Study Type and population Retinal signs Outcome Associations (95% CI) 
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1717, age>65 years 
AV nicking Prevalent stroke (496)  OR 1.84 (1.23-2.76) 
Cooper et al [148] 
(ARIC) 
Cross-sectional population-based 
study, n=1684, age 55-74 years 
AV nicking MRI-defined subclinical infarcts 
(183) 
HR 1.90 (1.25-2.88) 
Qiu et al [149] 
(AGES-Reykjavik 
Study) 
Cross-sectional cohort study; n=4176, 
mean age=76 years 
AV nicking Subcortical infarcts OR 1.33 (1.09-1.62) 
Yatsuya el al [94] 
(ARIC) 
Prospective cohort study; n=10496, age 
45-64 years, median follow-up=11.2 
years 
AV nicking Incident lacunar stroke (66) HR 2.38 (1.47-3.95) 
Cheung et al [145] 
(ARIC Brain MRI 
Study) 
Population-based prospective study; 
n=810, age≥55 years, median follow-
up=10.5 years 
AV nicking Incident silent cerebral infarct 
(164) 
Incident lacunar infarct (131) 
OR 2.82 (1.66-4.76) 
OR 2.48 (1.39-4.40) 
De Silva et al [93] 
(MCRS) 
Prospective cohort study; n=652 stroke 
patients, median follow-up=29 months 
AV nicking Recurrent cerebrovascular event 
(92) 
HR 2.28 (1.20-4.33) 
Mitchell et al [144] 
(BMES) 
Prospective cohort study; n=3583 
age>49 years, 7-year follow-up 
Focal arteriolar narrowing Incident stroke or TIA (132) 
 
OR 3.5 (1.5-8.2) 
 
Cooper et al [148] 
(ARIC) 
Cross-sectional population-based 
study, n=1684, age 55-74 
Focal arteriolar narrowing MRI-defined subclinical infarcts 
(183) 
HR 1.89 (1.22-2.92) 
Yatsuya el al [94] 
(ARIC) 
Prospective cohort study; n=10496, age 
45-64 years, median follow-up=11.2 
years 
Focal arteriolar narrowing Incident lacunar stroke (66) HR 2.22 (1.11-4.48) 
De Silva et al [93] 
(MCRS) 
Prospective cohort study; n=652 stroke 
patients, median follow-up=29 months 
Focal arteriolar narrowing Recurrent cerebrovascular event 
(92) 
HR 2.28 (1.20-4.33) 
Cooper et al [148] 
(ARIC) 
Cross-sectional population-based 
study, n=1684, age 55-74 years 
Microaneurysms (MA) 
Blot-hemorrhages 
MRI-defined subclinical infarcts 
(183) 
HR 3.17 (1.05-9.64) with 
MA and HR 2.95 (1.30-
6.71) with hemorrhages 
ARIC: Atherosclerosis Risk in Communities Study; BDES: Beaver Dam Eye Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study, MCRS: Multi-
center Retinal Stroke Study 
Table II-2: Associations of quantitative retinal vascular parameters with stroke 
Author and 
References (study) 





Wong et al [142] 
(ARIC) 
Prospective cohort study; n=10358, 
age 51-70 years, mean follow-up=3.5 
years 
Arteriovenous Ratio (AVR) Incident stroke (110) Decreasing AVR,  
p=0.03 
Wong et al [150] 
(BDES) 
Retrospective case-control study; 
n=413 patients and 1198 controls, 





OR 1.5 (1.1-2.1) with lowest quintile 
Cooper et al [148] 
(ARIC) 
Cross-sectional population-based 
study, n=1684, age 55-74 years 
AVR MRI-defined subclinical 
infarcts (183) 
OR 3.74 (1.51-9.24) in hypertensives, 
with lowest quintile 
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1285, age>65 years, 5-year 
follow-up 
AVR Incident stroke (356) HR 1.25 (p=0.010), per SD decrease  
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1717, age>65 years 
AVR Prevalent stroke (496) OR 1.18 (1.05-1.34), per SD decrease 
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1285, age>65 years, 5-year 
follow-up 
Central Retinal Arteriolar 
Equivalent (CRAE) 
Incident stroke (356) HR 1.17 (1.01-1.35), per SD decrease 
Longstreth et al [96] 
(CHS) 
Prospective cohort study study, 
n=1717, age>65 years 
CRAE Prevalent stroke (496) OR 1.15 (0.99-1.26), per SD decrease 
Wieberdink et al 
[151] 
(Rotterdam study) 
Prospective cohort study; n=5518, 
age≥55 years, mean follow-up=11.5 
years 
CRAE Incident stroke (623) HR 1.12 (0.99-1.23), per SD decrease 
Yatsuya et al [94] 
(ARIC) 
Prospective cohort study; n=10496, 
age 45-64 years, median follow-
up=11.2 years 
CRAE Incident lacunar stroke (66) OR 1.67 (1.23-2.26), per SD decrease 
ARIC: Atherosclerosis Risk in Communities Study; BDES: Beaver Dam Eye Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study 
 
  




Table II-2 (continued): Associations of quantitative retinal vascular parameters with stroke 
Author and 
References (study) 
Study Type and population Retinal Vascular Parameters Outcome Associations (95% CI) 
Wong et al [83] 
(CHS) 
Prospective cohort study; n=1992, 
age 69-97 years, 5-year follow-up 
Central Retinal Venular 
Equivalent (CRVE) 
Incident stroke (113) HR 1.7 (1.0-2.7) with highest quartile 
Ikram et al [152] 
(Rotterdam Study) 
Prospective cohort study; n=5540, 
mean follow-up=8.5 years 
CRVE Incident stroke (411) HR 1.12 (1.02-1.25), per SD increase 
Ikram et al [95] 
(Rotterdam Scan 
Study) 
Prospective cohort study; n=279, 
mean follow-up=3.3 years (SD 0.2) 
CRVE Incident lacunar infarct (27)  HR 1.59 (1.06-2.39), per SD increase 
Yatsuya et al [94] 
(ARIC) 
Prospective cohort study; n=10496, 
age 45-64 years, median follow-
up=11.2 years 
CRVE Incident lacunar stroke (66) OR 1.44 (1.09-1.91), per SD increase 
Wieberdink et al 
[151] 
(Rotterdam study) 
Prospective cohort study; n=5518, 
age≥55 years, mean follow-
up=11.5 years 
CRVE Incident stroke (623) 
Cerebral infarction (361) 
Intracerebral hemorrhage (50) 
HR 1.20 (1.09-1.33), per SD increase 
HR 1.28 (1.13-1.46), per SD increase 
HR 1.53 (1.09-2.15), per SD increase 
Kawasaki et al [100] 
(BMES) 
Nested case-control study; n=101 
stroke or stroke-related mortality, 
184 controls, mean age=73.8 years 
(SD 8.2) 
Spectrum fractal dimension Incident stroke event or 
mortality (101) 
OR 1.39 (1.06-1.83) per SD decrease 





Table II-3: Associations of retinal structural changes with neuroimaging markers of cerebral small vessel disease, arranged by small vessel disease markers 
Author and References 
(study) 
Study Type and population Outcome Retinal signs / parameters Associations (95% CI) 
Haan et al [153] 
(WHIMS & WHISE) 
Prospective cohort study; n=511 
women, age 64-79 years 
Ischemic lesion volume (includes 
lacunar infarcts & WML) 
Retinopathy* Higher total brain ischemic 
lesion volume (47%) in 
presence of retinopathy 
(p=0.04) 
Hanff et al [154]  
(ARIC) 
Prospective cohort study; n=830, 
age≥55 years, 10-year follow up 
Increase in brain microvascular 
disease score (WML progression and 
incident lacunes) 
Retinopathy* OR 3.18 (1.71-5.89) with 
highest quartile 
   AV nicking OR 1.93 (1.24-3.02) with 
highest quartile 
   Focal arteriolar narrowing OR 1.76 (1.19-2.59) 
Wong et al [143]  
(ARIC) 
Cross-sectional population-based 
study, n=1684, age 55-74 years 
Cerebral WML ≥Grade 3 (186) Retinopathy* 
AV nicking 
Focal arteriolar narrowing 
OR 2.5 (1.5-4.0) 
OR 2.1 (1.4-3.2) 
OR 2.1 (1.4-3.1) 
Qiu et al [149] 
(AGES-Reykjavik 
Study) 
Cross-sectional cohort study; n=4176, 
mean age=76 years 
Subcortical WML, highest quartile 
Periventricular WML, highest tertile 
Subcortical WML, highest quartile 
Periventricular WML, highest tertile 
AV nicking 
 
OR 1.71 (1.36-1.97) 
OR 1.61 (1.37-1.81) 
Focal arteriolar narrowing OR 1.40 (1.09-1.79) 
OR 1.40 (1.12-1.74) 
Longstreth et al [96] 
(CHS) 
Population-based cross-sectional study, 
n=1431, age≥65 years, no previous 
history of stroke or TIA 
Increase in WML grade (395) CRAE OR 1.17 (1.03-1.34), per SD 
decrease 
Cheung et al [145] 
(ARIC Brain MRI 
Study) 
Population-based prospective study; 
n=810, age≥55 years, median follow-
up=10.5 years 
Incident WML (182) 
WML progression, ≥2 grade increase 
(49) 
AV nicking OR 2.12 (1.18-3.81) 
OR 2.22 (1.00-5.88) 
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
ARIC: Atherosclerosis Risk in Communities Study; CHS: Cardiovascular Health Study; CRAE: Central Retinal Arteriolar Equivalent; CRVE: Central Retinal Venular 
Equivalent; MCRS: Multi-Center Retinal Stroke Study; PDR: Proliferative diabetic retinopathy; T1DM: Type 1 diabetes mellitus; WHIMS: Women’s Health Initiative 
Memory Study; WHISE:Women’s Health Initiative Sight Examination Study; WML: White matter lesions 
 
  




Table II-3 (continued): Associations of retinal structural changes with neuroimaging markers of cerebral small vessel disease, arranged by small vessel 
disease markers 
Author and References 
(study) 
Study Type and population Outcome Retinal signs / parameters Associations (95% CI) 
Ikram et al [95]  
(Rotterdam Scan 
Study) 
Prospective cohort study; n=279, age 
60-90, mean follow-up=3.3 years (SD 
0.2) 
Marked Periventricular WML 
progression (31) 
Marked Subcortical WML 
progression (25) 
CRVE OR 1.74 (1.02-2.95), per SD 
increase 
OR 2.50 (1.30-4.81), per SD 
increase 
Betterman et al [155] Case-control study, n=12 chronic 
ischemic white matter disease, 14 
controls, age 43-85 years 
Chronic white matter disease (14) CRVE Higher in WMD (p=0.006) 
Kim et al [156] Cross-sectional cohort study, n=4395, 
age=53.5 years (SD 9.4) 
WML only (930) Retinal nerve fiber layer defect 
(retinal photo) 
OR 1.54 (1.12-2.10) 
Lacunes and white matter lesions 
(WML) (60) 
Retinal nerve fiber layer defect 
(retinal photo) 
OR 2.66 (1.28-5.55) 
Qiu et al [157] 
(AGES-Reykjavik 
Study) 
Cross-sectional cohort study; n=4218,, 
mean age=76 years 
Multiple cerebral microbleeds (192) AV nicking 
Focal arteriolar narrowing 
Microaneurysms/ Hemorrhages 
OR 1.44 (1.06–1.95) 
OR 1.45 (1.01-2.09) 
OR 1.75 (1.25–2.45) 
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
ARIC: Atherosclerosis Risk in Communities Study; CHS: Cardiovascular Health Study; CRAE: Central Retinal Arteriolar Equivalent; CRVE: Central Retinal Venular 
Equivalent; MCRS: Multi-Center Retinal Stroke Study; PDR: Proliferative diabetic retinopathy; T1DM: Type 1 diabetes mellitus; WHIMS: Women’s Health Initiative 






Table II-4: Associations of retinal vascular changes with dementia, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population Retinal signs / parameters Outcome Associations (95% CI) 
Baker et al [104] 
(CHS) 
Population-based cross-sectional 
study, n=2211, age 69-97 years 
Retinopathy* Dementia (159) 
 
OR 2.10 (1.04-4.24) in hypertensives 
Qiu et al [108] 
(AGES-Reykjavik 
Study) 
Cross-sectional study; n=3906, age 
66-96 years 
Retinopathy* Vascular dementia (51) OR 1.95 (1.04-3.62) 
Schrijvers et al [158] 
(Rotterdam Study) 
Population-based cross-sectional 
study, n=6273, age≥55 years 
Retinopathy* Dementia (195) 
Alzheimer’s disease, AD (149) 
Vascular dementia (29) 
OR 1.92 (1.24-2.98) 
OR 1.89 (1.15-3.10) 
OR 2.00 (0.71-5.63) 
Baker et al [104] 
(CHS) 
Population-based cross-sectional 
study; n=2211, aged 69-97 
Focal arteriolar narrowing Dementia (159) 
AD and vascular dementia (49) 
OR 3.02 (1.51-6.02), in hypertensives 
OR 3.57 (1.31-9.75), in hypertensives 
de Jong et al [112] 
(Rotterdam study) 
Prospective cohort study; n=5553, 
age≥50 years, mean follow up=11.6 
years 
CRVE Incident dementia (655) 
Incident vascular dementia (73) 
HR 1.11 (1.00-1.22), per SD increase 
HR 1.44 (1.10-1.89), per SD increase 
de Jong et al [112] 
(Rotterdam study) 
Prospective cohort study; n=5553, 
age≥50 years, mean follow up=11.6 
years 
CRAE Incident dementia (655) 
Incident vascular dementia (73) 
HR 1.05 (0.96-1.16), per SD decrease 
HR 1.33 (0.99-1.78), per SD decrease 
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
CHS: Cardiovascular Health Study; CRAE: Central Retinal Arteriolar Equivalent; CRVE: Central Retinal Venular Equivalent 
  




Table II-5: Associations of retinal vascular changes with cognitive function, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population Retinal signs / parameters Cognitive Tests Associations (95% CI) 
Global Cognition     
Liew et al [110] 
(BMES) 
Population-based cross-sectional 
study; n=1988, age 49-97 years 
Retinopathy (269) Mini-Mental State Examination 
(MMSE<24) 
OR 1.7 (1.0-3.2) in hypertensives 
Haan et al [153] 
(WHIMS & WHISE) 
Prospective cohort study; n=505 
women, age 64-79 years 
Retinopathy (39) Modified Mini-Mental State 
Examination (3MSE) 
Lower 3ME scores over follow-up, 
mean difference=-1.01 (p-0.019) 
Ong et al [159] 
(SiMES) 
Population-based cross-sectional, 
n=1179, age 60-80 years 
Moderate to severe diabetic 
retinopathy 
Impaired Abbreviated Mental 
Test  
OR 5.57 (1.56-19.91) 
Gatto et al [109] 
(Los Angeles Latino 
Eye Study) 
Community-based cross-sectional 
study; n= 809 Latinos, mean 
age=70.3 years (SD 6.9) 
CRAE (<25
th
 percentile) Low Cognitive Abilities 
Screening Instrument-Short 
(CASI-S) score 
OR 2.04 (1.14-3.66) 
Liew et al [110] 
(BMES) 
Population-based cross-sectional 
study; n=1988, age 49-97 years 
CRVE Mini-Mental State Examination 
(MMSE<24) 
OR 1.4 (1.1-1.6) per SD increase, in 
hypertensives 
Cheung et al [114] 
(SiMES) 
Community-based cross-sectional 
cohort study, n=1202, age≥60 years 
Vascular fractal dimensions, 
lowest quintile 
Impaired Abbreviated Mental 
Test 
OR 1.71 (1.03-2.82) 
Domain specific     
Wong et al [160]  
(ARIC) 
Population-based cross-sectional 
study; n=8734, age 51-70 years 
Retinopathy* (590) Impairment in: 
Delayed word recall test,  
Digit Symbol subtest,  
Word Fluency test 
 
OR 2.60 (1.70-3.99) 
OR 1.91 (1.04-3.49) 
OR 2.03 (1.07-3.86) 
Baker et al [104] 
(CHS) 
Population-based cross-sectional 
study; n=2211; age 69-97 years 
Retinopathy* (164) Digit–Symbol Substitution Test Lower score in presence of retinopathy 
(39 vs. 42, p=0.002) 
Lesage et al [107] 
(ARIC) 
Prospective cohort study; n=803, 
age 55-72 years, 14-year follow-up 
Retinopathy*  Decline in Word Fluency Test  
 
Rapid decline in Digit Symbol 
Substitution Test score 
Adjusted score difference=-1.70 (-3.3 to 
-0.02) 
OR 2.18 (1.02-4.64)  
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
ARIC: Atherosclerosis Risk in Communities Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study; CRAE: Central Retinal Arteriolar Equivalent; 
CRVE: Central Retinal Venular Equivalent; SiMES: Singapore Malay Eye Study; T2DM: Type 2 diabetes mellitus 







Study Type and population Retinal signs / parameters Cognitive Tests Associations (95% CI) 
Domain specific     




study; n=3906; age 66-96 years 
Retinopathy* California Verbal Learning Test, 
Digit Symbol Substitution Test 
(DSST), Salthouse Figure 
Comparison Test, Stroop Test 
Presence of both retinopathy and cerebral 
microbleeds associated with slower 
processing speed (β= -0.25 [-0.37, -0.12]) 
and poorer executive function (β=-0.19[-
031, -0.07]).  
Ding et al [161] 
(The Edinburgh 
Type 2 Diabetes 
Study) 
Population-based cross-sectional 
study; n=1044 T2DM; age 60-75 
years 
Diabetic retinopathy (339) Faces and Family Pictures 
Subtest, Matrix Reasoning, 
Letter-Number Sequencing, and 
Digit Symbol Test (DST), 
Borkowski Verbal Fluency Test 
(VFT), Trail Making Test-Part B 
(TMTB). 
Poorer VFT (Ƞ2= 0.020), TMTB 
(Ƞ2=0.012), DST (Ƞ2=0.032) and general 
cognitive ability (Ƞ2= 0.020) in men. 
Ding et al [162] 
(The Edinburgh 
Type 2 Diabetes 
Study) 
Population-based cross-sectional 
study; n=954 T2DM; age 60-75 
years 
CRAE Faces and Family Pictures 
Subtest, Matrix Reasoning, 
Letter-Number Sequencing, and 
Digit Symbol Test (DST), 
Borkowski Verbal Fluency Test 
(VFT), Trail Making Test-Part B 
(TMTB). 
Lower logical memory scores (standardized 
β=-0.080, p<0.01) with increasing CRAE 
Kim et al [163] 
(CHS) 
Population-based cross-sectional 
study; n=1744, age≥65 years 
CRAE Digit Symbol Substitution Test 
score 
Mean difference=0.44 (0.07-0.80), per SD 
increase 
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
ARIC: Atherosclerosis Risk in Communities Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study; CRAE: Central Retinal Arteriolar Equivalent; 
SiMES: Singapore Malay Eye Study; T2DM: Type 2 diabetes mellitus 
 
  




Table II-5 (continued): Associations of retinal vascular changes with cognitive function, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population Retinal signs / parameters Cognitive Tests Associations (95% CI) 
Domain specific     
Ding et al [162] 
(The Edinburgh 
Type 2 Diabetes 
Study) 
Population-based cross-sectional 
study; n=954 T2DM; age 60-75 
years 
CRVE Faces and Family Pictures 
Subtest, Matrix Reasoning, 
Letter-Number Sequencing, and 
Digit Symbol Test (DST), 
Borkowski Verbal Fluency Test 
(VFT), Trail Making Test-Part B 
(TMTB). 
Lower logical memory scores (standardized 
β=-0.069, p<0.05) with increasing CRVE 





n=321; age 83-84 years 
Branching coefficient  
Branching angle 
Wechsler Logical Memory, 
Verbal Fluency and Raven’s 
Standard Progressive Matices 
Suboptimal branching coefficient 
associated with poorer scores in general 
cognitive ability (Ƞ2=0.034, p=0.02) and 
Verbal Fluency tests (Ƞ2=0.037, p=0.01). 
Suboptimal angles associated with and 
poorer scores in Logical Memory test 
(Ƞ2=0.026, p=0.03).    
* Retinopathy signs include microaneurysms, soft exudates, blot and flame-hemorrhages. 
ARIC: Atherosclerosis Risk in Communities Study; BMES: Blue Mountains Eye Study; CHS: Cardiovascular Health Study; CRVE: Central Retinal Venular Equivalent; 







Table II-6: Associations of retinal neuronal changes with Alzheimer’s disease, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population 
Retinal neuronal parameter  
(imaging technology, model) 
Outcome Associations (95% CI) 
Kergoat et al [165] Case-control study; n=30 AD 
patients, 30 controls, mean age=72.0 
years (AD), 72.1 years (controls) 
RNFL thickness (SLO, Nerve Fiber 
Analyzer GDx) 
AD RNFL thickness was not significantly different in 
AD compared to controls 
Kergoat et al [166] Case-control study; n=27 early AD, 
27 controls, mean age=70.1 years 
(AD), 71.7 years (controls) 
RNFL thickness (SLO, Heidelberg 
retinal tomograoh) 
AD RNFL thickness was not significantly different in 
AD compared to controls 
Parisi et al [167] Case-control study, n=17 AD, 14 
controls, mean age=70.4 years (AD),  
years (controls) 
RNFL thickness (TD-OCT, OCT 3) AD Reduced overall RNFL thickness in AD 
(99.9±8.95μm) compared to controls (59.5±16.7μm) 
(p<0.01), and in all quadrants (p<0.01) 
Iseri et al [134] Case-control study, n=14 AD, 15 
controls, mean age=70.1 years (AD), 
65.1 years (controls) 
RNFL thickness (TD-OCT, OCT 
3000) 
AD Reduced mean RNFL thickness in AD (59.5±16.70 
μm, p<0.01) compared to controls (99.9±8.95 μm), 
and signficantly thinner in all quadrants  
Berisha et al [113] Case-control study; n=9 AD (6 mild, 
3 moderate), 8 controls, mean 
age=74.3 years (AD), 74.3 years 
(controls) 
RNFL thickness (TD-OCT, Stratus) AD Reduced RNFL thickness in superior quadrant of 
AD patients (92.2 ± 21.6 μm, p=0.02) compared to 
controls (113.6 ± 10.7 μm) 
Paquet et al [168] Case-control study; n=26 AD 
patients (14 mild, 12 moderate to 
severe), 23 MCI patients, 15 
controls, mean age=78.3 years (mild 
AD), 78.8 years (mod-severe AD), 
78.7 years (MCI), 75.5 years 
(controls) 




Reduced mean RNFL thickness in MCI (89.3 ± 
2.7μm, p<0.001), mild AD (89.2 ± 2.9μm, p<0.01) 
and moderate-severe AD (76.6 ± 3.8μm, p<0.001) 
compared to controls (102.2 ± 1.8μm); moderate-
severe AD patients was statistically different from 
MCI patients (p <0.01) 
Lu et al [169] Case-control study; n=22 AD, 22 
controls, mean age=73 years (AD), 
68 years (controls) (p=0.054) 
RNFL thickness (TD-OCT, Stratus) AD Reduced average RNFL thickness (p=0.001)  
Reduced RNFL thickness in inferior and superior 
quadrants (p<0.05) 
AD: Alzheimer’s Disease; GCL: Ganglion cell layer; OCT: Optical coherence tomography; RNFL: Retinal nerve fiber layer; SD-OCT: Spectral domain-OCT; SLO: Scanning 
laser ophthalmoloscopy; TD-OCT: Time-domain OCT 
  




Table II-6 (continued): Associations of retinal neuronal changes with Alzheimer’s disease, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population 
Retinal neuronal parameter  
(imaging technology, model) 
Outcome Associations (95% CI) 
Kesler et al [170] Case-control study; n=30 AD, 24 
MCI, 24 controls, mean age=72.1 
years (SD 9.7) 
RNFL thickness (TD-OCT, Stratus) AD 
MCI 
Reduced average RNFL thickness in AD and MCI 
(p<0.05) compared to controls  
Reduced RNFL thickness in superior and inferior 
quadrants in AD (p<0.05) compared to controls  
Reduced RNFL thickness in inferior quadrant in MCI 
compared to controls (p<0.05) 
No significant difference between AD and MCI 
Moschos et al [171] Case-control study; n=30 AD, 30 
controls, age 42-84 years 
RNFL thickness (TD-OCT Stratus) AD Reduced RNFL thickness in inferior (p=<0.0001), 
superior (p<0.0001) and temporal quadrants (p=0.024) 
Kirbas et al [172] Case-control study; n=40 AD, 40 
controls, mean age=69.3 years 
(AD), 68.9 years (controls) 
RNFL thickness (SD-OCT) AD Reduced average RNFL thickness (p=0.001) 
Reduced RNFL in superior quadrant (p=0.001) 
Moreno-Ramos et al 
[173] 
Case-control study; n=10 AD, 10 
controls, 10 LBD, 10 PDD 
RNFL thickness (OCT) AD Reduced RNFL thickness (p<0.001 Mann-Whitney) 
Larossa et al [135] Case-control study; n=151 AD 
patients, 61 controls, age 55-90 
years 
RNFL thickness (SD-OCT, Cirrus 
OCT, Spectralis OCT) 
 
AD Reduced superior (p=0.010), inferior (p<0.001), 
temporal (p=0.023) RNFL thickness in AD by Cirrus 
OCT 
Reduced average (p=0.049), nasal (p=0.005), nasal 
inferior (p=0.020), temporal inferior (p<0.001), 
temporal superior (p<0.001) RNFL thickness by 
Spectralis 
All unadjusted 
Garcia-Martin et al 
[130] 
Case-control study; n=20 mild AD, 
28 controls, mean age=79.3 years 
(AD), 72.1 years (controls) 
Macular RNFL thickness (SD-OCT 
3D OCT-1000) 
AD Reduced RNFL thickness in all inner macular 
quadrants (all p<0.01) 
No significant difference in peripapillary RNFL 
AD: Alzheimer’s Disease; GCL: Ganglion cell layer; LBD: Lewy body dementia; OCT: Optical coherence tomography; PDD: Parkinson’s disease dementia; RNFL: Retinal 







Table II-6 (continued): Associations of retinal neuronal changes with Alzheimer’s disease, arranged by type of retinal parameters 
Author and 
References (study) 
Study Type and population 
Retinal neuronal parameter  
(imaging technology, model) 
Outcome Associations (95% CI) 
Marziani et al [133] Case-control study; n=21 AD, 21 
controls, mean age=79.3 years 
(AD), 77.0 years (controls) 
Macular RNFL thickness (SD-OCT 
Spectralis) 
Macular RNFL+GCL thickness 
(SD-OCT RTVue-100) 
AD  Reduced macular RNFL thickness in all sectors, mean 
diff -8.5 to-4.2μm (p<0.02) 
Reduced macular RNFL+GCL thickness in all sectors, 
mean diff -15.7 to 7.3μm (p<0.005) 
Iseri et al [134] Case-control study, n=14 AD, 15 
controls, mean age=70.1 years 
(AD), 65.1 years (controls) 
Macular thickness (TD-OCT, OCT 
3000) 
AD Reduced macular thickness in AD compared to 
controls, particularly in nasal, temporal and inferior 
quadrants (p<0.05), 
Reduced total macular volume in AD (6.80 ± 0.41 
mm
3




Larossa et al [135] Case-control study; n=151 AD 
patients, 61 controls, age 55-90 
years 
Macular retinal thickness (SD-
OCT, Cirrus OCT, Spectralis OCT) 
AD Reduced macular thickness in all sectors (p<0.05) in 
both Cirrus and Spectralis OCT 













1.  STUDY POPULATIONS 
To achieve the specific aims proposed, data from the following studies will be used:  
A. The Multi-Centre Retinal Stroke (MCRS) study (Specific Aim 1a) 
B. The Epidemiology of Dementia in Singapore (EDIS) study (Specific Aims 1b, 1d, and 2c) 
C. The Retinal Imaging in Dementia (RD) study (Specific Aims 1c, 2a, and 2b) 
1.1 Multi-Center Retinal Stroke (MCRS) study  
The MCRS Study is a cross-sectional observational study of patients with acute stroke, 
spanning three centers in Sydney, Melbourne and Singapore.[1] For this thesis only patients 
from the Singapore site were included. Patients with first-ever or recurrent stroke within 7 
days of onset were recruited from the Singapore General Hospital from 2005 to 2007. Patients 
were included if they were between 40-80 years old, of Chinese, Malay or Indian ethnicity, 
had ischemic stroke etiology and had retinal photographs of gradable quality.   
However, as the original Trial of Org 10172 in Acute Stroke Treatment (TOAST) definitions 
[2] result in a large proportion of patients with an undetermined classification, a pragmatic 
modification was adopted from the Greater Metropolitan Clinical Task Force for Stroke in 
New South Wales. References to hypertension and diabetes as risk factors for lacunar stroke 
are also removed to avoid risk factor bias in classification, resulting in modified criteria with 
a stronger clinico-neuroanatomical definition.[1, 3] Stroke was classified at clinical consensus 
meetings using this modified TOAST criteria by etiology into the following subtypes: large 
artery atherosclerotic stroke, cardioembolic stroke, lacunar stroke, stroke of other determined 
etiology and stroke of undetermined etiology. 
Controls were selected by frequency-matching to eligible stroke cases by 10-year age group, 
gender and race to participants of the Singapore Epidemiology of Eye Diseases (SEED) study 
[4, 5] who did not report history of previous stroke. Briefly, the SEED study is a population-





residents aged 40-80 years living in southwestern Singapore. Written informed consent was 
obtained from each participant or next-of-kin, and prior approval was obtained each institute’s 
Institutional Review Board.  
Cardiovascular risk factors were defined by physician-confirmed diagnosis before or during 
admission for stroke, or obtained from documentation in medical records; or in the case of the 
controls, self-reported history and medication use. Additional details are provided in Chapter 
IV. 
1.2 Epidemiology of Dementia in Singapore (EDIS) study 
The EDIS study is a cross-sectional community-based study conducted in conjunction with 
the SEED study of eye diseases in urban Chinese, Malay and Indian populations in Singapore. 
In order to efficiently utilize limited resources, it was decided to focus on those subjects who 
were most likely to have cognitive problems. Participants from selected SEED studies 
(Singapore Chinese Eye Study, SCES; and the Singapore Malay Eye Study-2, SiMES-2)[5, 6] 
who were older than or 60 years were screened for cognitive impairment using the 
Abbreviated Mental Test (AMT), a brief 10-question cognitive screening instrument 
previously validated in Singapore.[7] Subjects with ≤6 years of formal education and AMT 
score≤6, or subjects with >6 years of formal education and AMT score ≤8; or if the subject or 
main caregiver reported progressive forgetfulness was considered screen-positives. Screen 
positives were invited to take part in the second phase of the EDIS study, which included 
neuropsychological testing and brain magnetic resonance imaging (MRI) at the Memory, 
Aging and Cognition Center, National University Hospital.[8] Written informed consent was 
obtained from each participant or their primary caregiver, and prior approval was obtained 
from each institute’s Institutional Review Board.   
MRI was performed on a 3 Tesla Siemens Magnetom Trio Tim scanner, using a 32-channel 
head coil, at the Clinical Imaging Research Centre of the National University of Singapore. 





characteristics. MRI scans were graded visually for chronic and acute infarcts, lacunes, 
cerebral microbleeds, and semi-quantitatively for white matter hyperintensities and cerebral 
atrophy. Additionally, white matter hyperintensity volume, total brain volume, and total 
intracranial volume were quantified by automatic segmentation at the Erasmus University 
Medical Center Rotterdam, The Netherlands.[9-11] Additional details on imaging sequences, 
and grading protocols specific to each analysis are provided in Chapters V, and X. 
Neuropsychological assessment was administered by trained research psychologists to 
participants in their habitual language. Brief cognitive screening tests included the Mini-
Mental State Examination (MMSE), and the Montreal Cognitive Assessment (MoCA). 
Additionally, a formal neuropsychological battery (the Vascular Dementia Battery, or VBD) 
previously validated for Singaporean elderly was administered to all participants.[12] Specific 
cognitive domains tested in the battery include executive function, attention, language, visual 
memory, verbal memory, visuoconstruction and visuomotor speed. Details of tests used and 
calculation of Z-scores are provided in Chapter VII. 
Weekly consensus meetings were held for the diagnosis of cognitive impairment and 
dementia. Cognitive impairment without dementia (CIND) was defined as impairment in at 
least one domain of the neuropsychological test battery. CIND-mild was diagnosed when ≤2 
domains were impaired and CIND-moderate defined as, impairment of >2 domains. 
Diagnosis of dementia syndrome was made according to Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) criteria.[13] Additional details on inclusion and 
exclusion criteria for each analysis are provided in Chapters V, VII, and X. 
1.3 Retinal Imaging in Dementia (RD) study 
The RD study is a prospective case-control study of patients with clinically diagnosed 
dementia and mild cognitive impairment. Patients with Alzheimer’s disease (AD), or vascular 
dementia (VaD) were recruited from three study sites at the National University Hospital 





Singapore General Hospital Geriatic Clinic. Additionally, patients diagnosed with mild 
cognitive impairment (MCI) were recruited from the National University Hospital Memory, 
Aging and Cognition Center. Dementia syndrome was determined by clinician diagnosis in 
accordance to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-
IV) criteria.[13] All patients diagnosed with AD fulfilled National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINDS-ADRDA) criteria for probable or possible AD dementia,[14] and all 
patients diagnosed with VaD fulfilled National Institute for Neurological Disorders and 
Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences 
(NINDS-AIREN) criteria for VaD.[15] Additionally, patients with mild cognitive impairment 
(MCI) not amounting to dementia diagnosed according to Petersen’s criteria were recruited 
from the National University Hospital Memory, Aging and Cognition Center.[16] If available, 
the most recent computed tomography (CT) or MRI scan was reviewed by a trained 
neurologist blinded to patient characteristics for the presence of significant cerebrovascular 
disease. Significant cerebrovascular disease (CeVD) was defined as presence of cortical 
stroke, and/or ≥2 lacunes, and/or confluent white matter lesions in two regions of the brain on 
the age-related while matter changes (ARWMC) scale (score ≥8).[17]  Specific inclusion and 
exclusion criteria for each analysis are provided in Chapters VI, VIII, and IX. As this is an 
ongoing study, all analysis included in this thesis will only draw on data collected at the 
patient’s baseline visit. 
Participants from the SEED studies were eligible for selection as control if they did not have a 
self-reported history of stroke, and did not fail the Abbreviated Mental Test, a cognitive 
screening tool modified and validated for Singapore elderly.[7]. Details on selection criteria 
for controls are provided in Chapters VI, VIII, and IX. Written informed consent was 
obtained from each participant or their primary caregiver, and prior approval was obtained 






2.  ASSESSMENT OF RETINAL VASCULAR PARAMETERS 
Retinal microvascular changes were assessed using non-mydriatic retinal fundus photography. 
Retinal photographs centered on the optic disc and the macula was taken from both eyes were 
taken after pupil dilation using eye drops containing 1% tropicamide according to a 
standardized protocol adapted by all studies affiliated to the Singapore Eye Research 
Institute.[4, 5]  
The Singapore I Vessel Assessment (SIVA) system is a semi-automated computer-based 
program designed to assess quantitative structural retinal vascular parameters from optic-disc 
centered retinal fundus images in a region 0.5 to 2.0 disc diameter away from the optic disc 
margin. The main parameters extracted from the program (SIVA Version 3.0.0.0) for analysis 
are as follows (Figure III-1 and Figure III-2):  
Retinal vascular caliber  
Retinal vascular caliber is measured based on the revised Knudtson-Parr-Hubbard formula, as 
described elsewhere.[18, 19] Arteriolar and venular caliber were summarized as central 
retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE) 
respectively. 
Retinal vascular fractal dimension  
Fractal dimension is a measure of a fractal structure, which exhibits the property of self-
similarity, characterizing the distribution of a branching vascular system in two-dimensional 
space. It is a “global” measure that summarizes the entire branching pattern of the retinal 
vascular tree. Retinal vascular fractal dimension is calculated from skeletonized line tracing 
using the box counting method, which divides each digital photograph into a series of squares 
for various side lengths and the number of boxes is counted.[20, 21]. Smaller values indicate 
a simpler and sparser vascular network, while larger values indicate a more complex and 





Retinal vascular tortuosity  
Retinal vascular tortuosity is derived from the integral of the curvature square of along the 
path of the vessel, normalized by the total path length, taking into account the bowing and 
points of inflection [22, 23]. This measure is dimensionless as it is a ratio measure. Estimates 
are summarized as retinal arteriolar tortuosity and retinal venular tortuosity. Smaller values 
indicate straighter vessels.     
Retinal vascular branching parameters 
A series of parameters are used to quantify the relationship of parent and offspring vessel 
diameters and the angle subtended by branches at a bifurcation. At each bifurcation, the 
widths of the trunk vessel (d0) and its two branching vessels (d1,d2) are measured, as well as 
the branching angle. Branching angle (θ1 + θ2) is defined as the first angle subtended between 
2 daughter vessels at each vascular bifurcation.[24] Angular asymmetry is defined as the 
difference between 2 daughter angles (θ1 - θ2). Branching coefficient is defined as the ratio of 




. Asymmetry ratio is defined as 




. Estimates are summarized separately for 
arterioles and venules.  
Retinal photographs are deemed ungradable by SIVA only when less than four arterioles or 
four venules cannot be detected and traced by the software, or when more than half a quadrant 
of the measurement grid is occluded by pathology or lies outside the retinal image.  As 
measures from both eyes are highly correlated to each other, a randomly selected eye from 
each participant was graded for analysis. 
3.  ASSESSMENT OF RETINAL NEURONAL LAYERS 
Changes to the retinal neuronal layers are assessed by spectral domain-optical coherence 
tomography (SD-OCT), primarily by measuring thicknesses of the retinal nerve fiber layer 





After pupil dilation (as described above), SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec) was 
used to acquire macular scans and optic disc scans using the macular cube 200×200 and optic 
nerve head cube 200×200 scan protocols respectively in each eye. Additional details have 
been described elsewhere.[25, 26] GC-IPL thickness is detected and measured automatically 
from a 14.13mm
2
 elliptical annulus area centered on the fovea (Figure III-3) from macular 
cube scans, giving a series of GC-IPL parameters (average; and by superior, superonasal, 
inferonasal, inferior, inferotemporal, and superotemporal sectors). Peripapillary RNFL 
thickness and optic disc area are measured automatically from a calculation circle of diameter 
3.46mm centered on the optic disc using optic nerve head cube scans (Figure III-3). RNFL 
thickness are provided as average thickness, and thicknesses by superior, inferior, nasal, and 
temporal quadrants around the optic nerve head. Additional details are available in Chapter 
VIII.  
Scans were repeated if motion artefacts (as indicated by blood vessels discontinuity) or 
saccades were detected. Scans were deemed ungradable or unsuitable for analysis if signal 
strength was less than 5, or when there was retinal pathology affecting GC-IPL or RNFL 
thickness measurement (such as epiretinal membrane, macula edema, vitreomacular traction, 
age-related macular degeneration etc), or when there was GC-IPL or RNFL algorithm 
segmentation failure. As thickness measurements from both eyes are highly correlated to each 
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CHAPTER III FIGURES 
Figure III-1: Measurement of retinal vascular caliber using SIVA  
Retinal vessel calibers are measured using a semi-automated computer-based program from 
optic-disc centered fundus photographs.  The program automatically lays covers over traced 
vessels, and calibers are calculated for arterioles and venules separately. Arterioles are in red 







Figure III-2: Measurement of novel retinal vascular network parameters using SIVA 
All retinal vascular network parameters are measured within a grid drawn over a region 0.5 to 
2.0 disc diameters away from the optic disc margin (A1). Fractal dimension is calculated from 
a skeletonized line tracing using the box-counting method (A2). Tortuosity reflects the 
straightness/curliness of the vessels which is derived from the integral of the curvature square 
along the path of the vessel, normalized by the total path length (B). Branching parameters 
















Figure III-3: Measurement of GC-IPL and RNFL thickness from SD-OCT 
GC-IPL thickness is measured from a elliptical annulus area centered on the fovea (A) using 
macular cube scans, where automatic detection delineates the GC-IPL layer (between purple 
and yellow lines) as seen in the cross-section across the fovea (B). RNFL thickness is 
measured from a (purple) calculation circle around the optic disc using optic nerve head cube 
scans, where automatic detection delineates the RNFL layer (between red and purple lines) as 








CHAPTER IV:  
MICROVASCULAR STRUCTURE AND NETWORK IN THE 
RETINA OF PATIENTS WITH ISCHEMIC STROKE 




1. INTRODUCTION  
Microvascular damage, as reflected by cerebral small vessel disease (e.g. lacunar infarctions, 
and leukoaraiosis), has been implicated in the pathogenesis of ischemic stroke.[1, 2] However, 
it remains difficult to directly observe damage to the cerebral microcirculation in vivo, despite 
major advances in neuroimaging technologies. The retina provides a unique window to assess 
cerebral microvascular health directly and non-invasively in vivo, since the retinal blood 
vessels share many features with the brain including embryological origin, anatomical and 
physiological characteristics.  
In the last few years, there is increasing evidence that traditional indicators of retinal 
microvascular damage (e.g. retinopathy signs such as retinal hemorrhage and microaneurysms, 
and retinal vascular caliber changes) are associated with both cerebrovascular (including 
clinical stroke  and subclinical MRI-defined cerebral infarction);[3-5] and neurodegenerative 
diseases (including cognitive decline, dementia and cerebral atrophy).[6-8] These findings 
further support the concept that microvascular pathology may play an important role in the 
development of a wide range of age-related brain diseases, such as stroke and dementia, 
including Alzheimer’s disease. These retinal microvascular changes may represent not only 
cerebral small vessel damage[9, 10] but may also be the result of downstream effects of 
proximal large artery disease.[11] Retinopathy signs are, however, relatively late indicators of 
target organ damage in the eye and probably reflect advanced stages of structural 
microvascular damage including breakdown of the blood-retina barrier.[12, 13] 
Advances in digital retinal photography and computer image analysis have now enabled more 
objective quantitative assessment of retinal microvascular structure and pattern, which may 
reflect earlier and subtler changes in the retinal microcirculation, even before retinopathy 
signs appear. Additionally, such assessments can be carried out objectively even in the 
presence of retinopathy lesions. A range of novel retinal microvascular parameters have been 





optimal the retinal microcirculation is. In order to further test the hypothesis that 
microvascular changes may contribute to the etiology of ischemic stroke, we focused our 
study on these novel retinal parameters. 
In this study, we applied this novel and advanced image analysis technology to measure and 
summarize the pattern and geometry of the retinal vasculature and examined their 
associations with ischemic stroke and its major subtypes.  
2. METHODS  
2.1 Study population  
The Multi-Centre Retinal Stroke (MCRS) Study is a cross-sectional observational study of 
patients with acute stroke, spanning three centers in Sydney, Melbourne and Singapore.[14] 
For the present study only patients from the Singapore site were included. Patients presenting 
to the Singapore General Hospital with first-ever or recurrent stroke within 7 days of onset 
were recruited from 2005 to 2007. Patients were included if they were between 40-80 years 
old, of Chinese, Malay or Indian race, had ischemic stroke etiology, had adequate sitting 
ability to tolerate retinal photography, and had retinal photographs of gradable quality. 
Eligible stroke cases were matched to controls of the same 10-year age group, sex and race 
with no self-reported history of stroke selected from participants of the Singapore 
Epidemiology of Eye Diseases (SEED) study.[15, 16] In brief, the SEED study is population-
based study of eye disease in an age-stratified random sample of Chinese, Malay and Indian 
residents aged 40-80 years living in southwestern Singapore. Written informed consent was 
obtained from each participant or next-of-kin, and prior approval for the project was obtained 
from each institute’s Institutional Review Board.  
2.2 Assessment of retinal vascular parameters and retinopathy 
Retinal fundus photographs were taken from each eye after pupil dilation and graded 
according to a standardized protocol for participants of the MCRS study,[14] and the SEED 




studies [15, 16] as described in Chapter III. Measurement of quantitative retinal parameters, 
which capture the overall structure of the retinal microvessels was not influenced by the 
presence of localized retinopathy signs. Quantitative measures of the following retinal 
vascular parameters were extracted and used for analysis: retinal vascular caliber, fractal 
dimension, tortuosity and branching angle.[17-20] 
Qualified graders masked to participant characteristics and clinical status also evaluated 
fundus photographs from both eyes without assumption of cause for the presence of the 
following retinopathy lesions: focal arteriolar narrowing, arteriovenous nicking, 
microaneurysms, retinal hemorrhages, soft exudates, hard exudates, macular edema, 
intraretinal microvascular abnormalities, venous beading, new vessels at the disc or elsewhere, 
and disc swelling.  
2.3 Assessment of stroke and stroke subtypes 
All stroke patients were assessed by a standardized questionnaire with an interview conducted 
by trained medical staff, a neurological examination, and brain imaging (CT or MRI). Stroke 
was classified at clinical consensus meetings with research staff and clinicians using a 
modified version of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, 
as described in Chapter III.[14] Stroke subtypes were defined as large vessel atheroscelerotic 
stroke, small vessel lacunar stroke, cardioembolic stroke, stroke of other etiology and stroke 
of undetermined etiology. Further details on classification have been published elsewhere.[10, 
14]  
2.4 Assessment of cardiovascular risk factors 
Both patients with ischemic stroke and control participants from the SEED study (and their 
caregivers) were administered detailed questionnaires for information on smoking, and 
history of physician-diagnosed or medication use for hypertension, diabetes and 
hypercholesterolemia. Additionally, as part of clinical care for stroke, patients with ischemic 





cardiovascular risk factors, this included multiple blood pressure measurements, and fasting 
blood samples for glucose, HbA1C and lipids. Controls, as part of the SEED study, 
underwent extensive examination on the day of retinal photography, which included at least 2 
blood pressure measurements at the same sitting, and random blood samples for glucose, 
HbA1C and cholesterol. Hypertension was defined as systolic blood pressure of 140 mmHg 
or more, or diastolic blood pressure of 90 mmHg or more at examination, a reported history 
of physician-diagnosed hypertension or a self-reported history of anti-hypertensive 
medication use, or both. Diabetes was defined as random blood glucose of 200mg/dL 
(11.1mmol/L) or more, fasting blood glucose of 126mg/dL (7.0mmol/L) or more, HbA1C of 
7% or more, self-reported history of physician-diagnosed diabetes or self-reported history of 
anti-hyperglycemic medication use. Hypercholesterolemia was defined as total cholesterol of 
6.2mmol/l or more, or a self-reported history of physician-diagnosed hypercholesterolemia, or 
self-reported use of lipid-lowering medication use.  
2.5 Statistical analysis  
Baseline characteristics, prevalence of cardiovascular risk factors and retinal geometric 
parameters were compared between cases and controls using the student’s t-test for 
continuous variables and Pearson’s chi-squared test for categorical variables. Odds ratios (OR) 
and their 95% confidence intervals (CI) for stroke and its subtypes by per standard deviation 
(SD) increase or decrease in retinal vascular parameters were calculated. We initially adjusted 
for age, sex, and race; and additionally for hypertension, diabetes, hypercholesterolemia and 
smoking history. As proposed previously, due to the high correlation between arteriolar and 
venular caliber values (Pearson’s correlation coefficient: 0.691, p<0.001), all models testing 
vessel caliber were additionally adjusted for the companion vessel. Finally, all fully-adjusted 
models were additionally adjusted for the presence of retinopathy signs, in order to examine 
whether the associations between retinal vascular parameters and stroke were independent of 
retinopathy signs, which are considered to be a relatively late marker of microvascular 
damage. All analyses were carried out using SPSS version 17.0. 





Amongst the patients recruited into the Singapore component of the MCRS study, a total of 
557 patients were eligible for inclusion into this study, and 557 controls were subsequently 
selected from the SEED study cohorts by matching for 10-year age group, sex, and race. 
Comparisons of baseline characteristics between ischemic stroke cases and controls are 
presented in Table IV-1. In general, patients with ischemic stroke were more likely to be 
current smokers, have hypertension, diabetes and hypercholesterolemia. The most common 
stroke subtype was lacunar infarction (n=261, 47.0%), followed by large-artery stroke (n=185, 
33.3%), and cardioembolic stroke (n=54, 9.7%), while the remaining 56 (10.1%) strokes were 
of other or undetermined causes.  
As shown in Table IV-1, and in Figure IV-1 and Figure IV-2, patients with ischemic stroke 
had relatively smaller fractal dimensions (total, arteriolar and venular), higher arteriolar and 
venular tortuosity and narrower arteriolar calibers. After adjustment for age, sex, race and the 
cardiovascular risk factors of hypertension, diabetes, hypercholesterolemia and smoking 
history (Table IV-2), decreasing arteriolar and venular fractal dimension, increasing arteriolar 
and venular tortuosity, narrower arteriolar caliber, and wider venular caliber were associated 
with ischemic stroke, while associations with other branching parameters such as branching 
angle were not significant.  
Associations of these parameters were similar with stroke subtypes of lacunar, large artery 
and cardioembolic stroke, with no observable differences in effect sizes between different 
stroke etiologies (Table IV-2). Furthermore, when fully adjusted models were additionally 
adjusted for presence of clinically visible retinopathy signs, decreasing arteriolar and venular 
fractal dimension, increasing arteriolar and venular tortuosity, and narrower arteriolar caliber 
remained significantly associated with stroke.  





In this study, we demonstrate for the first time that the structure and pattern of quantitatively 
measured microvasculature in the retina is different in patients with ischemic stroke compared 
to healthy control subjects. Novel retinal measures indicative of a sparser and more tortuous 
vascular network, in addition to narrower arteriolar caliber and wider venular caliber, were 
associated with ischemic stroke and with its major etiological subtypes, independent of 
traditional cardiovascular risk factors, and clinically visible retinopathy signs.  
Several studies have previously suggested that cerebral small vessel disease is implicated in 
ischemic stroke, and considered to be highly related to, but not restricted to lacunar 
infarction.[21] Pathological processes in the brain such as atherosclerosis, lipohyalinosis and 
arteriosclerosis lead to the destruction and occlusion of small perforating vessels,[21, 22] and 
cause vessel wall remodeling that results in elongated and tortuous vessels associated with 
increased vascular leakage.[21] These changes affect the ability of cerebral arterioles to 
maintain control of local blood flow, predisposing areas served by these dysfunctional vessels 
to ischemic damage. In the retina, vessel rarefaction and collapse which leads to reduction in 
vascular fractal dimension, is associated to hypoxia;[23] whereas increased vessel tortuosity 
is indicative of vessel wall dysfunction and blood-retinal barrier damage.[24, 25] Our findings 
suggest that similar pathological changes in the small vessels of the brain and retina may 
adversely affect perfusion and vessel wall function. Our study provides direct in vivo data that 
show a difference in the pattern and structure of the microvascular network between patients 
with stroke compared to healthy controls. 
To our knowledge, this is the first study to have studied a comprehensive assessment of 
quantitatively measured retinal microvascular parameters in stroke cases. Previous studies 
have identified individual associations with specific parameters. For example, the link 
between retinal fractal dimension and stroke has been reported.[26, 27] Our study shows that 
reduced retinal fractal dimension  and increased retinal vessel tortuosity is associated with 
ischemic stroke, suggesting that the retinal vascular network can reflect corresponding 
microvascular abnormalities indicative of reduced vascular perfusion and barrier damage 




leading to ischemic damage in the cerebral vasculature.[28] Furthermore, since these 
morphological changes in the retinal microvasculature are similarly associated with both 
large-artery stroke and lacunar infarcts in our study, it suggests that structural changes to 
retinal microvessels not only reflect small vessel pathology, but may also result from 
downstream effects of large artery pathology in the retinal and cerebral circulations.[9, 11] 
Importantly, we have demonstrated that similar changes in retinal pattern and geometry are 
also implicated in cognitive dysfunction and dementia,[29, 30] suggesting that similar 
cerebral microvascular pathologies - as reflected by alterations in the retinal microvasculature 
– may underlie both stroke and dementia.  
The most studied parameter is retinal vascular caliber, and our study is consistent with 
previous population-based studies, which show narrower arteriolar caliber and wider venular 
caliber is associated with ischemic stroke. However, due to pulse period variation in vessel 
calibers,[31] measurements from a single time point may not be as useful in stroke risk 
stratification, and less time-variable structural retinal parameters may be more informative in 
evaluating cerebral microvascular damage. Fractals and tortuosity measures are attractive as 
they are relatively static, and reflect blood distribution optimality and efficiency; and in our 
study we found that subtle changes measured by these parameters remain associated with 
stroke even after adjustment for visible retinopathy signs. Hence, these novel structural 
parameters have potential advantages beyond that of qualitative signs. These should definitely 
be further validated and studied in prospective studies. 
Several limitations need to be discussed. Firstly, as we had no data on hemorrhagic strokes, 
we could only focus on ischemic stroke. Secondly, because patients were required to sit 
upright for retinal photography, we were limited to patients with relatively mild strokes. 
Thirdly, the definition of cardiovascular risk factors was not exactly similar in cases (fasting 
blood samples) and controls (random blood samples), confounding may not have been fully 





determine the temporal sequence of these associations.  Further longitudinal studies are 
required to establish whether changes in retinal vascular geometry are related with the risk of 
incident stroke and whether they are indeed indicative of cerebrovascular risk beyond 
conventional risk indicators. Strengths of our study include the large sample size, population-
matched controls, and objective measurement of quantitative retinal vascular parameters. 
Retinal vascular changes reflective of a sparser and more tortuous network in the 
microcirculation are seen in patients with ischemic stroke, beyond the effects of age, vascular 
risk factors, and clinically visible retinopathy signs. These data provide convincing evidence 
of global alterations in the retinal microvasculature in stroke. Furthermore prospective studies 
are required to confirm these associations before they can be implemented as a screening tool. 
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CHAPTER IV TABLES  
Table IV-1. Comparison of baseline characteristics and retinal geometric parameters in stroke 








Demographics and cardiovascular risk factors  
Male, n (%) 356 (63.9%) 356 (63.9%) 1.000 
Age (years), mean (SD)  61.9 (9.36) 61.9 (9.11) 0.988 
Chinese race, n (%) 451 (81.0) 451 (81.0) 1.000 
Malay race, n (%) 63 (11.3) 63 (11.3) 
Indian race, n (%) 43 (7.7) 43 (7.7) 
Never smoker, n (%) 274 (50.9) 396 (71.1) <0.001 
Ex-smoker, n (%) 92 (17.1) 112 (20.1) 
Current smoker, n (%) 163 (30.3) 49 (8.8) 
Hypertension, n (%) 377 (67.8) 235 (42.2) <0.001 
Diabetes, n (%) 226 (40.6) 60 (10.9) <0.001 
Hypercholesterolemia, n (%) 259 (46.5) 219 (39.7) 0.025 
Retinal Vessel Parameters, mean (95%CI)  
Total Fractal Dimension 1.379 (1.373-1.385) 1.421 (1.416-1.425) <0.001 
Arteriolar Fractal Dimension 1.153 (1.147-1.159) 1.198 (1.193-1.203) <0.001 
Venular Fractal Dimension 1.185 (1.179-1.190) 1.208 (1.204-1.213) <0.001 




0.646 (0.622-0.670) 0.605 (0.592-0.618) 0.003 




0.852 (0.835-0.869) 0.785 (0.769-0.802) <0.001 
Arteriolar Caliber 127.8 (126.7-128.8) 134.5 (133.1-135.9) <0.001 
Venular Caliber 198.6 (197.0-200.2) 199.4 (197.4-201.4) 0.564 
Arteriolar branching angle () 75.2 (74.1-76.3) 75.7 (74.8-76.6) 0.511 
Venular branching angle () 77.5 (76.4-78.6) 77.8 (76.8-78.7) 0.720 
Presence of retinopathy signs, n 
(%) 
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*Adjusted for age, sex, race, arteriolar and venular caliber.  
†Adjusted for age, sex, race, smoking status, hypertension status, diabetes status, and hypercholesterolemia status.  
‡ Adjusted for age, sex, race, smoking status, hypertension status, diabetes status, hypercholesterolemia status and retinopathy signs. 
§Additionally adjusted for other vessel caliber. 
 




CHAPTER IV FIGURES  
Figure IV-1: Retinal fractal dimensions in an acute stroke patient and control subject 
Retinal fundus photo grading by semi-automated computer software (SIVA) showing vessel 
path tracing of images from a stroke patient (A) and a healthy control subject (B), with fundus 
image on the left and vessel path tracing for fractals on the right. Stroke patient (A) has a 







Figure IV-2: Retinal vessel tortuosity in an acute stroke patient and control subject 
Retinal fundus photo grading by semi-automated computer software (SIVA) showing vessel 
path tracing of images from a stroke patient (A) and a healthy control subject (B), with fundus 
image on the left and magnified image of vessel path tracing for arterioles (red) and venules 
(blue) on the right. Stroke patient (A) has more tortuous venules compared to the healthy 
control (B).   
 





CHAPTER V:  
MICROVASCULAR NETWORK ALTERATIONS IN RETINA 






In addition to Alzheimer’s disease (AD), cerebrovascular disease is an important cause and 
contributor to cognitive decline and dementia.[1, 2] Magnetic resonance imaging (MRI) has 
become increasingly important in unraveling the role of vascular pathology involved in 
cognitive impairment and dementia. Improvements in MRI hard- and software have made it 
possible to visualize brain pathology more accurately. Recently, cerebral microbleeds (CMB) 
detected on MRI have been suggested as another manifestation or marker of cerebral small 
vessel disease, in addition to traditional markers such as white matter lesions (WML) and 
lacunar infarcts.[3]  
However, direct in vivo visualization of the involvement of cerebral small vessels is difficult 
to achieve. As the retinal and cerebral microvasculature share several anatomical and 
physiological features,[4-6] the retina may provide a non-invasive “window” into the status of 
these small cerebral vessels. Previous studies have shown that clinically visible retinopathy 
signs are associated with an increased risk of clinical cerebrovascular disease,[7-9] including 
stroke and dementia, and subclinical markers of cerebral small vessel disease.[10-12] 
Furthermore, quantitative changes in retinal vessel width, such as narrower arteriolar caliber 
and wider venular caliber, have been shown to be associated with these subclinical and 
clinical age-related brain pathologies.[11-14] 
More recently, a series of quantitative retinal vascular parameters such as fractal dimension 
and tortuosity have been proposed to provide information on the cerebral microvasculature 
even before the appearance of retinopathy signs. For example, it has been shown that both 
patients with ischemic stroke and those with AD have a sparser and more tortuous 
microvascular network in the retina [15, 16], suggesting that AD and stroke may share similar 
underlying microvascular pathology. However, data on the association between these retinal 
vascular parameters and cerebral small vessel disease, in particular CMB, are largely lacking. 




Therefore, we investigated whether there was a link between these quantitative retinal 
parameters and cerebral small vessel disease on MRI. 
2. METHODS 
2.1 Study population 
The Epidemiology of Dementia in Singapore (EDIS) study draws participants from the 
Singapore Epidemiology of Eye Disease (SEED) Study, which is a population-based study 
among Chinese, Malays and Indians.[17, 18] In the present study we restricted analysis to the 
Chinese component of EDIS, as the recruitment of the other ethnicities is still ongoing. In 
order to use the limited resources in an efficient way, it was decided to focus on those 
subjects who were most likely to have some cognitive problems. Hence, in the first phase of 
the EDIS Study, Chinese participants from SCES aged ≥ 60 years (n=1,538) were screened 
using the 10-point Abbreviated Mental Test (AMT) and a self-report of progressive 
forgetfulness. Screen-positives were defined as AMT score ≤ 6, among those with ≤ 6 years 
of formal education, or ≤ 8 among those with > 6 years of formal education;[12] or if the 
subject or caregiver reported progressive forgetfulness [yes/no].[13] Screen-positive subjects 
(n=612) were invited to take part in the second phase of this study, which included an 
extensive neuropsychological test battery and brain magnetic resonance imaging (MRI). Of 
these 612 participants, 300 agreed to participate in phase II and hence were included in the 
present study. The details of the study methodology have been described elsewhere.[19] 
Ethics approval for the EDIS study was obtained from the SingHealth Institutional Review 
Board and the National Healthcare Group Domain-Specific Review Board. The study was 
conducted in accordance with the Declaration of Helsinki. Written informed consent was 
obtained prior to recruitment.   
2.2 Assessment of retinal vascular parameters 
Retinal fundus photographs were taken from each eye after pupil dilation and graded 





vascular parameters were extracted and used for analysis: retinal vascular caliber, fractal 
dimension, and tortuosity. Details of these parameters and reliability assessment have been 
described in Chapter III and previously elsewhere.[15, 20] 
2.3 Neuroimaging 
MRI was performed on a 3 Tesla Siemens Magnetom Trio Tim scanner, using a 32-channel 
head coil, at the Clinical Imaging Research Centre of the National University of Singapore. 
Subjects with claustrophobia, contraindications for MRI, or those who were unable to tolerate 
the procedure were excluded. All MRIs were graded by one radiologist and two clinicians 
blinded to the neuropsychological and clinical data. Any disagreement was brought to 
consensus for the final decision. The following MRI markers were collated for each subject: 
1. Presence of lacune was defined on T2-weighted (repetition time [TR] = 3000ms, time to 
echo [TE] = 10.1ms, matrix = 256x247 mm
3
) and Fluid Attenuated Inversion Recovery 
(FLAIR) images (TR = 9.3ms, TE = 140ms, matrix = 256x192 mm
3
) using the University of 
Edinburgh Neuroimaging stroke scale.[21, 22] The inter- and intrarater reliability as 
expressed by kappa statistic ranged from 0.59 to 0.80. 
2. CMB were graded based on location, size and number on Susceptibility Weighted Imaging 
(SWI) Sequence (TR = 27 sec, TE, 20 sec; image matrix, 192x256mm
3
) using the Brain 
Observer Microbleed Scale.[23] CMB were also categorized into one of three locations: lobar 
(cortical gray-white junction, subcortical white matter), deep (basal ganglia, internal and 
external capsules and thalamus) and posterior fossa (brainstem and cerebellum). Inter-rater 
and intra-rater reliability as expressed by kappa statistic ranged from 0.78 to 0.89. 
3. Total brain volume, and total intracranial volume were quantified by automatic brain tissue 
segmentation from Proton density weighted T1 and T2 weighted images, while white matter 
lesion volumes were automatically segmented using FLAIR images, as described 
previously.[24-26] 




2.4 Assessment of other vascular risk factors 
Demographic and vascular risk factors including age, sex, smoking, hypertension, diabetes, 
hyperlipidemia, height and weight were collected and verified by medical records. Blood tests 
included full blood count, fasting blood glucose and serum lipids including total cholesterol. 
Systolic and diastolic blood pressures were measured using a digital automatic blood pressure 
monitor (OMRON-HEM 7203, Japan) after resting for five minutes. Mean arterial blood 
pressure was calculated as two-thirds of the diastolic blood pressure plus one-third of the 
systolic blood pressure. Subjects were categorized into non-smokers and smokers (past and 
current smokers). Body mass index (BMI) was defined as weight in kilograms divided by 
height in meters squared. Hypertension was defined as systolic blood pressure ≥140 mmHg 
and/or diastolic blood pressure ≥90 mmHg or use of anti-hypertensive medication. Diabetes 
was defined as HbA1c ≥6.5%, or receiving treatment for diabetes. Hyperlipidemia was 
defined as total cholesterol ≥4.14 mmol/l or use of lipid-lowering medications. 
2.5 Statistical analysis  
Quantitative retinal vascular measures (retinal vascular caliber, fractal dimension, and 
tortuosity) from arterioles and venules were used as determinants and expressed as per 
standard deviation (SD) increase or decrease, whereas markers of cerebral small vessel 
disease were taken as outcomes. To examine the associations with lacunar infarcts and CMBs, 
logistic regression was used. As WML volumes were not normally distributed, values were 
log-transformed. Linear regression was used to model log-transformed WML volumes. These 
models were initially adjusted for age and sex, additionally for smoking, body mass index, 
mean arterial blood pressure, fasting blood glucose and total cholesterol; and finally for other 
MRI markers. In order to examine the robustness of any association with CMB, we decided to 
use different categorizations for CMB, as described previously:[2] (a) multiple (≥2) versus 
none/single (<2) CMB, (b) multiple categories of CMBs (0, 1 or ≥ 2) and (c) CMB counts 





the goodness-of-fit criterion assessed with the Pearson’s Chi-square statistic. For all the 
models, association measures were expressed with the corresponding 95% confidence 
intervals (CI). All statistical analyses were performed on standard statistical software (SPSS 
Version 17, SPSS Inc., USA). 
3. RESULTS  
Out of the 300 subjects who participated in the second phase of the EDIS Study, 39 subjects 
were excluded from the analysis: 18 had no MRI scans (due to claustrophobia, or 
contraindications), and 21 subjects did not have gradable retinal photographs. Baseline 
characteristics of the remaining 261 subjects are shown in Table V-1. In summary, 46 
subjects had evidence of ischemic stroke on their MRI scan, of whom 36 had lacunes; while 
83 subjects had CMB present, of whom 33 had multiple CMB, including 2 subjects who had 
more than 20 CMB (23 and 43 CMBs). The median WML volume was 1.90 (interquartile 
range: 4.48) ml. Figure V-1 shows the prevalence of these markers of cerebral small vessel 
disease stratified according to 5-year age categories. All MRI lesions showed a higher 
prevalence with increasing age. Comparing the frequency of these MRI lesions across 
different age categories, CMBs were more prevalent in the younger age categories compared 
to lacunes, whereas in those aged ≥80 years, the prevalence of CMB and lacunes were 
comparable. Although WML volume is not directly comparable across age categories with the 
other markers, the median WML volume in the youngest category was relatively small and 
showed a steep increase at older age. 
Table V-2 describes age and sex-adjusted associations of retinal vascular parameters with 
log-transformed WML volumes, and the presence of lacunes and multiple CMB. The 
presence of lacunes was not associated with any retinal vascular parameters. WML volume 
was initially associated with increasing venular caliber in age and sex-adjusted models (Table 
V-2), while multiple CMB was associated with narrower arteriolar caliber, wider venular 
caliber and reduced arteriolar fractal dimensions. However, associations with WML were 




attenuated when adjusted for smoking, body mass index, mean arterial blood pressure, fasting 
blood glucose and total cholesterol; and further when including MRI markers. Associations 
with multiple CMB remained consistent, after adjustment for vascular risk factors and MRI 
markers (Table V-3). Similar associations were observed when different categorizations of 
CMBs were used. In addition to narrower arteriolar caliber, wider venular caliber, and smaller 
arteriolar fractal dimension, analyses using Poisson regression models, showed that higher 
arteriolar tortuosity was also associated with an increasing number of CMBs (Table V-3). 
Figure V-2 shows examples of subjects with CMB who had relatively smaller fractal 
dimension and higher tortuosity compared to subjects without CMB. 
4. DISCUSSION 
In this study, elderly persons with a sparser and more tortuous retinal vascular network were 
more likely to have CMBs, independent of vascular risk factors and other cerebral markers 
such as WML and lacunes. These data suggest that early retinal changes may provide insight 
into specific early markers of cerebral small vessel disease, such as CMBs. 
Thus far there have been no data from population-based studies examining the link between 
these retinal vascular paramters and CMBs. Though, using the same latest computer-assisted 
method to measure the retinal microvasculature, we did recently observe similar retinal 
microvascular network changes (a sparser and more tortuous retinal network) in patients with 
stroke and Alzheimer’s disease,[15, 16] suggesting that both clinical outcomes and subclinical 
pathology on MRI may share similar underlying microvascular mechanisms. Furthermore, 
there are several reports describing rare hereditary conditions involving both retinal and 
cerebral microvessels including cerebroretinal vasculopathy, hereditary endotheliopathy with 
retinopathy, nephropathy and stroke (HERNS), cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leucoencephalopathy (CADASIL) and hereditary retinal 
arteriolar tortuosity. For example, persons with CADASIL have a decreased retinal vascular 





arteriolar tortuosity, besides the presence of retinal arteriolar tortuosity and retinal 
hemorrhages, CMBs have been observed on MRI.[28] Although these studies in rare 
hereditary conditions affecting the retinal and brain microvessels consist of small numbers or 
case series, these data do provide initial evidence that these retinal parameters such as fractal 
dimension or tortuosity may be early markers of microvascular pathology in the brain 
reflected on MRI lesions such as CMBs. Taken together, findings from our current study 
further support data from histopathological studies that CMBs are a marker of microvascular 
pathology.[29] 
Most studies that have examined the link between retinal changes and cerebral small vessel 
disease have focused on clinically visible retinopathy signs and on WML and lacunar infarcts. 
Data from both the Atherosclerosis Risks in Communities Study and the Cardiovascular 
Health Study reported that persons with retinopathy signs were more likely to have both 
WML and MRI-defined subclinical infarcts.[10-12] More recently, the AGES-Reykjavik 
Study reported that among a large community-based cohort of 4,218 older adults, traditional 
retinopathy signs were associated with the presence of multiple CMB.[30] These associations 
were present independent of major potential confounders, including high blood pressure, 
ischemic brain lesions, and other vascular factors. Taken together, these studies provided 
evidence that microvascular lesions in both the retina and the brain may occur concomitantly 
as part of generalized microvascular disease resulting from common pathophysiological 
mechanisms. Retinopathy signs are, however, relatively late indicators of target organ damage 
in the eye and probably reflect advanced stages of structural microvascular damage including 
breakdown of the blood-retina barrier (Figure V-3; blue line).  
Initial studies using the computer analysis techniques focused on earlier markers such as 
generalized arteriolar narrowing and venular dilatation. Longitudinal data from the Rotterdam 
Study showed that specifically wider venular caliber was associated with progression of both 
periventricular and subcortical white matter lesions, and incident lacunar infarcts on MRI.[14] 
However, in the cross-sectional analyses from this study there was no statistically significant 




association between retinal calibers and these markers of cerebral small vessel disease. The 
lack of an association in the cross-sectional analyses may suggest that early changes in the 
retinal microvasculature (e.g. venular dilatation) do not reflect the actual severity of cerebral 
small vessel disease, but may precede the development of WML and lacunes. Furthermore, in 
our cohort we found that in contrast to WML and lacunes, prevalence of CMB was already 
high at a younger age, suggesting that CMBs may manifest before the appearance of the other 
cerebral small vessels disease markers. These data are in accordance with observations made 
in the spontaneously hypertensive stroke-prone (SHRSP) rat model showing that the 
development of CMBs as an important early milestone in the pathogenesis of cerebral small 
vessel disease.[31] Overall, our current analyses are that these newer retinal vascular 
parameters such as fractal dimension and tortuosity showed a significant cross-sectional 
association with CMBs, but not with more traditional makers of cerebral small vessel disease 
(Figure V-3; green line). Finally, our findings suggest that although these MRI lesions can 
occur concomitantly and increase with advancing age, there may be differences in 
pathophysiology underlying these lesions.  
Several methodological issues need to be discussed. Firstly, nearly 50% of screen-positive 
subjects did not participate in the second phase of the EDIS study, as described previously.[19] 
Those (n=312) who did not participate were relatively older and had higher mean arterial 
blood pressure. This might have led to an underestimation of the prevalence of MRI markers 
of cerebral small vessel disease, and obscured associations between WML and lacunes with 
retinal vascular parameters. Thus, the association between retinal parameters and CMB that 
was found may be underestimated. Secondly, also due to small numbers, we were not able to 
study in detail the associations with the specific location of CMB. Strengths of our study 
include quantitative assessment of retinal photographs using standardized protocols, and 
quantitative measurement of MRI markers such as white matter lesion volume. 
In conclusion, we report that elderly persons with early retinal changes such as a sparser and 





independent of cardiovascular risk factors and other markers of small vessel disease on MRI. 
This provides further evidence that CMB may be an early manifestation of cerebral small 
vessel disease.  
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CHAPTER V TABLES 
Table V-1: Baseline characteristics of study participants  
Baseline characteristics Mean (SE)/ n (%) 
Age, years  70 (0.4) 






Hypertension, 196 (75.1) 
Diabetes,  69 (26.4) 
Hyperlipidemia,  154 (59.0) 
Systolic blood pressure, mmHg  147.0 (1.2) 
Diastolic blood pressure, mmHg  76.7 (0.7) 
Mean arterial blood pressure, mmHg  100.2 (0.7) 
Fasting blood glucose, mmol/l  5.1 (0.09) 
Fasting total cholesterol, mmol/l  4.9 (0.05) 







Table V-2: Distribution of MRI markers expressed as number (%) with presence of discrete 
MRI markers and mean (standard error) of volumetric MRI markers in study participants.  
Neuroimaging (n=261) Mean (SE)/ n (%) 
Discrete MRI markers 
Presence of ischemic stroke 
 
46 (17.6) 
Presence of lacunes  36 (13.8) 
Presence of any CMB 83 (31.8) 
Presence of multiple CMB 33 (12.6) 
 Isolated multiple lobar CMB 22 (8.4) 
 Isolated multiple deep and posterior fossa 
CMB 
Combined lobar, deep or posterior fossa CMB 
9 (3.4) 
2 (0.8) 
Volumetric MRI markers 
Total brain volume, ml 
 
895.6 (5.4) 
Total intracranial volume, ml 1096 (6.1) 
White matter lesion volume,* ml 1.90 (4.48) 
* Expressed as median (inter-quartile range) due to the skewed distribution  




Table V-3: Age-sex adjusted regression models of retina vascular parameters for white 
matter lesion (WML) volume, and multiple cerebral microbleeds (CMB≥2)  






OR (95% CI) 
(n=36/261) 
Presence of multiple 
CMBs† 
OR (95% CI) 
(n=33/261) 
Caliber 
Arteriolar, per SD 
decrease‡ 
0.32 (-0.05; 0.69) 1.26 (0.65; 2.45) 2.10 (1.06; 4.15) 
Venular, per SD 
increase‡  
0.38 (0.02; 0.75) 1.57 (0.83; 2.98) 2.29 (1.19; 4.40) 
Fractal dimension, per SD decrease 
Arteriolar  0.06 (-0.16; 0.27) 1.31 (0.90; 1.91) 1.89 (1.27; 2.82) 
Venular  -0.10 (-0.32; 0.12) 1.11 (0.95; 1.64) 1.30 (0.88; 1.92) 
Tortuosity, per SD increase 
Arteriolar  -0.05 (-0.27; 0.16) 0.78 (0.52; 1.17) 1.07 (0.73; 1.56) 
Venular  0.12 (-0.09; 0.33) 0.99 (0.67; 1.46) 0.94 (0.63; 1.40) 
Linear regression models with log-transformed WML volumes as the dependent variable. 
†Logistic regression models with the presence of lacunes or multiple CMB as the dependent 
variable. 







Table V-4: Multivariable-adjusted odds ratios (ORs) for the presence of multiple cerebral 
microbleeds (CMBs) and rate ratios (RRs) for CMB counts (with 95%CI) presented as per 
standard deviation difference in retinal parameters  
 
ORs for presence of multiple 
CMB 








OR (95% CI) 
(n=32/258) 
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Tortuosity, per SD increase     


















Multivariable-adjusted odds ratios for the presence of multiple cerebral microbleeds (with 
95% confidence intervals) 
†Multivariable-adjusted rate ratios for the cerebral microbleed counts (with 95% confidence 
intervals). Additionally, 2 outliers (subjects with 23 and 43 CMBs) were excluded to satisfy 
the goodness-of-fit criterion for Poisson regression models 
‡Model I: Adjusted for age, sex, smoking, body mass index, mean arterial blood pressure, 
fasting blood glucose and cholesterol  
§Model II: Adjusted for confounders from model I, and total white matter volume, total brain 
volume/total intracranial volume, and presence of stroke 
#Adjusted for fellow vessel caliber 
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Figure V-2: MRI scans and corresponding retinal photographs of study subjects 
MRI scans (A-D) showing absence (left column) or presence (right column) of cerebral 
microbleeds (CMB; white arrows) and retinal fundus photos graded by computer software 
(A'-D') showing vessel path tracing of images from participants, with red for arterioles and 
blue for venules. In a subject with CMB retinal arteriolar fractal dimension (C,C’) is smaller 
compared to a subject without CMB (A,A'). In another subject with CMB, retinal arteriolar 
tortuosity (D,D’) is higher compared to a subject without CMB (B,B').  
 




Figure V-3: Postulated timeline of retinal markers and neuroimaging markers in cognitive 
impairment 
Among preclinical imaging markers for cognitive impairment, white matter lesions and 
lacunar infarcts may be relatively “late” markers as they are related to retinopathy signs (blue 
line), whereas cerebral microbleeds are related to “early” retinal parameters such as fractal 
dimension and tortuosity (green line) and hence may be an early manifestation of cerebral 








CHAPTER VI:  
RETINAL MICROVASCULAR CHANGES IN ALZHEIMER’S 
DISEASE & VASCULAR DEMENTIA 





Microvascular pathology in the form of cerebral small vessel disease is a well-documented 
cause of vascular dementia (VaD),[1] and lesions such as lacunes, white matter lesions, and 
microbleeds are also common in Alzheimer’s disease (AD).[2] The presence of cerebral small 
vessel disease aggravates amyloid deposition and lowers the threshold of amyloid pathology 
required to cause symptomatic disease in AD.[3, 4] Despite the clinical differentiation 
between AD and VaD, these findings suggest that microvascular damage is a common theme 
in both major subtypes of dementia.  
Cerebral microvascular pathology is also related to ischemic stroke.[5-7] In particular, 
cerebral small vessel disease increases the risk of stroke and vascular-related mortality,[8-10] 
while stroke occurrence is also linked to progression of white matter lesions and lacunar 
infarcts.[11, 12] Although ischemic stroke is also a major risk factor for cognitive decline and 
dementia, it remains difficult to predict amongst stroke patients who will eventually develop 
dementia. Hence, studying the similarities and differences in microvascular pathology of 
ischemic stroke, AD and VaD may be the key to unravelling vascular mechanisms 
responsible for cognitive decline and dementia.  
One of the major barriers in studying cerebral microvascular pathology is the inability to 
directly observe the cerebral microvessels in vivo using neuroimaging techniques such as 
magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA). In contrast, 
the retinal blood vessels can be easily visualized non-invasively using simpler techniques 
such as digital fundus photography. Since the retinal blood vessels share anatomical, 
physiological and functional similarities with the small vessels of the brain, the retina presents 
a unique window from which we can indirectly assess cerebral microvascular damage.[13]  
Large population-based studies have separately shown that microvascular damage in the form 
of retinopathy signs is associated with cerebrovascular disease (both stroke and cerebral small 





retinal vascular parameters, such as vessel caliber, fractal dimensions and tortuosity have also 
found similar patterns in retinal microvascular changes in association with early cognitive 
impairment, AD, and even acute stroke.[19-22] However, it remains unknown if the retinal 
microvasculature in AD with significant cerebrovascular disease (CeVD) and VaD is affected 
differently from those with only AD. Also it remains unclear if retinal microvascular changes 
in AD and VaD are any different from subjects with only cerebrovascular disease (e.g. acute 
stroke) but no dementia. 
In this case-control study, we first examined the associations of retinal vascular parameters 
with the dementia subtypes of AD without CeVD, AD with CeVD, and VaD in comparison 
with non-demented, non-stroke population-based controls. Next, we directly examined if 
retinal vascular changes in these subtypes of dementia were different from patients with acute 
ischemic stroke.  
2. METHODS  
2.1 Study population  
Patients diagnosed with dementia syndrome (Alzheimer’s type and Vascular dementia) in 
accordance to the Diagnostic and Statistical Manual of Mental Disorders, 4
th
 edition (DSM-IV) 
criteria were recruited from dementia/memory clinics at three tertiary hospitals in Singapore 
(National University of Hospital, Khoo Teck Puat Hospital and Singapore General Hospital), 
between July 2009 and August 2013. All patients underwent neuropsychiatric assessment and 
were assessed clinically by neurologists and geriatricians. Computed tomography (CT) and 
magnetic resonance imaging (MRI) scans, when available, were also reviewed as part of the 
diagnostic process. All AD cases complied with the National Institute of Neurological 
Disorders and Stroke-Alzheimer disease and Related Disorders (NINCDS-ADRDA)[23] and 
VaD cases also complied with the National Institute of Neurological Disorders and Stroke and 
Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-
AIREN) criteria.[24]  




CT/MRI scans of dementia patients closest to the date of recruitment were reviewed for the 
presence of cerebrovascular disease. AD cases with presence of previous infarct or lacunes on 
neuroimaging, and/or presence of white matter lesions equivalent to or more than a score of 8 
on the Age-Related White Matter Changes (ARWMC) scale[25] were considered to have 
significant cerebrovascular disease (CeVD). Severity of cognitive impairment was assessed 
using the Clinical Dementia Rating scale. Patients aged 45-85 years, and of Chinese, Malay or 
Indian ethnicity, with gradable quality retinal photographs were eligible for matching to 
stroke patients and non-stroke controls. 
Non-cognitively impaired, non-stroke controls were selected from the Singapore 
Epidemiology of Eye Disease program, which included the Singapore Chinese Eye Study, the 
Singapore Malay Eye Study, and the Singapore Indian Eye Study.[26, 27] SEED participants 
above 60 years of age were screened for cognitive impairment using the Abbreviated Mental 
Test (AMT), which has been modified and validated for Singapore elderly.[28, 29] 
Participants were eligible for selection if they did not fail the AMT, had no self-reported 
history of stroke, and had retinal photographs of gradable quality. Non-stroke controls were 
matched to dementia cases by sex, ethnicity and 5-year age group. 
Patients with acute stroke were selected from the Multi-Centre Retinal Stroke (MCRS) study, 
a cross-sectional observational study of patients with acute ischemic stroke. For this study, 
only patients from the Singapore site were included. Patients presenting to the Singapore 
General Hospital with first-ever or recurrent stroke within 7 days of onset were recruited from 
2005 to 2007, and were assessed by a standardized questionnaire with an interview conducted 
by trained medical staff, a neurological examination, and brain imaging (CT or MRI). Details 
of the study have been described elsewhere.[21] Participants were eligible for selection if they 
were aged 45-85 years, and had gradable quality retinal photographs. As there were 
insufficient stroke patients available for matching to all eligible dementia cases, a subset of 
128 dementia patients with matches to 128 acute stroke patients by sex, ethnicity and 5-year 





Written, informed consent was obtained from each participant; the study conducted adhered 
to the Declaration of Helsinki. Ethics approval was obtained from the Singhealth Institutional 
Review Board and National Healthcare Group Domain Specific Review Board. 
2.2 Assessment of retinal vascular parameters   
All participants had retinal photographs were taken from each eye and graded according to a 
standardized protocol as described in Chapter III. Quantitative vascular parameters for 
arteriolar and venular caliber, fractal dimension and tortuosity were extracted and used for 
analysis. Assessment of these quantitative parameters was not influenced by the presence of 
localized retinopathy signs. Additional details have been described elsewhere.[21, 30] 
2.3 Assessment of other risk factors 
Hypertension, diabetes, and hypercholesterolemia status in dementia patients were obtained 
from their referring physician during recruitment, while detailed information on history of 
anti-hypertensive medication, anti-diabetic drugs, insulin use, cholesterol-lowering 
medication, smoking, angina and acute myocardial infarction was collected at the study 
interview with the patient and their primary caregiver. Acute stroke subjects underwent 
standard clinical assessment after the acute phase for stroke to determine cardiovascular risk 
factors, including multiple blood pressure measurements, and fasting blood samples for 
glucose, HbA1C and lipids, as part of clinical care for stroke. Control subjects, as part of the 
SEED protocol, were administered a detailed questionnaire by trained interviewers to obtain 
detailed information on medical history, and underwent an extensive examination, as 
described elsewhere.[26, 27]  
Hypertension was defined as systolic blood pressure of 140 mmHg or more, or diastolic blood 
pressure of 90 mmHg or more at examination, a reported history of physician-diagnosed 
hypertension or a self-reported history of anti-hypertensive medication use, or both. Diabetes 
was defined as random blood glucose of 200mg/dL (11.1mmol/L) or more, fasting blood 
glucose of 126mg/dL (7.0mmol/L) or more, HbA1C of 7% or more, self-reported history of 




physician-diagnosed diabetes or self-reported history of anti-hyperglycemic medication use. 
Hypercholesterolemia was defined as total cholesterol of 6.2mmol/l or more, or a self-
reported history of physician-diagnosed hypercholesterolemia, or self-reported use of 
cholesterol-lowering medication. Smoking status was categorized as never, past and current. 
History of ischemic heart disease was defined as a having previous history of either angina or 
acute myocardial infarction.  
2.4 Statistical analysis  
Dementia patients were classified into the following subtypes: AD without CeVD, AD with 
CeVD, and VaD. Baseline demographic characteristics and prevalence of risk factors were 
compared between dementia subtypes and matched non-stroke controls, and between 
dementia subtypes and matched acute stroke subjects using the analysis of variance (ANOVA) 
for continuous variables and Pearson’s chi-square test for categorical variables. Retinal 
vascular parameters were compared between dementia subtypes using analysis of covariance 
(ANCOVA), adjusting for age, sex, and ethnicity; additionally for history of hypertension, 
diabetes, hypercholesterolemia, and smoking status. Odds ratios (OR) and their 95% 
confidence intervals (CI) by per standard deviation (SD) change in the retinal vascular 
parameters of vessel caliber, fractal dimensions, and tortuosity were calculated for each 
dementia subtype separately for both arteriolar and venular measures using controls and acute 
stroke patients as the reference group. Logistic regression models were adjusted for age, sex, 
and ethnicity; and additionally for history of hypertension, diabetes, hypercholesterolemia, 
and smoking status. All models for arteriolar and venular caliber were further adjusted for 
other vessel caliber. All statistical analysis was performed using standard statistical analysis 
software (Stata 11; StataCorp LP, USA).  
3. RESULTS  
Of the dementia patients recruited, a total of 151 were eligible for inclusion into this study, 





SEED. Dementia cases were further classified into three subtypes of dementia - AD without 
CeVD (n=62), AD with CeVD (n=47), and VaD (n=42). Baseline characteristics and risk 
factor profiles of dementia patients by subtype and in comparison to controls from SEED are 
presented in Table VI-1. In brief, patients with dementia were more likely to be hypertensive 
or diabetic compared to controls. Patients with AD without CeVD were less likely to be 
smokers.   
Logistic regression models of dementia subtypes using non-demented, non-stroke controls as 
the reference group showed that all three subtypes of dementia was associated with narrower 
retinal venules and increased arteriolar and venular tortuosity, while only AD without CeVD 
was associated with narrower retinal arterioles (Table VI-2). Dementia related to CeVD (AD 
with CeVD and VaD) was associated with decreasing arteriolar fractal dimensions, AD-
related dementia (AD without CeVD and AD with CeVD) was associated with decreasing 
venular fractal dimensions (Figure VI-1). 
Direct comparison of retinal vascular parameters between AD without CeVD, AD with CeVD, 
and VaD cases showed that there was no significant difference between the dementia 
subtypes except for venular tortuosity. Venular tortuosity was significantly higher in AD 
without CeVD compared to VaD in pairwise comparisons (multivariable adjusted mean 






). There was no significant 
association of retinal vascular parameters with severity of dementia as assessed by global 
CDR. 
A subset of 128 dementia patients were matched to 128 acute stroke patients for the next 
analysis. Comparison of baseline characteristics between selected dementia patients by 
subtype and matched acute stroke patients are presented in Table VI-3. Briefly, VaD patients 
were slightly younger, and more likely to have hyperlipidemia, while patients with AD 
without CeVD were less likely to be smokers.  




Using logistic regression models to compare each dementia subtype to patients with acute 
stroke (Table VI-4), all three subtypes were significantly associated with narrower retinal 
venules, and increased arteriolar and venular tortuosity (Figure VI-2). Additionally, while 
VaD was associated with higher venular fractal dimension compared to stroke, there was no 
significant association with arteriolar fractal dimensions.  
4. DISCUSSION 
In this study, we demonstrated that compared with non-cognitively impaired persons, patterns 
of retinal microvascular changes in AD without CeVD, AD with CeVD and VaD were largely 
similar to each other. Secondly, we observed that there were significant differences in retinal 
microvascular changes observed in AD and VaD compared to acute ischemic stroke.  
A few population-based studies and case-control studies have shown that retinal 
microvascular changes are associated with dementia.[19, 31, 32] However, associations of 
these retinal vascular changes in relation to different subtypes of dementia have yet to be 
demonstrated. In this study, we show that microvascular damage in the form of a sparser 
retinal vessel network (reduced fractal dimensions), more tortuous retinal vessels, and 
narrowing of the retinal venules, are similarly associated with AD without CeVD, AD with 
CeVD, and VaD. These findings are consistent with previous studies in retinal vascular 
changes in AD, and also in line with previous studies showing that reduced fractal dimensions 
are associated with early cognitive impairment and cerebral small vessel disease.[20, 22, 33]  
Retinal vascular changes, quantified easily and objectively from retinal vascular imaging, are 
potential markers of concomitant changes in the cerebral microvasculature.[13] Since changes 
in retinal vascular parameters were largely similar across dementia subtypes, this supports the 
hypothesis that there are indeed similar and overlapping cerebral microvascular pathology 
underlying both AD and VaD – as reflected by the structural changes in the retinal 
microvasculature. However, the currently studied retinal vascular parameters do not appear to 





Retinal vascular changes as markers of microvascular pathology have been linked to dementia 
and stroke independently. We previously reported that reduced vascular fractal dimensions 
and increased vessel tortuosity in arterioles and venules were associated with AD and major 
subtypes of ischemic stroke in separate studies, suggesting that AD and stroke may share 
similar underlying microvascular pathology.[19, 21] In this study, by directly comparing 
dementia patients with acute stroke patients, we found that reduction of vascular fractal 
dimensions in AD without CeVD, AD with CeVD, and VaD was comparable to that in acute 
stroke. Combined with previous findings that reduced retinal vascular fractal dimensions is 
also associated early cognitive impairment,[20, 22] this suggests that reduction in fractal 
dimensions may be an early marker of cognitive impairment which may not progress beyond 
a certain point.[34, 35] In contrast, both arteriolar and venular tortuosity was compounded in 
all three subtypes of dementia compared to that in acute stroke, mirroring histological 
changes in the cerebral microvasculature of patients with AD and cerebral small vessel 
disease.[36, 37] Hence, suggesting that vessel wall dysfunction and barrier is prolonged and 
progresses with the development of dementia.[38, 39]  
Our findings also highlight that while acute stroke was associated with wider retinal venules, 
both AD and VaD was consistently associated with narrower retinal venules. This association 
with vessel narrowing was persistent even in the in the presence of concomitant 
cerebrovascular disease. This raises the possibility of a separate mechanism affecting 
microvascular perfusion in dementia,[35, 40] and presents venular narrowing as a potential 
marker for dementia. The patterns of retinal microvascular changes in dementia (AD and VaD) 
highlight that microvascular pathology occurs early in cognitive decline, overlaps with 
cerebrovascular disease, and progresses with the development of dementia. Our study 
provides further support for the vascular hypothesis in dementia and AD, and suggests that 
modification of vascular risk factors may be important in preventing or delaying dementia.[41]  
To the best of our knowledge, this is first study to have directly compared retinal 
microvascular changes in AD and VaD with stroke. Additional strengths of this study are that 




CT/MRI scans were reviewed to objectively determine the presence of CeVD in patients with 
dementia, and that a relatively large sample size of dementia patients with varying severity of 
AD and VaD was captured. The limitations of our study are: First, since participants of the 
SEED studies did not undergo CT and MRI scans and stroke history was only ascertained 
through patient interview, we could not eliminate the possibility that there may be a 
proportion of selected controls with subclinical underlying cerebrovascular disease. Also, as 
acute stroke patients were not screened for cognitive impairment, we assumed that they have 
not developed dementia. However, any possible misclassification would have resulted in bias 
towards the null hypothesis, suggesting that actual effects may have been stronger. Second, 
our dementia patients had varying types of CeVD, ranging from cortical or strategic strokes to 
predominant small vessel disease, and a single classification of significant CeVD was used. 
Current numbers limited the ability to evaluate differential effects of large artery disease and 
small vessel disease on the microvasculature in the AD and VaD groups. Third, although we 
could ascertain the presence of CeVD in patients with AD, we could not eliminate the 
possibility that a proportion of VaD patients may have AD pathology, since amyloid imaging 
or CSF biomarkers was unavailable. Nevertheless, as diagnostic criteria used (DSM-IV and 
NINDS-AIREN) were specific for VaD,[42] we are fairly confident that possible 
misclassification has been kept to a minimum. 
In conclusion, similar patterns of retinal microvascular changes in the major subtypes of 
dementia suggest that there may be similar vascular pathological mechanisms leading to 
cognitive decline in both AD and cerebrovascular disease. Additionally, vessel tortuosity in 
AD and VaD was significantly increased compared to those with acute stroke, even in 
patients with AD without CeVD; this suggests the presence of considerable microvascular 
damage in AD even in the absence of overt vascular disease. These data provide considerable 
evidence that there is substantial overlap in vascular pathology in both dementia and stroke 





microvasculature changes may be used to characterize cerebral microvasculature 
vulnerabilities early in persons-at-risk, such as those with cerebrovascular risk factors. 
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CHAPTER VI TABLES 
Table VI-1: Demographic and risk factor profiles of dementia patients by subtype in 












Age, mean (SD) 73.6 (6.0) 73.7 (4.8) 73.4 (5.0) 72.3 (8.2) 0.591 
Male, n (%) 77 (51.0) 29 (46.8) 25 (53.2) 23 (54.8) 0.856 
Chinese, n (%) 121 (80.1) 48 (77.4) 37 (78.7) 36 (85.7) 0.957 
Malay, n (%) 22 (14.6) 10 (16.1) 8 (17.0) 4 (9.5)  
Hypertension, n (%) 97 (64.2) 44 (71.0) 41 (87.2) 37 (88.1) 0.001 
Diabetes, n (%) 39 (25.8) 24 (38.7) 22 (46.8) 21 (50) 0.005 
Hyperlipidemia, n 
(%) 
88 (58.3) 37 (59.7) 32 (68.1) 33 (78.6) 0.085 
Ever smokers, n (%) 47 (31.1) 12 (19.4) 22 (46.8) 15 (35.7) 0.022 
CDR global=1, n (%) - 48 (78.7) 32 (68.1) 23 (60.5) 0.141 








Table VI-2: Multivariable adjusted odds ratios (95%CI) of retinal vascular parameters for the 











Caliber per SD decrease‡ 
Arteriolar 1.00 (ref) 1.91 (1.06-3.43) 1.82 (1.02-3.27) 1.37 (0.76-2.48) 
Venular 1.00 (ref) 4.72 (2.45-9.07) 2.97 (1.55-5.67) 2.66 (1.36-5.17) 
Fractal dimensions per SD decrease 
Arteriolar 1.00 (ref) 1.39 (1.01-1.94) 1.76 (1.23-2.51) 1.58 (1.09-2.29) 
Venular 1.00 (ref) 1.39 (1.01-1.91) 1.58 (1.11-2.26) 1.22 (0.85-1.74) 
Tortuosity per SD increase 
Arteriolar 1.00 (ref) 5.76 (3.66-9.07) 5.26 (3.30-8.39) 4.10 (2.56-6.57) 











Caliber per SD decrease‡ 
Arteriolar 1.00 (ref) 2.00 (1.08-3.69) 1.43 (0.78-2.65) 1.08 (0.57-2.05) 
Venular 1.00 (ref) 5.66 (2.84-11.3) 4.09 (2.02-8.29) 3.62 (1.75-7.49) 
Fractal dimensions per SD decrease 
Arteriolar 1.00 (ref) 1.36 (0.97-1.90) 1.76 (1.20-2.57) 1.49 (1.01-2.20) 
Venular 1.00 (ref) 1.40 (1.02-1.94) 1.75 (1.20-2.55) 1.30 (0.89-1.88) 
Tortuosity per SD increase 
Arteriolar 1.00 (ref) 6.22 (3.86-10.0) 5.37 (3.28-8.80) 4.33 (2.63-7.14) 
Venular 1.00 (ref) 8.37 (5.00-14.0) 4.56 (2.80-7.42) 4.57 (2.74-7.62) 
* Model I adjusted for age, sex, and race. 
† Model II adjusted for age, gender, and race, self-reported history of hypertension, diabetes, 
hypercholesterolemia, and smoking status. 






Table VI-3: Demographic and risk factor profiles of selected acute ischemic stroke subjects 
and matched dementia cases by subtype of dementia  












Age, mean (SD) 71.6 (6.1) 72.7 (4.6) 72.9 (4.8) 69.5 (7.4) 0.047 
Male, n (%) 64 (50.8) 23 (46.0) 23 (52.3) 18 (56.3) 0.830 
Chinese, n (%) 109 (86.5) 46 (92.0) 35 (79.6) 28 (87.5) 0.788 
Malay, n (%) 13 (10.3) 3 (6) 7 (15.9) 3 (9.4)  
Hypertension, n (%) 94 (74.6) 35 (70.0) 38 (86.4) 28 (87.5) 0.111 
Diabetes, n (%) 56 (44.4) 17 (34.0) 20 (45.5) 16 (50.0) 0.476 
Hyperlipidemia, n 
(%) 
64 (50.8) 29 (58.0) 30 (68.2) 26 (81.3) 0.009 
Ever smokers, n (%) 45 (37.5) 9 (18.0) 21 (47.7) 11 (35.5) 0.020 
CDR global=1, n (%) - 39 (79.6) 31 (70.5) 15 (53.6) 0.056 
CDR global≥2, n (%) - 10 (20.4) 13 (29.6) 13 (46.4)  
*P-values are calculated using ANOVA for continuous variables, and Pearson’s chi2 test for 
categorical variables 
 




Table VI-4: Multivariable adjusted odds ratios (95%CI) of retinal vascular parameters for the 
subtypes of dementia compared to acute stroke subjects. 
Model I* 









Caliber per SD decrease‡ 
Arteriolar 1.00 (ref) 1.17 (0.62-2.21) 1.08 (0.58-2.00) 1.19 (0.62-2.31) 
Venular 1.00 (ref) 7.36 (3.47-15.6) 5.30 (2.57-10.9) 3.53 (1.67-7.47) 
Fractal dimensions per SD increase 
Arteriolar 1.00 (ref) 1.45 (1.02-2.07) 1.13 (0.79-1.60) 1.23 (0.81-1.85) 
Venular 1.00 (ref) 1.17 (0.84-1.64) 1.06 (0.74-1.52) 1.53 (1.00-2.34) 
Tortuosity per SD increase 
Arteriolar 1.00 (ref) 2.77 (1.84-4.18) 2.34 (1.54-3.55) 1.93 (1.22-3.05) 
Venular 1.00 (ref) 4.14 (2.63-6.51) 3.05 (1.94-4.80) 3.21 (1.95-5.28) 
Model II† 









Caliber per SD decrease‡ 
Arteriolar 1.00 (ref) 1.38 (0.70-2.72) 0.90 (0.47-1.73) 1.02 (0.50-2.06) 
Venular 1.00 (ref) 9.36 (4.12-21.3) 7.84 (3.43-17.9) 5.20 (2.22-12.2) 
Fractal dimensions per SD increase 
Arteriolar 1.00 (ref) 1.33 (0.91-1.95) 1.04 (0.72-1.50) 1.18 (0.77-1.82) 
Venular 1.00 (ref) 1.18 (0.82-1.68) 1.03 (0.73-1.47) 1.58 (1.01-2.47) 
Tortuosity per SD increase 
Arteriolar 1.00 (ref) 2.66 (1.73-4.09) 2.30 (1.50-3.55) 1.86 (1.15-3.00) 
Venular 1.00 (ref) 4.50 (2.77-7.30) 2.96 (1.85-4.74) 3.03 (1.80-5.09) 
* Model I adjusted for age, sex, and race. 
† Model II adjusted for age, gender, and race, self-reported history of hypertension, diabetes, 
hypercholesterolemia, and smoking status. 





CHAPTER VI FIGURES 
Figure VI-1:  Retinal microvasculature in non-stroke control, AD without CeVD and VaD 
Retinal fundus photo grading by semi-automated computer software (SIVA) showing vessel 
path tracing of images from a non-demented, non-stroke control subject (A), a patient with 
AD without CeVD (B) and a patient with VaD (C). Red lines represent tracing of arterioles 
while blue lines represent tracing of venules. AD without CeVD patient (B) and VaD patient 
(C) have smaller fractal dimensions and higher vessel tortuosity in both arterioles and venules 
compared to control subject (A).  
 
  




Figure VI-2:  Retinal microvasculature in acute stroke, AD with CeVD and VaD 
Retinal fundus photo grading by semi-automated computer software (SIVA) showing vessel 
path tracing of images from an acute stroke subject (A), a patient with AD with CeVD (B) 
and a patient with VaD (C). Red lines represent tracing of arterioles while blue lines represent 
tracing of venules. AD with CeVD patient (B) and VaD patient (C) have narrower venules 






CHAPTER VII:  
RETINAL MICROVASCULAR NETWORK CHANGES IN 
MILD COGNITIVE IMPAIRMENT 





An increasing amount of evidence suggests that vascular pathology is an independent and 
important contributor to the development of dementia, including Alzheimer’s disease and its 
preclinical stages.[1] In particular, cerebral small vessel disease has been associated with 
increased risk of cognitive decline and dementia.[2, 3] Although modern neuroimaging 
modalities have contributed immensely to our understanding of microvascular pathology in 
dementia and cognitive impairment, it remains difficult to directly observe the cerebral 
microvasculature in vivo. As the retinal and cerebral microvasculature share many anatomical 
and physiological aspects, the retina provides a viable window to directly observe changes to 
the cerebral microvasculature.[4] 
Thus far, studies have shown that traditional signs of retinal microvascular damage, such as 
retinopathy signs (e.g. retinal hemorrhage) are associated with both dementia and its earlier 
preclinical stages.[5-7] However, retinopathy signs are relatively late indicators of damage in 
the eye, and indicate advanced stages of structural microvascular damage, such as breakdown 
of the blood-retina barrier, and are not commonly seen. With recent advances in digital retinal 
imaging and analysis techniques, we are now able to quantify objectively the structure and 
pattern of the retinal microvascular network, which may reflect earlier and more subtle 
changes before the appearance of overt signs. Novel retinal vascular parameters such as 
fractal dimensions, which reflect the optimality of the vascular network, are of particular 
interest, as they have recently been found to be associated with both stroke and dementia.[8, 9] 
In view of these associations with clinical disease, we hypothesized that these early retinal 
vascular network changes may also be present even in the preclinical stages of dementia. In 
this study, we examined the association between retinal vascular network parameters, 
particularly vascular fractal dimensions, and preclinical cognitive impairment in a Chinese 







2.1 Study population 
The Epidemiology of Dementia in Singapore (EDIS) study recruits participants from the 
Singapore Epidemiology of Eye Disease (SEED) Study, which is a population-based study 
among Chinese, Malays and Indians aged 40-85years.[10, 11] In order to efficiently utilize 
limited resources, it was decided to focus on those subjects who were most likely to have 
cognitive problems. In the present study we restricted analysis to the Chinese component of 
EDIS (from the Singapore Chinese Eye Study, SCES), as the recruitment of the other 
ethnicities is still ongoing. Hence, in the first phase of the EDIS, ethnic Chinese participants 
aged ≥60 years (n=1,538) who failed the Abbreviated Mental Test (AMT), or if the subject or 
main caregiver reported progressive forgetfulness were considered screen-positives (Chapter 
III). Screen-positive subjects (n=612) were invited to take part in the second phase of the 
EDIS study, which included neuropsychological testing and brain magnetic resonance 
imaging (MRI). Details of the study methodology have been described elsewhere.[12] Of the 
612 screen-positives, a total of 300 agreed to participate in the second phase August 2010 to 
February 2012. Ethics approval for the EDIS study was obtained from the Singhealth 
Institutional Review Board and the National Healthcare Group Domain-Specific Review 
Board (DSRB). Written informed consent was obtained from all participants prior to 
recruitment.   
2.2 Assessment of retinal vascular parameters 
Retinal fundus photographs were taken from each eye after pupil dilation and graded 
according to a standardized protocol as described in Chapter III.[10] The following retinal 
vascular parameters were extracted and used for analysis: retinal vascular fractal dimension, 
tortuosity, and caliber. Details of these parameters and reliability assessment have been 
described in Chapter III and previously elsewhere.[13, 14]. 
 




2.3 Neuropsychological assessment 
Trained research psychologists administered cognitive testing to participants in their habitual 
language. Brief cognitive screening tests included the Mini-Mental State Examination 
(MMSE), the Montreal Cognitive Assessment (MoCA), and the Informant Questionnaire on 
Cognitive Decline in the Elderly. Additionally, a formal neuropsychological battery (the 
Vascular Dementia Battery, or VBD) previously validated for Singaporean elderly was 
administered to all participants.[15] The following domains, using the respective 
neuropsychological tests in parentheses, were examined: 
- Executive Function (Frontal Assessment Battery, Maze Task),  
- Attention (Digit Span, Visual Memory Span and Auditory Detection),  
- Language (Boston Naming Test and Verbal Fluency),  
- Visual Memory (Picture Recall, WMS-R Visual Reproduction), 
- Verbal Memory (Word List Recall and Story Recall),  
- Visuoconstruction (Weschler Memory Scale – Revised (WMS-R) Visual Reproduction 
Copy Task, Clock Drawing, WAIS-R subtest of Block Design),  
- Visuomotor speed (Symbol Digit Modality Test, Digit Cancellation). 
Additional details have been published previously.[12] Z-scores were derived for individual 
subtests, and Z-scores for individual domains were generated by summing up the Z-scores of 
each subtest under that domain and dividing by number of subtests. A final global composite 
Z-score was computed using all domain specific Z-scores. Participants were considered to 
have failed a test if they scored lower than education-adjusted 1.5 SDs below established 
normal means on each individual test. Failure in at least half of the tests in each domain was 
considered as impairment in the domain. 
2.4 Diagnosis of cognitive impairment and dementia  
Weekly consensus meetings were held with study clinicians, neuropsychologists, clinical 





assessment, blood investigations, neuropsychological testing and MRI scans were reviewed. 
Non-cognitively impaired (NCI) was diagnosed when participants were not impaired in any 
of the domains tested. Cognitively impaired no dementia (CIND) was defined as impairment 
in one or more domains in the neuropsychological test battery. CIND-mild was diagnosed 
when less than or two domains were impaired, and CIND-moderate was diagnosed when 
more than two domains were impaired. Dementia syndrome was diagnosed in accordance to 
the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria. Seven 
participants who were diagnosed with dementia were excluded from final analysis.  
2.5 Assessment of other risk factors 
Demographic and vascular risk factors including age, sex, smoking, hypertension, diabetes, 
hyperlipidemia, height and weight were collected using a detailed questionnaire. Blood tests 
included full blood count, random blood glucose and serum lipids including total cholesterol. 
Systolic and diastolic blood pressures were measured using a digital automatic blood pressure 
monitor (OMRON-HEM 7203, Japan) after resting for five minutes. Mean arterial blood 
pressure was calculated as two-thirds of the diastolic blood pressure plus one-third of the 
systolic blood pressure. Participants were categorized into non-smokers and ever-smokers 
(past and current smokers). Body mass index (BMI) was calculated as the weight in kilograms 
divided by their height in meters squared.  
MRI was performed on a 3T Siemens Magnetom Trio Tim scanner, using a 32-channel head 
coil, at the Clinical Imaging Research Centre of the National University of Singapore. Scans 
were graded by one radiologist and two clinicians blinded to the neuropsychological and 
clinical data for the presence of stroke and cerebral microbleeds (Brain Observer Microbleed 
Scale).[16] White matter lesions (WML) volume, total brain volume, and total intracranial 
volume were quantified by automatic segmentation as described in Chapter V at the Erasmus 
University Medical Center Rotterdam, The Netherlands.[17-19] The ratio of total brain 




volume to total intracranial volume was used as a marker for cerebral atrophy. Additional 
details are available in Chapter V. 
2.6 Statistical analysis 
For the comparison of baseline demographic and risk factors between participants with 
gradable and ungradable retinal fundus images, and between the different diagnostic groups, 
Pearson’s chi-square test was used for categorical variables with independent t-tests and 
analysis of variance (ANOVA) for continuous variables. Kruskal-Wallis one-way analysis of 
variance was used to compare WML volumes, MMSE scores, and MoCA scores as they were 
not normally distributed. Multinomial logistic regression models were constructed to calculate 
odds ratios (OR) and their 95% confidence intervals (CI) for CIND-mild and CIND moderate 
by per standard deviation (SD) increase or decrease in retinal vascular parameters. Models 
were firstly adjusted for age and sex, then additionally for risk factors of education level, 
socioeconomic status, mean arterial blood pressure, fasting blood glucose, serum cholesterol, 
smoking status, and MRI brain imaging markers. Similarly adjusted linear regression models 
were also constructed for z-scores from individual domains and the composite Z-score for all 
domains (VBD composite score) to test for linear relationships between retinal vascular 
parameters and cognitive performance. All statistical analysis was performed using SPSS 
Version 17.0 (SPSS Inc., USA). 
3. RESULTS 
Of the 300 Chinese participants recruited into the EDIS study, 7 participants diagnosed with 
clinical dementia were excluded from this study. From the remaining 293 participants, the 
additional 25 excluded participants (due to poor retinal image quality) from the analysis were 
similar in baseline characteristics compared to the included participants, except for education 
level (less with Primary education and above, p=0.045), socioeconomic status (lower, 
p=0.006), and presence of any previous stroke on neuroimaging (higher, p=0.043). In the 268 





general, participants who were CIND-mild or CIND-moderate were more likely to be women, 
older, had lower education and socioeconomic status, higher diastolic blood pressures, 
prevalent stroke, higher WML volume, and lower total brain volume/intracranial volume ratio 
(Table VII-1).  
In multinomial age-sex adjusted logistic regression models, reduced retinal arteriolar fractal 
dimension was associated with higher risk of being CIND-moderate, while reduced venular 
fractal dimension was associated with higher risk of being CIND-mild and CIND-moderate 
(Table VII-2). After further adjustment for other risk factors such as socioeconomic status, 
blood pressure, glucose, cholesterol levels, and MRI markers, reduced fractal dimensions 
remained associated with both clinical outcomes of CIND-mild and CIND-moderate (Table 
VII-3).  
In age-sex adjusted linear regression models for global cognitive function as expressed as 
composite VDB Z-scores in the entire cohort showed that both reduced arteriolar and venular 
fractal dimensions and reduced arteriolar vessel tortuosity was associated with poorer 
cognitive performance (Table VII-2). However, the association of cognitive impairment with 
arteriolar tortuosity was attenuated after additional adjustment for other risk factors and MRI 
markers (Table VII-3).  
As there were significant associations between fractal dimensions and global cognitive 
function, associations with specific cognitive domains were also investigated in this cohort. 
Reduced fractal dimensions were associated with lower scores in verbal memory, 
visuoconstruction, and visuomotor speed (Table VII-4).  
4. DISCUSSION 
In this Chinese population, persons with a sparser vascular network in the retina were more 
likely to have poorer global cognitive performance, and have significant cognitive impairment, 
independent of traditional risk factors and MRI markers. In particular, they performed worse 
in specific cognitive domains of verbal memory, visuoconstruction and visuomotor speed.   




Thus far, previous studies examining the relationship between retinal microvascular changes 
and cognitive dysfunction have mainly focused on clinically visible retinopathy signs. In the 
Atherosclerosis Risk in Communities (ARIC) study,[20] classic retinopathy lesions were 
clearly associated with cognitive impairment. However, findings from other studies, including 
the Los Angeles Latino Eye Study (LALES), the Cardiovascular Health Study (CHS), the 
Blue Mountain Eye Study (BMES), and the AGES-Reykjavik Study, have been less clear.[6, 
21-23] For example, in the BMES,[23] these associations were only present among subjects 
with hypertension, whereas in the AGES-Reykjavik Study,[6] retinopathy combined with the 
presence of cerebral microbleeds was associated with cognition. These discrepancies could 
partly be due to not only differences in the cognitive tests used, such as the Mini Mental State 
Examination, or the Abbreviated Mental Test,[21, 23, 24] but also differences in the specific 
cognitive domains tested such as psychomotor speed, executive function, and verbal 
memory.[20, 21] Finally, retinopathy signs are considered relatively late indicators of 
vascular damage in the eye, and indicate advanced stages of structural microvascular damage. 
Recent advances in digital retinal imaging have enabled us to quantify early changes in the 
retinal microvasculature.  
In this present study, we focused on retinal vascular fractal dimensions. In addition to its 
potential to reflect earlier and more subtle changes before the appearance of overt signs, 
fractal dimensions in particular have the advantage of being parameters that do not vary with 
pulse cycles such as vessel diameters. One previous study has shown that decreased fractal 
dimensions was related to cognitive dysfunction.[24] However, in the study only a brief 10-
point screening test (Abbreviated Mental Test) was employed. In the current study, an 
extensive neuropsychological test battery was employed to assess a range of cognitive 
domains, allowing us to not only study individual domains, but also comprehensively stage 
our subjects into categories with increasing severity of impairment. Our data provide 
additional support that these changes in the retinal vascular network are associated with 





dimensions are associated with preclinical stages of dementia are in line with previous studies 
showing that these retinal parameters are linked to not only clinical outcomes such as acute 
ischemic stroke and dementia, but also markers of cerebral small vessel disease such as 
lacunar infarcts and cerebral microbleeds.[8, 9, 25-27] Pathophysiologically, a sparser 
network as reflected by a reduced fractal dimension is a consequence of retinal vessel 
rarefaction and collapse, which may lead to hypoxia in the retina.[28] Similarly in the brain, 
destruction and occlusion of the small perforating vessels have been observed,[29] suggesting 
that there may be parallel pathological mechanisms at work in the brain and retina leading to 
microvascular changes. Taken together, these morphological changes in the retinal 
microvasculature suggest that subtle microvascular changes may already be present in the 
preclinical stages of dementia, further providing evidence for vascular disease as an important 
contributor to the development of cognitive impairment and dementia. 
Some methodological issues need to be discussed. Since approximately half of the screen 
positive subjects declined to take part in phase II of the study (cognitive assessment and 
neuroimaging phase), eligible subjects who refused to participate may have had poorer 
cognitive function leading to an underestimation of the effect sizes.[12] Nevertheless, we still 
found a consistent association between retinal vascular network complexity and cognitive 
impairment, suggesting that the true association may be stronger. Strengths of our study 
include comprehensive and standardized assessment of cognitive ability over a range of 
domains, and quantitative assessment of retinal photographs using standardized semi-
automated protocols. 
In conclusion, our study found that a sparser retinal microvascular network is associated with 
cognitive impairment and poorer performance on cognitive scores, independent of 
cardiovascular risk factors and MRI markers of cerebral small vessel disease. This provides 
additional evidence for the importance of microvascular pathology in the development of 
cognitive impairment.  
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Female, n (%)  53 (43.8) 42 (53.8) 47 (68.1) 0.005 
Age, mean (sd) 67.3 (4.8) 71.1 (6.3) 74.1 (5.4) <0.001 
Above primary education, n (%) 110 (90.9) 61 (76.9) 41 (59.4) <0.001 
Low socioeconomic status, n (%) 58 (48.7) 52 (71.2) 57 (83.8) <0.001 
BMI, mean (sd) 23.9 (3.2) 23.8 (3.3) 24.5 (4.1) 0.456 
Systolic blood pressure, mean 
(SD) 
146.3 (19.1) 145.4 (17.9) 149.1 (21.6) 0.477 
Diastolic blood pressure, mean 
(SD) 
78.9 (10.1) 75.2 (10.1) 74.8 (10.9) 0.010 
Hypertension, n (%) 88 (72.7) 59 (75.6) 61 (88.4) 0.040 
Random blood glucose, mmol/L 
(SD) 
6.41 (2.50) 6.61 (3.09) 6.65 (2.44) 0.810 
Diabetes, n (%) 26 (21.5) 19 (24.4) 22 (31.9) 0.278 
Serum total cholesterol, mmol/L 
(SD) 
5.32 (1.01) 5.06 (0.97) 5.33 (1.05) 0.493 
Hyperlipidemia, n (%) 67 (55.4) 48 (61.5) 48 (69.6) 0.154 
Ever smokers, n (%) 35 (28.9) 24 (30.8) 22 (31.9) 0.906 
MMSE score, median (IQR) 27 (2) 25 (4) 21 (5) <0.001† 
MoCA score, mean (IQR) 24 (4) 20 (5) 16 (6) <0.001† 
MRI markers     
Presence of stroke, n (%) 5 (4.1) 14 (17.9) 21 (30.4) <0.001 
Presence of cerebral microbleed, 
n (%) 
33 (27.3) 24 (30.8) 23 (33.3) 0.510 
White matter lesion volume, 
median ml (IQR) 
1.37 (3.19) 1.82 (4.26) 3.28 (10.39) 0.002† 
Total brain volume/intracranial 
volume, ratio (sd) 
0.820 (0.018) 0.817 (0.018) 0.812 (0.018) 0.013 
*Chi-square test was used for categorical variables and Student’s t-test for continuous 
variables unless stated otherwise.  







Table VII-2: Age-sex adjusted associations of retinal vascular parameters with global 
cognitive performance, expressed as mean differences (95%CI) in normalized test scores, and 
with diagnosis of cognitive impairment status expressed as odds ratios (95%CI).  
Retinal vascular parameters 
Age-sex adjusted (268) 
B (95%CI)* OR (95% CI) 






Caliber    
Arteriolar, per SD decrease† 0.072 (-0.091, 0.234) 0.70 (0.39-1.24) 0.81 (0.43-1.53) 
Venular, per SD increase† -0.080 (-0.240, 0.081) 0.99 (0.57-1.72) 1.17 (0.63-2.16) 
Fractal Dimension    
Arteriolar, per SD decrease -0.165 (-0.247, -0.073) 1.37 (0.99-1.89) 1.73 (1.19-2.53) 
Venular, per SD decrease -0.151 (-0.242, -0.061) 1.38 (1.00-1.90) 1.79 (1.24-2.60) 
Tortuosity    
Arteriolar, per SD increase 0.143 (0.053, 0.234) 0.86 (0.63-1.17) 0.73 (0.51-1.05) 
Venular, per SD increase 0.073 (-0.017, 0.164) 0.90 (0.67-1.23) 0.85 (0.60-1.22) 
*Expressed as mean differences with 95% confidence intervals 
† Adjusted additionally for other vessel caliber  




Table VII-3: Multivariable adjusted associations of retinal vascular parameters with global cognitive performance, expressed as mean differences (95%CI) in 
normalized test scores, and with diagnosis of cognitive impairment status expressed as odds ratios (95% CI). 
Retinal vascular parameter 
Model I* (244)  Model II† (243) 
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* Adjusted for age, gender, race, education level, low socioeconomic status, mean arteriolar blood pressure, random blood glucose, total cholesterol and 
presence of stroke 
† Adjusted for age, gender, race, education level, low socioeconomic status, mean arteriolar blood pressure, random blood glucose and total cholesterol, 
presence of stroke and cerebral microbleeds, total white matter lesion volume, and total brain volume/intracranial volume. 






Table VII-4: Associations between retinal vascular fractal dimensions with specific cognitive domain scores expressed as mean differences (95%CI). 
 Executive 
Function 
Attention Language Visual Memory Verbal Memory Visuoconstruction Visuomotor 
speed 
Arteriolar fractal dimension per SD decrease      




























Venular fractal dimension per SD decrease      




























 Adjusted for age, gender, race, education level, mean arteriolar blood pressure, fasting blood glucose, total cholesterol, and presence of stroke 
†Adjusted for age, gender, race, education level, mean arteriolar blood pressure, fasting blood glucose, total cholesterol, presence of stroke, cerebral 
microbleeds, total white matter lesion volume, and total brain volume/intracranial volume. 
 





CHAPTER VIII:  
RETINAL NEURONAL ALTERATIONS IN PATIENTS WITH 







Alzheimer's disease (AD), the most common form of dementia, is associated with a specific 
pattern of pathological changes in the brain that result in neurodegeneration and the 
progressive development of dementia.[1] The hippocampus and entorhinal cortex have 
consistently demonstrated early neuronal damage in AD, but the detection of early changes in 
vivo in these areas is problematic.[2, 3]  
The retina develops as an extension of central nervous system and shares similar 
embryological, anatomical and physiological properties with the cerebral neurons, offering a 
possible “window” to study neurodegenerative disorders in vivo.[4, 5] Previous histological 
studies have demonstrated that patients with AD have loss of retinal ganglion cells (RGCs) 
and optic nerve axons.[6-8] Moreover, a few clinical studies have reported changes in optic 
nerve head (e.g. increased cup-to-disc ratio), observed clinically or using retinal photography, 
among AD patients.[9, 10] However, the clinical usefulness of optic nerve head evaluation is 
limited, due to high inter-observer variability in such assessment, particularly with subtle 
changes of optic nerve.[9]  
Optical coherence tomography (OCT) is a noninvasive in vivo optical biopsy and cellular-
resolution imaging technology based on the principle of low-coherence interferometry, and 
has made remarkable advances in assessing optic nerve axons quantitatively in the last two 
decades, particularly for the diagnosis of glaucoma.[11, 12] Several studies have used OCT to 
assess peripapillary retinal nerve fiber layer (RNFL) thickness in AD and reported RNFL 
reduction in AD patients compared with normal controls.[13-19]  
Importantly, improved spatial resolution of spectral-domain OCT (SD-OCT) now allows 
measurement of the RGC layer; composed of cell bodies; and the inner plexiform layer 
containing the RGC dendrites, and hence more detailed assessment of RGCs in the macular 
region.[20, 21] Since the macula contains more than 50% of total RGCs and that RGC cell 
body size is 10 to 20 times the diameter of their axons, we hypothesize that changes in the 




ganglion cell-inner plexiform layer (GC-IPL) thickness at the macula will be more sensitive 
than RNFL axonal reduction to neurodegenerative processes. In this study, we examined the 
associations of macular GC-IPL and RNFL thicknesses, as measured by SD-OCT, with mild 
cognitive impairment (MCI) and AD.  
2. MATERIALS AND METHODS 
2.1 Study population 
We conducted a case-control study of AD and MCI patients compared with controls selected 
from a population-based study of eye disease in Singapore. AD and MCI patients were 
enrolled consecutively from July 2009 to May 2013 from three study sites (dementia/memory 
clinics from the National University Hospital, Khoo Teck Puat Hospital and Singapore 
General Hospital, Singapore). All patients underwent clinical and neuropsychiatric 
assessment. Computed tomography or MRI scans were reviewed as part of the diagnostic 
process. AD patients fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4
th
 
edition (DSM-IV) criteria for dementia syndrome (Alzheimer’s type)[22] and National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's 
Disease and Related Disorders Association (NINDS-ADRDA) criteria for probable or 
possible AD.[23] Diagnosis of MCI was in accordance to Petersen et al’s criteria.[24] We 
excluded patients with a history of glaucoma and presence of glaucomatous characteristics 
from fundus photographs. Presence of cataract, diabetic retinopathy and maculopathy were 
not part of exclusion criteria, unless the pathologies affected the SD-OCT image quality 
(signal strength less than 5) or when it caused GC-IPL or RNFL algorithm segmentation 
failure. 
Cognitively normal controls were selected from a population-based study, the Singapore 
Chinese Eye Study (SCES). Additional details of the SCES are reported elsewhere.[25, 26] 
SCES participants aged 60 years or above with normal Abbreviated Mental Test (AMT) 





from fundus examination and had a reliable and normal visual field (without a visual field 
defect) were eligible to be selected as a control. 
Written, informed consent was obtained from each participant; the study conducted adhered 
to the Declaration of Helsinki. Ethical approval was obtained from the Singapore Eye 
Research Institute Institutional Review Board and National Healthcare Group Pte Ltd Domain 
Specific Review Board.  
2.2 Assessment of retinal neuronal layers  
Figure VIII-1 shows detailed cross-sectional image of the retinal layers centered at the 
macula obtained using a commercially available SD-OCT from a human subject. SD-OCT 
(Cirrus HD-OCT; Carl Zeiss Meditec) macular and optic disc cube scans were obtained from 
study participants and assessed according to standardized protocol described in Chapter 
III.[20, 25]  Cognitively impaired patients with at least one type of scan with gradable quality 
were included for analysis. Of the cases, 20 patients were excluded. Among these 20 patients, 
8 were excluded due to macular pathology affecting GC-IPL and RNFL segmentation 
algorithm. The remaining 12 were excluded due to poor image quality (primarily motion 
artefacts due to poor fixation) on both macular and optic disc scans. 
Macular GC-IPL thickness and peripapillary RNFL thickness measurements were extracted 
for analysis. Figure VIII-2 shows an output of the Cirrus HD-OCT GC-IPL segmentation 
algorithm in a MCI subject. Figure VIII-3 shows an output of the Cirrus HD-OCT RNFL 
segmentation algorithm in an AD patient. 
2.3 Assessment of other variables 
AD and MCI patients were categorized into 3 groups based on clinical dementia rating (CDR) 
global scores at admission into the study. Years since first cognitive symptom to date of 
admission into study were also calculated. Self-reported history of systemic diseases 
(hypertension, hypercholesterolemia, diabetes mellitus) and medication use were elicited from 




the patient and their primary caregiver at the study interview. Smoking was defined as those 
currently smoking any number of cigarettes (i.e. current vs. past/never). Previous myocardial 
infarction was ascertained from self-report.  
2.4 Statistical analysis  
All statistical analyses were performed using SPSS statistics version 21.0 and R version 3.1.1 
(The R foundation for statistical computing).  We randomly selected one eye from each 
participant for final analysis. Analyses of variance (ANOVA), chi-squared test, and Wilcoxon 
rank-sum test were used to compare the characteristics among the groups (AD, MCI and 
controls) in the study. Analysis of covariance (ANCOVA) models were used to estimate 
mean GC-IPL and RNFL thicknesses in each group adjusted for age, gender, ethnicity, SD-
OCT signal strength (Model 1) and further adjusted for hypertension, diabetes and, history of 
myocardial infarction (Model 2). Models for RNFL were additionally adjusted for optic disc 
area. Area under receiver operating characteristic curves (AUCs) was used to assess the 
ability of GC-IPL and RNFL thicknesses to discriminate AD, MCI and AD/MCI from 
cognitively normal controls adjusting for age and gender.  
3. RESULTS  
We included 100 AD patients, 41 MCI patents and 123 cognitively normal subjects in the 
final analysis. Table VIII-1 shows the characteristics of the AD, MCI and control groups. AD 
and MCI patients were older, more likely to be female, hypertensive, diabetic and had history 
of myocardial infarction, but had lower blood pressure compared to cognitively normal 
control subjects.  
Table VIII-2 shows the relationship of GC-IPL thicknesses with AD, MCI and cognitively 
normal control groups. GC-IPL thickness showed significant reduction across all groups in all 
the sectors (all p-values≤0.016). Compared with the cognitively normal controls, AD patients 
had significantly reduced GC-IPL thicknesses in all the sectors after adjusting for age, gender, 





infarction (both Models 1 & 2). MCI patients also had significantly reduced GC-IPL 
thicknesses in the majority of sectors compared with cognitively normal controls (except in 
superotemporal sector in Model 1). The associations of MCI in superior and inferionasal 
sectors were attenuated after additional adjustment for hypertension, diabetes and history of 
myocardial infarction (Model 2). There were no significant differences in GC-IPL thickness 
between AD and MCI. Additional adjustment with age
2
 or restricting analysis to only Chinese 
cases and controls yielded similar results (Table VIII-5). 
Table VIII-3 shows the relationship of RNFL thicknesses between the AD, MCI and 
cognitively normal control groups. RNFL thickness showed significant reduction across the 
groups in average, superior and inferior quadrants in Model 1, but this was only statistically 
significant in the superior quadrant in Model 2. Compared with the cognitively normal 
controls, the AD patients had significantly reduced average, superior and inferior RNFL 
thicknesses, but the associations were attenuated in average and inferior quadrant in Model 2. 
There were no significant differences in RNFL thickness between MCI and controls, and AD 
and MCI. Results for both RNFL and GC-IPL remained largely similar when persons with 
diabetes were excluded. 
Table VIII-4 shows the AUCs of GC-IPL and RNFL thicknesses to discriminate AD, MCI 
and AD/MCI from cognitively normal controls, adjusting for age and gender. Among the GC-
IPL parameters, the AUC of inferior sector had highest value to discriminate AD and 
AD/MCI from cognitively normal controls, while the AUC of inferotemporal sector had 
highest value to discriminate MCI from cognitively normal controls. 
4. DISCUSSION  
In this study, we demonstrate that macular GC-IPL thinning is associated with both MCI and 
AD, strengthening the link between RGC neuronal loss and cognitive decline. RNFL thinning 
was not as strongly associated with either MCI or AD, with only superior quadrant 
peripapillary RNFL reduction significantly associated with AD. 




RGCs, the neurons located in the GCL in the retina, become myelinated when they leave the 
eyes, forming the optic nerve and providing the connection between the eye and the central 
nervous system.[28] With rapid advancements in OCT technology, more detailed and precise 
quantitative assessment of retinal neuronal and axonal neurodegenerative pathologies can 
now be performed using SD-OCT. We showed that patients with AD have macular GC-IPL 
and peripapillary RNFL reduction, as measured by SD-OCT. This is consistent with previous 
histological studies [6-8] and animal studies,[29, 30] supporting the hypothesis that changes 
in RGCs and optic nerve axons reflect neurodegenerative pathology in AD. Our findings are 
consistent with previous clinical studies where reduced RNFL thickness, particularly in the 
superior quadrant, as measured by less sensitive time-domain OCT, was observed in AD 
patients.[13-18]  
Second, we found that macular GC-IPL neuronal loss is more strongly related to MCI 
compared to RNFL axonal loss, suggesting that RGC neuronal loss is first detectable in the 
macula because of the dense population of RGCs in this region. Macular GC-IPL, a new SD-
OCT parameter that reflects the thickness of RGC bodies and dendrites in the retina, is based 
on a sampling of approximately 50% of the RGC population whose cell bodies are more than 
10 to 20 times the diameter of their axons.[31] Blanks et al previously demonstrated 
substantial loss of RGCs in the foveal/parafoveal region in AD in a postmortem study.[32] 
RGC dendrites are confined to the IPL of the retina. There is increasing evidence that in 
neurodegenerative conditions, morphological alterations of dendrites (e.g. reduction in 
dendritic length and branches) occurs in both the retina and in the central nervous system.[28] 
In addition, Williams et al reported that RGC dendritic changes precede cell loss in a mouse 
model of AD, suggesting that the IPL may be a useful marker for the early detection of AD-
related neurodegeneration.[33] Therefore, it is reasonable that GC-IPL thickness is likely a 
more sensitive marker than RNFL thickness for assessing neurodegeneration pathology in 





To our knowledge, there is only one other study which has analyzed the association between 
GCL, measured by SD-OCT, in AD patients. Marziani et al reported significant reductions in 
combined RNFL and GCL thickness (RNFL + GCL) in macular region assessed by another 
SD-OCT (Spectralis SD-OCT, Heidelberg Engineering, Heidelberg, Germany) in 21 AD 
patients compared with healthy controls.[34] However, as the RNFL is also affected by RGC 
structure, including the RNFL in the ganglion cell analysis in the macular region may affect 
the sensitivity for detecting ganglion cell body and dendritic abnormalities.[35] Using the 
latest SD-OCT ganglion cell analysis algorithm, our study measured the GC-IPL without 
including the RNFL, which compared to macular ganglion cell complex thickness (RNFL, 
GCL and IPL combined) is less influenced by RNFL thickness variation.[35]   
We proposed that RGCs loss may be a biomarker of neuronal degeneration in AD and 
assessment of RGCs neuronal and axonal degeneration (GC-IPL and RNFL reduction) using 
SD-OCT may potentially be able to track disease progression and monitor neuroprotective 
effect of novel therapeutic agents in clinical trials. Recent reports have also used SD-OCT to 
assess RGC neuronal abnormalities in other neurodegenerative diseases such as multiple 
sclerosis and Parkinson disease.[36, 37] Nevertheless, it is noted that SD-OCT can only 
assess a small part of the central nerve system, specifically that corresponding to the RGCs, 
even though neurodegenerative diseases tends to affect the central nervous system in a diffuse 
manner. Moreover, it is important to note that there is age-related reduction in RGCs and 
RGC axons in the normal retina.[38, 39] Thus, assessment of the RGC neuronal and axonal 
loss in AD should take into account the normal age-related loss of RGCs (age-related loss of 
GC-IPL is about -0.3µm/year).[38, 39] Future studies including replication by different 
groups and more analyses using longitudinal data will be important to clarify the role of SD-
OCT imaging in reflecting pathological neuronal loss in AD and MCI. 
The strengths of this study include a large sample size of uniformly diagnosed AD and MCI 
patients, and comprehensive and objective assessment of RGC neuronal and optic nerve 
axonal loss using a commercially available SD-OCT modality. Our study has a number of 




limitations. First, due to the cross-sectional nature of our data, the causal and temporal 
relationships between GC-IPL and RNFL with MCI, AD cannot be examined. Second, cases 
and controls were selected from different study populations (hospital outpatient cases and 
population-based controls). Although both consisted of elderly Singaporeans, the control 
population was relatively younger and had only Chinese participants, which may have 
resulted in sampling bias and residual confounding. Nevertheless, the mean difference (~4 to 
5µm) is larger than the expected age-related loss (age-related loss of GC-IPL is about -
0.3µm/year).[41,42] Third, there may be residual confounding factors (e.g., depressive 
symptoms) that we have not controlled for that could bias or modify the associations observed 
in our sample. Fourth, presence of maculopathy (e.g. epiretinal membrane, diabetic macular 
edema and age-related macular degeneration) might affect the measurement of retinal 
thickness. Nevertheless, we have examined all the intra-retinal segmentation to confirm the 
accuracy of macular GC-IPL measurement. 
In summary, reduction in macular GC-IPL thickness is strongly associated with both MCI and 
AD, while peripapillary RNFL thinning is associated with only AD. Retinal SD-OCT may 
provide a new noninvasive paradigm for quantitative evaluation of RGC neuronal and optic 
nerve axonal loss for assessing neurodegeneration in AD and MCI, providing a potential new 
tool for identifying neuronal loss which may facilitate earlier intervention in AD and 
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CHAPTER VIII TABLES 
Table VIII-1: Baseline characteristics of AD cases, MCI cases and cognitively normal controls in the study 
 AD 
(n=100) 





Gender, n (Male/Female) 43/57  13/28  67/56  0.027 
Race, n (Chinese/Malay/Indian) 79/15/6  29/3/9  123/0/0  <0.001 
CDR global score, n (0-0.5/1/2-3) 0/77/22  41/0/0  -  <0.001 
Years since first cognitive symptom, 
mean (SD) 
3.1 (2.4)  2.2 (1.4)  -  0.033 
Age, years, mean (SD) 73.5 (6.23)  70.4 (10.2)  65.7 (3.77)  <0.001 
Systolic blood pressure, mmHg, mean 
(SD) 
133.0 (19.3)  136.5 (20.9)  139.9 (17.2)  0.027 
Diastolic blood pressure, mmHg, mean 
(SD) 
70.0 (10.8)  71.2 (10.3)  77.4 (9.14)  <0.001 
Smoking, % (current vs. past/never) 9.0  9.76  11.4  0.838 
Hypertension, % 82.0  58.5  40.7  <0.001 
Diabetes, % 47.0  17.1  13.0  <0.001 
Hypercholesterolemia, % 63.0  63.4  52.8  0.240 
History of myocardial infarction, % 13.0  9.76  2.44  0.010 







Table VIII-2: Adjusted means (SE) and mean differences (SE) of GC-IPL thickness in AD, MCI and controls 
 AD (n=99) MCI (n=41) Controls 
(n=123) 
































Average 72.73 (1.09) 73.73 (1.35) 77.79 (1.31) <0.001  -5.06 (1.27) <0.001 -4.06 (1.55) 0.009 -1.00 (1.50) 0.505 
Superior  72.66 (1.43) 73.48 (1.76) 77.65 (1.71) 0.003  -4.99 (1.66) 0.003 -4.17 (2.03) 0.042 -0.82 (1.96) 0.675 
Superonasal  75.85 (1.28) 76.86 (1.58) 80.93 (1.53) 0.001  -5.07 (1.49) 0.001 -4.07 (1.82) 0.026 -1.01 (1.75) 0.565 
Inferonasal  73.65 (1.27) 75.04 (1.57) 78.80 (1.52) 0.001  -5.15 (1.48) 0.001 -3.76 (1.81) 0.039 -1.38 (1.74) 0.428 
Inferior sector 70.61 (1.42) 70.87 (1.75) 76.83 (1.70) <0.001  -6.21 (1.65) <0.001 -5.95 (2.02) 0.004 -0.26 (1.95) 0.894 
Inferotemporal  72.25 (1.27) 72.89 (1.57) 77.51 (1.53) <0.001  -5.26 (1.48) <0.001 -4.62 (1.81) 0.011 -0.64 (1.75) 0.716 
Superotemporal  71.51 (1.28) 73.10 (1.58) 75.11 (1.53) 0.016  -3.59 (1.49) 0.016 -2.01 (1.82) 0.271 -1.58 (1.75) 0.367 
Model 2            
Average 71.69 (1.27) 72.44 (1.58) 76.21 (1.54) 0.001  -4.52 (1.35) 0.001 -3.78 (1.56) 0.016 -0.75 (1.56) 0.632 
Superior  70.88 (1.66) 71.89 (2.06) 75.68 (2.02) 0.007  -4.80 (1.76) 0.007 -3.79 (2.03) 0.064 -1.01 (2.03) 0.621 
Superonasal  75.38 (1.49) 76.75 (1.85) 80.36 (1.81) 0.002  -4.99 (1.58) 0.002 -3.62 (1.83) 0.049 -1.37 (1.83) 0.454 
Inferonasal  74.06 (1.49) 75.10 (1.85) 78.68 (1.81) 0.004  -4.63 (1.58) 0.004 -3.58 (1.83) 0.051 -1.04 (1.83) 0.569 
Inferior  68.90 (1.65) 68.01 (2.04) 73.83 (2.00) 0.005  -4.93 (1.75) 0.005 -5.83 (2.02) 0.004 0.89 (2.02) 0.659 
Inferotemporal  71.02 (1.48) 70.82 (1.83) 75.17 (1.80) 0.009  -4.16 (1.57) 0.009 -4.35 (1.81) 0.017 0.20 (1.81) 0.914 
Superotemporal  69.94 (1.49) 71.68 (1.84) 73.36 (1.80) 0.031  -3.42 (1.58) 0.031 -1.67 (1.82) 0.359 -1.75 (1.82) 0.338 
*p- value of main effect by treating groups as a continuous variable; 
+
P-value represents the pair-wise comparison between two groups 
Model 1: Adjusted for age, gender, ethnicity and SD-OCT signal strength; Model 2: Adjusted for age, gender, ethnicity, SD-OCT signal strength, 
hypertension, diabetes and history of myocardial infarction 














































Average 86.83 (1.44) 89.21 (1.76) 90.37 (1.71) 0.038  -3.53 (1.70) 0.038 -1.15 (2.03) 0.570 -2.38 (1.98) 0.231 
Superior  105.7 (2.34) 110.9 (2.86) 113.5 (2.77) 0.005  -7.81 (2.75) 0.005 -2.64 (3.29) 0.423 -5.17 (3.21) 0.108 
Nasal  68.54 (1.60) 68.93 (1.96) 68.10 (1.90) 0.815  0.44 (1.88) 0.815 0.82 (2.25) 0.715 -0.39 (2.19) 0.861 
Inferior  108.2 (2.59) 112.2 (3.17) 114.3 (3.07) 0.046  -6.11 (3.05) 0.046 -2.07 (3.65) 0.570 -4.03 (3.55) 0.257 
Temporal  64.89 (1.89) 65.10 (2.30) 65.25 (2.23) 0.873  -0.36 (2.22) 0.873 -0.15 (2.65) 0.955 -0.21 (2.59) 0.936 
Model 2            
Average 85.89 (1.64) 87.00 (2.02) 87.51 (2.00) 0.365  -1.62 (1.78) 0.365 -0.50 (2.00) 0.801 -1.11 (2.02) 0.581 
Superior  105.1 (2.69) 109.1 (3.31) 111.1 (3.26) 0.039  -6.04 (2.92) 0.039 -2.06 (3.27) 0.529 -3.98 (3.30) 0.229 
Nasal  68.01 (1.83) 66.89 (2.26) 65.33 (2.22) 0.179  2.68 (1.99) 0.179 1.56 (2.23) 0.484 1.12 (2.25) 0.619 
Inferior  107.1 (2.96) 108.8 (3.65) 109.6 (3.60) 0.434  -2.52 (3.21) 0.430 -0.76 (3.60) 0.830 -1.76 (3.64) 0.630 
Temporal  63.23 (2.21) 63.29 (2.73) 63.54 (2.69) 0.896  -0.31 (2.40) 0.900 -0.25 (2.69) 0.930 -0.06 (2.72) 0.980 
*p- value of main effect by treating groups as a continuous variable; 
+
P-value represents the pair-wise comparison between two groups 
Model 1: Adjusted for age, gender, ethnicity and SD-OCT signal strength; Model 2: Adjusted for age, gender, ethnicity, SD-OCT signal strength, 






Table VIII-4. Area under the receiver operating characteristic curves (AUCs) of GC-IPL and RNFL thicknesses in discriminating AD, MCI and AD/MCI 
from cognitively normal controls, adjusted for age and gender. 
 AD vs. control  MCI vs. controls  AD/MCI vs. control 
 AUC 95% CI  AUC 95% CI  AUC 95% CI 
GC-IPL thickness 
Average 0.658 (0.531-0.784)  0.661 (0.529-0.793)  0.659 (0.540-0.777) 
Superior sector 0.602 (0.475-0.728)  0.642 (0.510-0.775)  0.614 (0.498-0.729) 
Superonasal sector 0.589 (0.468-0.711)  0.623 (0.485-0.759)  0.599 (0.485-0.713) 
Inferonasal sector 0.647 (0.515-0.780)  0.666 (0.539-0.793)  0.653 (0.536-0.769) 
Inferior sector 0.722 (0.592-0.850)  0.674 (0.542-0.805)  0.707 (0.592-0.822) 
Inferotemporal sector 0.685 (0.515-0.822)  0.688 (0.558-0.818)  0.686 (0.560-0.811) 
Superotemporal sector 0.625 (0.508-0.741)  0.608 (0.475-0.742)  0.620 (0.507-0.732) 
RNFL         
Average 0.601 (0.478-0.724)  0.608 (0.475-0.742)  0.597 (0.491-0.702) 
Superior quadrant 0.596 (0.464-0.728)  0.556 (0.424-0.688)  0.584 (0.467-0.701) 
Nasal quadrant 0.480 (0.352-0.607)  0.468 (0.341-0.595)  0.476 (0.363-0.590) 
Inferior quadrant 0.640 (0.521-0.760)  0.609 (0.480-0.738)  0.631 (0.519-0.743) 
Temporal quadrant 0.504 (0.385-0.622)  0.534 (0.410-0.659)  0.513 (0.406-0.620) 
 
  




Table VIII-5: Comparison of average ganglion cell-inner plexiform layer (GC-IPL) thickness in Alzheimer’s disease (AD) and mild cognitive impairment 







  AD vs. 
Controls 
 MCI vs. 
Controls 
 AD vs. MCI  
Model 2 Mean thickness (SE) p*  Mean 
Difference (SE) 
p† Mean Difference 
(SE) 
p† Mean Difference 
(SE) 
p† 
GC-IPL thickness, µm           
Average 73.34 (1.23) 73.68 (1.77) 77.68 (1.29) 0.001  -4.33 (1.32) 0.001 -4.00 (1.60) 0.013 -0.33 (1.64) 0.840 
Superior sector 73.24 (1.70) 73.92 (2.44) 77.63 (1.79) 0.016  -4.38 (1.83) 0.017 -3.71 (2.21) 0.095 -0.68 (2.27) 0.766 
Superonasal sector 77.86 (1.44) 77.41 (2.07) 82.23 (1.51) 0.004  -4.38 (1.55) 0.005 -4.83 (1.87) 0.010 0.45 (1.92) 0.814 
Inferonasal sector 75.02 (1.46) 74.99 (2.11) 79.63 (1.54) 0.003  -4.62 (1.58) 0.004 -4.65 (1.91) 0.016 0.03 (1.96) 0.988 
Inferior sector 67.91 (1.62) 68.14 (2.33) 73.07 (1.71) 0.003  -5.15 (1.74) 0.003 -4.92 (2.11) 0.020 -0.23 (2.17) 0.916 
Inferotemporal 
sector 
71.83 (1.44) 71.64 (2.07) 75.86 (1.52) 0.009  -4.03 (1.55) 0.010 -4.22 (1.87) 0.025 0.19 (1.93) 0.921 
Superotemporal 
sector 
74.1 (1.48) 75.6 (2.13) 77.2 (1.56) 0.052  -3.10 (1.59) 0.052 -1.59 (1.93) 0.409 -1.51 (1.98) 0.447 
RNFL thickness, µm†           
Average 88.64 (1.68) 89.22 (2.36) 88.98 (1.74) 0.860  -0.34 (1.82) 0.853 0.24 (2.13) 0.910 -0.58 (2.22) 0.794 
Superior quadrant 108.2 (2.78) 112.4 (3.89) 112.5 (2.86) 0.158  -4.33 (3.00) 0.150 -0.12 (3.51) 0.973 -4.21 (3.65) 0.250 
Nasal quadrant 65.65 (1.89) 62.09 (2.65) 61.66 (1.95) 0.056  3.99 (2.04) 0.052 0.43 (2.39) 0.848 3.56 (2.49) 0.154 
Inferior quadrant 111.3 (3.07) 114.4 (4.31) 112.7 (3.16) 0.710  -1.34 (3.32) 0.686 1.72 (3.89) 0.658 -3.07 (4.04) 0.449 
Temporal quadrant 69.47 (2.40) 68.30 (3.36) 68.82 (2.47) 0.813  0.65 (2.59) 0.801 -0.52 (3.03) 0.864 1.17 (3.15) 0.711 
SE= standard error 
*p-value of main effect by treating groups as a continuous variable; †p-value of pair-wise comparison between the two groups 





CHAPTER VIII FIGURES 
Figure VIII-1: Detailed retinal layers of a cross-sectional SD-OCT image centered at the 
macula from a human subject 
 
 




Figure VIII-2: Cirrus HD-OCT GC-IPL thickness measurement in a MCI subject  
The GC-IPL thickness map uses warm colors to represent high values, and cool colors to 
represent low values. Measured thicknesses are compared to the device’s internal normative 
age-matched database, generating a deviation map, and a significance map color-coded to 
match GC-IPL thickness values. Values within the normal range are green (p=5%-95%), 
borderline values are yellow (1%<p<5%), and values outside the normal range are red 







Figure VIII-3: Cirrus HD-OCT RNFL thickness measurement in an AD subject  
The RNFL thickness map uses warm colors to represent high values, and cool colors to 
represent low values. Measured thicknesses are compared to the device’s internal normative 
age-matched database, generating a deviation map, and a significance map color-coded to 
match RNFL thickness values. Values within the normal range are green (p=5%-95%), 
borderline values are yellow (1%<p<5%), and values outside the normal range are red 









CHAPTER IX:  
RETINAL NEURONAL ALTERATIONS IN VASCULAR 






Although Alzheimer’s disease (AD) is the most common and most studied cause of dementia, 
cerebrovascular disease (CeVD) is present in up to a third of AD cases.[1] After AD, CeVD is 
the leading cause of cognitive impairment and dementia, but it remains debatable whether AD 
and vascular dementia have overlapping or separate pathological mechanisms.[2, 3]  
There is increasing interest in using the retina as a model to study AD and cerebrovascular 
disease. The retina shares physiological and anatomical similarities to the cerebral neurons,[4, 
5] and studies have shown that functional and anatomical changes in the retina are present in 
AD.[6-8] In vivo non-invasive retinal imaging techniques such as optical coherence 
tomography (OCT)[9-13] have demonstrated that retinal nerve fibre layer (RNFL) thinning is 
associated with mild cognitive impairment and AD (Chapter 9).  
Improvements in spectral domain-OCT (SD-OCT) have resulted in higher resolution and 
sensitivity in the retinal layers posterior to the RNFL, allowing identification and 
measurement of the ganglion cell-inner plexiform layer (GC-IPL).[14, 15] The RNFL is 
mainly composed of retinal ganglion cell (RGC) axons, while the GC-IPL contains both the 
cell bodies and dendrites of the RGCs. Reduction in dendritic complexity and area occurs 
prior to ganglion cell death,[16-18] and combined with the larger size of the cell bodies 
compared to axon widths, it is likely that the GC-IPL changes may be more sensitive to 
neuronal damage than the RNFL.  
Since previous studies have been mainly restricted to AD, it is unclear whether retinal 
neuronal and axonal structural alterations as indicated by GC-IPL and RNFL thinning with 
SD-OCT occurs in the presence of CeVD, particularly in vascular dementia (VaD) and AD 
with CeVD. We hypothesize that dementia with CeVD is also associated with damage to the 
retinal ganglion cell dendrites and axons. Hence, in this case-control study, we examine if the 
GC-IPL and RNFL thinning is also present in VaD and in AD in the presence of concomitant 
CeVD, and if there are differences with AD without CeVD. 




2. METHODS  
2.1 Study population  
Patients aged 85 years and below, with a Clinical Dementia Rating (CDR) global score of 1.0 
and above, and diagnosed with dementia syndrome (Alzheimer’s type or Vascular dementia) 
in accordance to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition 
(DSM-IV) criteria [19] were recruited from three tertiary hospitals in Singapore, between July 
2009 and August 2013 as part of the Retinal Imaging in Dementia (RD) study. Additionally, 
all patients diagnosed with AD fulfilled National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders 
Association (NINDS-ADRDA) criteria,[20] and all patients diagnosed with VaD fulfilled 
National Institute for Neurological Disorders and Stroke–Association Internationale pour la 
Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria.[21] All patients 
underwent neuropsychiatric assessment and were assessed clinically by neurologists or 
geriatricians.  
Controls were selected from a population-based study of eye diseases in Singapore, the 
Singapore Chinese Eye Study (SCES).[22] SCES participants above 60 years of age were 
eligible for selection if they passed the Abbreviated Mental Test (AMT),[23] had no self-
reported history of stroke, no signs of glaucomatous changes on retinal fundus examination, 
and did not have abnormal scores on visual field testing.  
Written, informed consent was obtained from each participant; the study conducted adhered 
to the Declaration of Helsinki. Ethics approval was obtained from the Singhealth Institutional 
Review Board and National Healthcare Group Pte Ltd Domain Specific Review Board. 
2.2 Assessment of retinal neuronal layers   
Participants with no history of glaucoma, or presence of dense cataract obstructing 





imaging. SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec) macular and optic disc cube scans 
were obtained from study participants and assessed according to standardized protocol 
described in Chapter III.[14, 24] Examples of GC-IPL thickness analysis are presented in 
Figure IX-1. Participants with signs of glaucomatous changes on retinal fundus examination 
were further excluded. Macular GC-IPL thickness and peripapillary RNFL thickness 
measurements were extracted for analysis.   
2.3 Assessment of cerebrovascular disease 
Computed tomography (CT) or magnetic resonance imaging (MRI) scans were assessed by 
trained blinded research clinicians. Significant cerebrovascular disease (CeVD) was defined 
as presence of cortical stroke, and/or ≥2 lacunes, and/or confluent white matter lesions in two 
regions of the brain on the age-related while matter changes (ARWMC) scale (score ≥8).[25]  
2.4 Assessment of other risk factors 
History of smoking, hypertension, diabetes, hypercholesterolemia, angina and acute 
myocardial infarction was collected by study clinicians at an interview with patients and their 
primary caregiver. Control subjects were administered a detailed questionnaire by trained 
interviewers to obtain detailed information on medical history, and underwent an extensive 
examination, as described elsewhere.[22] Hypertension was defined as systolic blood pressure 
≥140mmHg or diastolic blood pressure≥90mmHg at examination, a reported history of 
physician-diagnosed hypertension, or self-reported history of antihypertensive medication use. 
Diabetes was defined as random blood glucose ≥200mg/dL (11.1mmol/L), fasting blood 
glucose ≥126mg/dL (7.0mmol/L), self-reported history of anti-diabetic medication or insulin 
use. Hypercholesterolemia was defined as total cholesterol ≥6.2mmol/L, or history of 
cholesterol-lowering medication use. History of ischemic heart disease was defined as a 
having previous history of angina or acute myocardial infarction.  
 




2.5 Statistical analysis  
Baseline characteristics were compared using the student’s t-test or analysis of variance 
(ANOVA) for continuous variables and Pearson’s chi-square test for categorical variables. 
GC-IPL and RNFL thickness measurements were taken from a randomly selected eye from 
each participant for analyses. Linear regression models were generated with GC-IPL and 
RNFL thickness measurements as the outcome, with dementia subtypes as determinants. 
Results are expressed as mean differences in GC-IPL and RNFL thicknesses to controls and 
their 95% confidence intervals (CI). Models were adjusted for age, sex, race, scan signal 
strength (Model I) and additionally for hypertension, diabetes and, history of ischemic heart 
disease (Model II). Models for RNFL thickness were further adjusted for optic disc area.  All 
statistical analysis was performed on Stata Release 11 (StataCorp LP, USA). 
3. RESULTS  
Out of 176 dementia patients eligible for SD-OCT imaging, a total of 146 (83.0%) patients 
had OCT scans suitable for analysis, with 155 cognitively normal controls with OCT scans of 
sufficient quality were included for analysis. Comparisons of baseline characteristics between 
dementia cases and controls, and between each dementia subtype are presented in Table IX-1. 
In general, patients with dementia were older, more likely to be female, and have 
hypertension, diabetes, hypercholesterolemia, or history of ischemic heart disease. There were 
a total 30 patients with VaD, and 116 with AD, of whom 44 (37.9%) had CeVD. Patients with 
VaD were more likely to be younger than those with AD, while AD patients with no CeVD 
were more likely to be in milder stages of dementia (CDR global score=1). Figure IX-2 
shows the distribution of average GC-IPL thickness, average RNFL thickness, superior and 
inferior quadrant RNFL thickness by dementia subtypes. 
Table IX-2 shows that significant reduction in average GC-IPL thickness was present in all 
three dementia categories (VaD, AD with CeVD, and AD without CeVD) compared to 





three dementia subtypes. However, RNFL thickness was only significantly reduced in VaD 
cases compared to controls, mainly restricted to the superior and inferior quadrants around the 
optic nerve head. Similar results were obtained when analysis was repeated in only Chinese 
subjects (Table IX-3). In fully adjusted models (Model II) for GC-IPL and RNFL thicknesses, 
total variance was explained most by dementia subtypes (GC-IPL partial R
2
: AD without 
CeVD 0.0209, AD with CeVD 0.0252, VaD 0.0739; RNFL partial R
2
: AD without CeVD 





: 0.0225).  
GC-IPL and RNFL thicknesses were not significantly different between demented patients 
with CDR global score=1 and patients with CDR global score≥2 (adjusted mean difference in 
GC-IPL thickness: 0.239μm (p=0.908); RNFL thickness: 0.324μm (p=0.885). 
Although GC-IPL thinning was evident in all dementia subtypes, pair-wise comparisons of 
GC-IPL thickness across dementia subtypes showed that GC-IPL thickness in VaD patients 
was significantly reduced compared to AD without CeVD (adjusted mean difference: -
5.233m, p=0.026), while GC-IPL thickness in AD with CeVD was not significantly reduced 
compared to both AD without CeVD (adjusted mean difference -1.564m, p=0.443) and VaD 
(adjusted mean difference: 3.669m, p=0.151).  
4. DISCUSSION 
In this study, we found that GC-IPL thinning was present in all three categories of dementia, 
VaD, AD with CeVD and AD without CeVD. Additionally, associations of GC-IPL thinning 
with each category of dementia was stronger compared to RNFL thinning.  RNFL thinning 
was present in VaD and AD with CeVD, primarily in the superior and inferior quadrants 
around the optic nerve head. 
Reduction in dendritic complexity and area occurs prior to RGC death and loss,[26] 
suggesting that the GC-IPL may be more sensitive for neurodegeneration in the eye, since 




GC-IPL thinning was more consistently associated with all three categories of dementia than 
RNFL thinning. Loss of dendritic integrity precedes axonal damage and neuronal cell death 
also occurs in glaucoma.[16, 17] Similarly, synaptic dysfunction and dendrite loss in neurons 
of the hippocampus and visual cortex has not only been observed in AD,[27, 28] but also in 
response to cerebral ischemia.[29]  
In contrast to earlier studies using OCT technology showing that RNFL thinning was present 
in AD, we did not find the same association in this study. As a leading cause and contributor 
to cognitive decline and dementia, CeVD is often neglected. A majority of these studies [9-12] 
had no information on CeVD and other systemic vascular disease. A portion of these AD 
cases may have had concomitant vascular pathology unaccounted for. Additionally, RNFL 
measurements were unadjusted for scan signal strength and optic disc area, both of which 
significantly affect RNFL measurements.[24, 30] Furthermore, measurements were primarily 
taken from time domain-OCT rather than SD-OCT. Measurement of RNFL thickness from 
time domain-OCT are  smaller than SD-OCT at lower RNFL values but larger than SD-OCT 
at higher RNFL values,[31, 32] which could have resulted in an overestimation in the 
difference between AD and controls.  
The clinical profiles of patients with AD and VaD have significant overlap,[2] and similar 
damage to brain structures are observed in both AD and CeVD.[33] Cortical and subcortical 
grey matter atrophy is associated with cognitive decline in cerebral ischemia,[34-36] 
independent of lesion size and ischemic event.[37] In this study, we show that neuronal 
damage in the form of GC-IPL thinning is not only associated with AD, but also strongly 
correlated with dementia in the presence of CeVD. This suggests that the link between 
cognitive performance, cortical atrophy and retinal neuronal damage is not independent of 
cerebrovascular disease. Additional studies in retinal imaging technology combined with 
advanced neuroimaging techniques such as MRI and positron emission tomography over 
follow-up could provide alternative insight into both AD and vascular mechanisms driving 





Although VaD had the greatest reduction in GC-IPL and RNFL thicknesses, because 
neuroimaging was not available in the control group, and a further control group with CeVD 
but no dementia was not available, it may be premature to conclude that the retinal neuronal 
layers are more sensitive to vascular pathology as opposed to neurodegenerative damage.  
Strengths of this study are that a relatively large sample size of dementia patients with varying 
severity of AD and VaD was captured, CT and MRI scans available to determine the presence 
of CeVD, and the use of a commercially available imaging modality to obtain quantitative 
measurements of both GC-IPL and RNFL thickness. The major limitations of our study are: 
first, although we could ascertain the presence of CeVD in patients with clinical AD, we 
could not eliminate the possibility that a proportion of VaD patients may have AD pathology, 
since amyloid imaging or CSF biomarkers was unavailable. Nevertheless, although the 
various criteria used (DSM-IV and NINDS-AIREN) were not highly sensitive, they were 
specific for VaD,[38] hence we are fairly confident that possible misclassification has been 
kept to a minimum. Second, the VaD group had varying types of CeVD, ranging from cortical 
or strategic strokes to predominant small vessel disease. We were unable to conduct 
additional analyses for subtypes of VaD. Third, cases and controls were derived from 
different study populations (hospital outpatient cases and population-based controls). Both 
were of elderly residents in Singapore, the control population was relatively younger, and this 
may have resulted in selection bias and residual confounding. However, age was a lesser 
contributing factor to changes in GC-IPL and RNFL thicknesses compared to dementia. 
Finally, as a control group with CeVD without dementia was unavailable, we are unable to 
conclude if GC-IPL and RNFL thinning observed in vascular dementia and AD with CeVD 
was specific to cerebrovascular pathology and independent of dementia.  
In conclusion, macular GC-IPL thinning was present in both VaD and AD, suggesting that 
retinal neuronal and axonal damage, as assessed by GC-IPL thinning by SD-OCT is also 
present in dementia associated with CeVD. Further studies on retinal neuronal and axonal 
markers may provide insight to specific mechanisms underlying dementia in AD and VaD.  
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CHAPTER IX TABLES 





p AD without CeVD 
(n=72) 





Baseline Characteristics        
Age, mean (SD) 65.0 (3.8) 74.6 (7.5) <0.001 74.8 (6.9) 76.6 (5.4) 71.5 (10.3) 0.016 
Female, n (%) 63 (40.6) 83 (56.8) 0.005 45 (62.5) 26 (59.1) 12 (40.0) 0.105 
Chinese/Malay/Others, n  155/0/0 114/23/9 <0.001 55/10/7 37/6/1 22/7/1 0.475 
Hypertension, n (%) 60 (38.7) 119 (81.5) <0.001 57 (79.2) 39 (88.6) 23 (76.7) 0.331 
Diabetes, n (%) 19 (12.3) 68 (46.6) <0.001 32 (44.4) 23 (52.3) 13 (43.3) 0.660 
Hyperlipidemia, n (%) 78 (50.3) 98 (67.1) 0.003 43 (59.7) 32 (72.7) 23 (76.7) 0.161 
Current smokers, n (%) 19 (12.3) 13 (9.2) 0.389 6 (8.3) 5 (11.9) 2 (7.1) 0.750 
Ischemic heart disease, n (%) 5 (3.2) 21 (14.4) 0.001 8 (11.1) 9 (20.5) 4 (13.3) 0.373 
Systolic BP, mmHg (SD) 138.7 917.2) 135.0 920.8) 0.101 131.3 (19.9) 139.3 (20.8) 137.7 (22.1) 0.112 
Diastolic BP, mmHg (SD) 77.6 (8.9) 69.6 (11.1) <0.001 68.0 (9.7) 70.9 (12.9) 71.5 (11.1) 0.244 
Global clinical dementia rating 
(CDR) <2/≥2 
   62/10 27/17 20/10 0.006 




Table IX-2: Mean differences (95%CI) of GC-IPL and RNFL thicknesses of each dementia 
subtype compared to controls 
 Model I* 
OCT parameters, 
mean (95%CI) 
AD without CeVD 
(n=72) 




GC-IPL thickness, µm  (95%CI) 
Average -5.18 (-8.16,-2.20) -7.22 (-10.7, -3.76) -10.5 (-14.1, -6.91) 
Temporal-superior 
segment 
-5.30 (-8.61, -1.99) -6.29 (-10.1, -2.45) -11.0 (-15.0, -7.00) 
Superior segment -5.19 (-8.70, -1.68) -7.74 (-1.8, -3.66) -9.91 (-14.1, -5.69) 
Nasal-superior segment -4.71 (-8.09, -1.34) -5.66 (-9.58, -1.74) -7.94 (-12.0, -3.88) 
Nasal-inferior segment -4.15 (-7.35, -0.96) -6.14 (-9.86, -2.43) -8.77 (-12.6, -4.93) 
Inferior segment -6.06 (-9.30, -2.82) -9.09 (-12.9, -5.32) -12.1 (-16.0, -8.20) 
Temporal-inferior 
segment 
-5.68 (-9.16, -2.20) -8.44 (-12.5, -4.40) -12.9 (-17.1, -8.74) 
RNFL thickness, μm  (95%CI) 
Average -1.63 (-5.25, 1.98) -5.13 (-9.33, -0.92) -7.88 (-12.2, -3.52) 
Superior quadrant -3.95 (-9.65, 1.74) -8.80 (-15.4, -2.18) -9.39 (-16.2, -2.53) 
Inferior quadrant -2.65 (-8.88, 3.58) -10.5 (-17.8, -3.28) -18.3 (-25.8, -10.8) 
Temporal quadrant -0.28 (-4.72, 4.17) -0.66 (-5.82, 4.51) -2.16 (-7.51, 3.19) 
Nasal quadrant 0.76 (-3.19, 4.70) -3.35 (-4.94, 4.23) -1.64 (-6.39, 3.11) 
 Model II† 
OCT parameters, 
mean (95%CI) 
AD without CeVD 
(n=72) 




GC-IPL thickness, µm  (95%CI) 
Average -4.40 (-7.49, -1.32) -5.86 (-9.51, -2.20) -9.65 (-13.3, -6.00) 
Temporal-superior 
segment 
-4.58 (-8.02, -1.13) -4.99 (-9.07, -0.91) -10.2 (-14.2, -6.12) 
Superior segment -4.20 (-7.81,-0.59) -7.92 (-10.2, -1.64) -8.82 (-13.1, -4.55) 
Nasal-superior segment -4.10 (-7.61, -0.59) -4.55 (-8.71, -0.39) -7.27 (-11.4, -3.11) 
Nasal-inferior segment -3.63 (-6.98, -0.28) -5.36 (-9.34, -1.39) -8.25 (-12.2, -4.29) 
Inferior segment -5.11 (-8.45, -1.77) -7.37 (-11.3, -3.41) -11.0 (-15.0, -7.11) 
Temporal-inferior 
segment 
-4.78 (-8.40, -1.16) -6.95 (-11.2, -2.66) -12.0 (-16.3, -7.70) 
RNFL thickness, μm ‡  (95%CI) 
Average 0.09 (-3.67, 3.85) -2.73 (-7.18, 1.72) -6.32 (-10.7, -1.90) 
Superior quadrant -2.76 (-8.71, 3.19) -7.42 (-14.5, -0.38) -8.46 (-15.5, -1.46) 
Inferior quadrant 0.41 (-6.09, 6.92) -6.17 (-13.9, 1.53) -15.4 (-23.1, -7.78) 
Temporal quadrant 0.34 (-4.37, 5.05) 0.42 (-5.16, 5.99) -1.53 (-7.07, 4.02) 
Nasal quadrant 2.75 (-1.36, 6.86) 2.41 (-2.45, 7.27) 0.17 (-4.66, 5.01) 
* Model I adjusted for age, sex, race, and signal strength.  
† Model II adjusted for age, sex, race, signal strength, hypertension, diabetes, and history of 
ischemic heart disease.  






Table IX-3: Mean differences (95%CI) of GC-IPL and RNFL thicknesses of each dementia 
subtype compared to controls in Chinese subjects. 
  Model II*  
 AD without CeVD 
(n=55) 




GC-IPL thickness, µm   
Average -4.39 (-7.45, -1.33) -5.78 (-9.49, -2.07) -12.1 (-16.0, -8.20) 
Temporal-superior 
segment 
-5.02 (-8.52, -1.53) -4.81 (-9.04, -0.58) -12.9 (-17.3, -8.44) 
Superior segment -3.89 (-7.55, -0.22) -5.53 (-9.97, -1.08) -10.9 (-15.5, -6.21) 
Nasal-superior 
segment  
-4.01 (-7.49, -0.53) -4.17 (-8.38, 0.04) -9.82 (-14.2, -5.41) 
Nasal-inferior 
segment 
-3.52 (-6.82, -0.22) -5.19 (-9.20, -1.19) -11.3 (-15.5, -7.10) 
Inferior segment -5.23 (-8.65, -1.81) -7.47 (-11.6, -3.33) -13.3 (-17.6, -8.94) 
Temporal-inferior 
segment 
-4.57 (-8.15, -1.00) -7.37 (-11.7, -3.04) -13.8 (-18.3, -9.24) 
RNFL thickness, µm†   
Average 0.70 (-3.01, 4.42) -2.49 (-6.96, 1.99) -6.51 (-11.2, -1.82) 
Superior quadrant -2.09 (-8.08, 3.91) -8.05 (-15.3, -0.82) -8.37 (-15.9, -0.79) 
Inferior quadrant 2.30 (-4.07, -8.67) -4.80 (-12.5, 2.88) -15.9 (-23.9, -7.83) 
Temporal quadrant -0.27 (-5.24, 4.70) 0.43 (-5.57, 6.42) -1.96 (-8.24, 4.32) 
Nasal quadrant 3.31 (-0.88, 7.50) 2.70 (-2.35, 7.75) 0.29 (-5.00, 5.58) 
*Model II adjusted for age, sex, signal strength, hypertension, diabetes, and history of 
ischemic heart disease.  
†RNFL models were additionally adjusted for optic disc area  




CHAPTER IX FIGURES 
Figure IX-1: Examples of GC-IPL thickness analysis 
Transverse sections are on the left, with GC-IPL demarcated by purple and yellow lines, from 
a control (A), an AD without SCeVD patient (B), and a VaD patient (C). Thickness maps are 
on the right, warmer colors indicating thicker GC-IPL. Average GC-IPL thicknesses for these 
















CHAPTER X:  
RETINAL NEURODEGENERATION ON OPTICAL 






Alzheimer’s disease is characterized by brain atrophy in the cortical and subcortical grey and 
white matter especially the hippocampus and entorhinal cortex. Structural neuroimaging has 
shown that diffuse atrophy is present even in the early stages of dementia.[1-3] Advanced 
automated segmentation techniques, such as voxel based morphometry, allow quantification 
of grey and white matter volumes using magnetic resonance imaging (MRI).[4] Grey matter 
loss is related to progressive mild cognitive impairment (MCI) and conversion to dementia in 
the MCI group.[5-7] Global and regional grey matter volume measurements are now crucial 
biomarkers in detecting neuronal loss and progression of cognitive decline. However, MRI 
remains a time-consuming and expensive technique. Moreover, some patients have 
contraindications for undergoing MRI such as claustrophobia, cardiac pacemakers, and 
inability to tolerate the procedure.  
As the retina shares developmental, physiological and anatomical features with the brain,[8, 9] 
retinal imaging is now increasingly used in studying neurodegenerative disease. Both 
histopathological and clinical studies have shown that patients with Alzheimer’s disease have 
functional visual deficits and anatomical changes in retinal structures.[10, 11] 
Structural changes to the optic nerve can be non-invasively measured in vivo using techniques 
such as spectral domain-optical coherence tomography (SD-OCT). Recent advances in SD-
OCT have made it possible to automatically measure the retinal nerve fiber layer (RNFL) and 
the ganglion cell-inner plexiform layer (GC-IPL). Unmyelinated axons of the retinal ganglion 
cells form the RNFL, while the GC-IPL contains the cell bodies and dendrites of these cells. 
Previous studies have linked RNFL thinning to a number of brain diseases, such as 
Alzheimer’s disease,[12-14] Parkinson’s disease, and multiple sclerosis.[15-17] However, 
studies have not examined if neuronal changes in the retina are associated with global or 
regional cerebral atrophy assessed from MRI. Therefore, we examined the relationship of 




RNFL and GC-IPL thickness, with cerebral white and grey matter volumes on MRI in an 
elderly population from Singapore.   
2.  METHODS 
2.1 Study population 
The on-going Epidemiology of Dementia in Singapore (EDIS) study draws participants from 
the Singapore Epidemiology of Eye Disease (SEED) study, a multi-ethnic population-based 
study among persons aged 40 to 85 years. For this study, we focused on participants drawn 
from the first follow-up examination of the Singapore Malay Eye Study (SiMES) component 
of the SEED study who had OCT data available.[18] In order to use the limited MRI imaging 
resources efficiently, it was decided to focus on those subjects who were most likely to have 
cognitive problems. Hence, in the first phase of the EDIS-SiMES Study, participants from 
SiMES aged ≥ 60 years (n=1014) were screened using the Abbreviated Mental Test (AMT) 
and a self-report of progressive forgetfulness. Screen-positive subjects (n=448) were invited 
to take part in the second phase of this study, which included an extensive neuropsychological 
test battery and brain MRI. Of these 448 participants, 307 agreed to participate in phase II and 
hence were included in the present study. Cognitively impaired no dementia (CIND) was 
defined as impairment in one or more domains in the neuropsychological test battery, as 
described previously.[19] Dementia was diagnosed in accordance to the Diagnostic and 
Statistical Manual of Mental Disorders-IV criteria. The details of the study methodology have 
been described elsewhere.[19] Ethics approval for the EDIS study was obtained from the 
SingHealth Institutional Review Board and the National Healthcare Group Domain-Specific 
Review Board. The study was conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained prior to recruitment.   
2.2 Neuroimaging 
MRI was performed on a 3T Siemens Magnetom Trio Tim scanner, using a 32-channel head 





Subjects with claustrophobia, contraindications for MRI, or those who were unable to tolerate 
the procedure were excluded.  
Intracranial volume (ICV), grey matter and white matter volumes were quantified by 
automatic segmentation at the Erasmus University Medical Center Rotterdam, The 
Netherlands.[20, 21] Brain tissue segmentation was quantified by Proton density T1 and T2 
weighted images. Imaging parameter and classification algorithms for automated 
segmentation have been described elsewhere.[19] Total brain volume was calculated as the 
sum of grey matter and white matter volumes of the five regions; frontal, parietal, occipital, 
temporal and central regions.  
2.3 Assessment of retinal neuronal layers  
SD-OCT (Cirrus HD-OCT; Carl Zeiss Meditec) macular and optic disc cube scans were 
obtained from study participants and assessed according to standardized protocol described in 
Chapter III.[22, 23] Participants were also excluded if they had a diagnosis of glaucoma from 
study ophthalmologists. Macular GC-IPL thickness and peripapillary RNFL thickness 
measurements were taken from a randomly selected eye from each participant for analysis.  
2.4 Assessment of other vascular risk factors 
Demographic and vascular risk factors including age, sex, smoking, hypertension, diabetes, 
hyperlipidemia, height and weight were collected and verified by medical records. Blood tests 
included full blood count, fasting blood glucose and serum lipids including total cholesterol. 
Systolic and diastolic blood pressures were measured using a digital automatic blood pressure 
monitor (OMRON-HEM 7203, Japan) after resting for five minutes. Mean arterial blood 
pressure (MABP) was calculated as two-thirds of the diastolic blood pressure plus one-third 
of the systolic blood pressure. Subjects were categorized into non-smokers and smokers (past 
and current smokers). Body mass index (BMI) was defined as weight in kilograms divided by 
height in meters squared. Hypertension was defined as systolic blood pressure ≥ 140 mmHg 
and/or diastolic blood pressure ≥ 90 mmHg or use of anti-hypertensive medication. Diabetes 




was defined as HbA1c ≥6.5%, or receiving treatment for diabetes. Axial length for study eyes 
was measured using IOLMaster V3.01 (Carl Zeiss; Meditec AG Jene, Germany).  
2.5 Statistical analysis  
Grey and white matter volumes were used as determinants and expressed as per standard 
deviation (SD) decrease, whereas GC-IPL and RNFL thickness were taken as outcomes. 
Linear regression models were used to estimate mean change [95% confidence intervals (CI)] 
in GC-IPL and RNFL thickness per SD decrease in total brain volume, grey matter, and white 
matter volumes. Models were initially adjusted for age and sex, additionally MABP, blood 
glucose, serum cholesterol, with axial length and OCT scan signal strength from the eye 
chosen, and total intracranial volume to correct for head size. RNFL models were additionally 
adjusted for optic disc area. Separate linear regression models were constructed for occipital, 
temporal, frontal, parietal lobes and the central regions. All statistical analyses were 
performed on standard statistical software (SPSS Version 17, SPSS Inc., USA). 
3. RESULTS  
Screening and assessments of the Malay cohort was performed from February 2011 to July 
2013. Of the 307 subjects who participated in the second phase of the EDIS Study, 143 were 
excluded from the analysis: 21 had no MRI scans (due to claustrophobia, or 
contraindications), 14 were diagnosed with glaucoma, 87 did not complete OCT scanning, 
while 34 had ungradable OCT scans. Comparison of the 164 participants included and 143 
participants excluded are shown in Table X-1. In summary, excluded participants were more 
likely to be older, have diabetes, lower BMI, and more likely to be CIND or dementia. Mean 
total brain volume was 863.5ml (SD, 89.1ml), mean grey matter volume 507.2ml (SD, 
53.2ml), mean white matter volume 357.9ml (SD, 42.1ml) and mean total intracranial volume 
1056.0ml (SD, 100.1ml). Mean RNFL thickness was 90.6 μm (SD, 10.3 μm), while mean 





Decreasing total brain volume was weakly associated with GC-IPL thinning (mean change in 
GC-IPL per SD decrease in brain volume: -1.26m, 95%CI -2.53 to 0.01m), while 
decreasing total grey matter volume was more strongly associated with GC-IPL thinning 
(mean change in GC-IPL per SD decrease in grey matter volume: -1.40m, 95%CI -2.66 to -
0.14m) in age-sex adjusted models. In contrast, reduction in white matter volume was not 
significantly associated with GC-IPL thinning (mean change in GC-IPL per SD decrease in 
white matter volume: -0.80m, 95%CI -2.02 to 0.41m). However, these associations became 
non-significant after additional adjustment for MABP, blood glucose, plasma cholesterol 
levels, smoking, axial length, OCT scan signal strength and total intracranial volume. Both 
age-sex and multivariable-adjusted models for RNFL thickness were not statistically 
associated with total brain, grey or white matter volume.  
Region-specific analyses (Table X-2 and Table X-3) showed that decreasing grey matter 
volume in both occipital and temporal lobes was associated with GC-IPL thinning in both 
age-sex and multivariable-adjusted models, whereas only decreasing temporal lobe grey 
matter volume was associated with RNFL thinning independent of risk factors, axial length 
and intracranial volume. Reduction in grey and white matter volumes in the frontal, parietal 
lobes and central regions were not significantly associated with GC-IPL or RNFL thickness 
changes.  
When participants with dementia (n=3; all Alzheimer’s Disease) were further excluded from 
analysis, these associations remained unaltered.  
4. DISCUSSION 
In this study, we found that reduction in grey matter volume in the occipital and temporal 
lobes was associated with GC-IPL thinning in the retina, independent of systemic vascular 
risk factors, in elderly persons without glaucoma or clinical retinal diseases. However, there 
was no evidence of an association between global grey and white matter volumes or regional 
white matter volumes with GC-IPL and RNFL thickness. This suggests that thinning in the 




retinal neuronal layers may provide insight into region-specific grey matter atrophy in elderly 
persons at risk of cognitive decline. 
Thickness measurements of the GC-IPL and RNFL are both markers of retinal ganglion cell 
structural integrity, with the RNFL being mainly composed of retinal ganglion cell axons, 
whereas the GC-IPL is composed of both the cell bodies and dendrites of the retinal ganglion 
cells. As reduction in dendritic complexity and area occurs prior to retinal ganglion cell death 
and loss,[24] this suggests that the GC-IPL may be more informative and sensitive to 
neurodegenerative damage compared to the RNFL. 
Our findings that reduction in grey matter volumes in the occipital and temporal lobes is 
linked to RNFL and GC-IPL thinning suggest the presence of a neurodegenerative pathway 
linking these regions of the brain directly to the eye. The visual association cortex in the 
inferior temporal lobe and the occipital lobes are particularly susceptible to neurofibrillary 
tangles and amyloid plaque deposition,[25, 26] and this correlates with atrophy and reduced 
metabolism especially in the occipital and temporoparietal regions.[27] As a result, these 
pathological depositions disrupt connections within the visual tract, potentially causing 
retrograde neuronal degeneration down the optic nerve,[25] resulting in region-specific 
relationships between the temporal and occipital lobe atrophy with retinal neuronal damage. 
Retrograde damage to the optic nerve, and hence retinal ganglion cells, would then be 
reflected as RNFL and GC-IPL thinning, as shown in a number of clinical studies in mild 
cognitive impairment and Alzheimer’s disease.[12, 14, 28] 
The association of occipital and temporal lobe grey matter atrophy with GC-IPL thinning was 
present in persons with no dementia. In conjunction with how the occipital and adjacent 
temporal lobes appear to be an early site of amyloid and neurofibril accumulation,[25, 26, 29] 
this suggests that GC-IPL thinning may reflect neurodegeneration in these regions of interest 
even before the onset of dementia. Hence, the GC-IPL shows promise as a novel early 





assess if the GC-IPL is useful in tracking grey matter volume changes longitudinally, and if 
this association is related to cognitive performance and decline. 
There are a few limitations to our study. Firstly, about 33.6% of screen-positive subjects did 
not participate in the second phase of the EDIS study, and of those who participated, nearly 
40% of them either did not successfully complete OCT scanning or had scans unsuitable for 
analysis. Therefore, the generalizability of our study results may be limited. Secondly, the 
cross-sectional design of the study limits the interpretation of the results with respect to the 
cause and effect. Third, visual fields were not tested in our subjects. Hence, we were unable 
to examine whether retinal thinning was correlated to visual field defects. Fourth, as is the 
case with any technology (including OCT and MRI), each has its own limitations and 
contraindications. For OCT, ocular co-morbidities and any inability to undergo OCT 
assessment form the most important limitations. In terms of prognostic utility, we do not think 
that OCT on its own will be sufficient to assess neurodegeneration in the brain. Different and 
complementary imaging modalities such as the OCT and MRI should be combined to obtain a 
thorough assessment of neurodegeneration in the brain. In terms of limitations, this means 
that subjects with prominent ocular co-morbidities may benefit more from a brain MRI, while 
subjects with pacemakers, claustrophobia, who cannot undergo MRI, may benefit more from 
OCT to get an impression of the extent of neurodegneration. The main strengths of our study 
include direct in vivo quantitative assessment of neuronal damage in the retina and the brain 
using OCT and MRI, and a cohort spanning varying degrees of cognitive impairment status.  
In conclusion, retinal neuronal damage, as reflected by GC-IPL thinning, is independently 
associated with grey matter loss in the occipital and temporal lobes. In contrast, there was no 
evidence of an association between global grey and white matter volumes or regional white 
matter volumes with GC-IPL and RNFL thickness. These findings suggest that changes in 
retinal ganglion cells as assessed by high-resolution OCT technology may provide novel 
markers for specific neurodegenerative changes in the brain. 
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CHAPTER X TABLES 
Table X-1: Comparison of baseline characteristics of included and excluded participants of 
this study 
Baseline characteristics Included (n=164) Excluded (n=143) p-value 
Age, years (SD) 69.0 (6.5) 73.3 (6.8) <0.001 





21.0 (4.1) 20.0 (4.0) 0.045 
Hypertension, n (%) 138 (84.1) 131 (91.6) 0.056 
Diabetes, n (%) 44 (26.8) 59 (41.3) 0.008 
Hyperlipidemia, n (%) 133 (81.1) 112 (78.3) 0.571 
Systolic blood pressure, mmHg 
(SD) 
150.1 (19.5) 154.1 (21.6) 0.091 
Diastolic blood pressure, mmHg 
(SD) 
79.7 (11.6) 78.4 (12.0) 0.352 
MABP, mmHg (SD) 101.7 (11.3) 102.8 (11.5) 0.435 
Random blood glucose, mmol/l 
(SD) 
6.86 (3.02) 7.51 (3.04) 0.073 
Total cholesterol, mmol/l (SD) 5.27 (1.31) 5.17 (1.35) 0.531 
Ever Smokers, n (%) 46 (28.0) 44 (30.8) 0.617 
    
Cognitive status    
Not cognitively impaired, n (%) 36 (22.0) 22 (15.4) <0.001 
CIND, n (%) 125 (76.2) 101 (70.6)  







Table X-2: Age-sex-adjusted estimated mean change in GC-IPL and RNFL thicknesses 
(95%CI) per standard deviation change in MRI markers 
 GC-IPL thickness 
(95%CI), m 
RNFL thickness  
(95%CI), m 
per SD decrease in Occipital lobe   
Grey+White matter volume -1.83 (-3.05, -0.61) -2.33 (-4.16, -0.51) 
Grey matter volume -2.04 (-3.20, -0.88) -2.46 (-4.20, -0.71) 
White matter volume -0.80 (-2.04, 0.45) -1.23 (-3.08, 0.62) 
per SD decrease in Temporal  
lobe 
  
Grey+White matter volume -2.32 (-3.52, -1.11) -2.77 (-4.58, -0.96) 
Grey matter volume -2.55 (-3.71, -1.40) -3.03 (-4.78, -1.28) 
White matter volume -1.14 (-2.35, 0.06) -1.40 (-3.20, 0.39) 
per SD decrease in Frontal lobe   
Grey+White matter volume -0.97 (-2.22, 0.28) -1.35 (-3.20, 0.50) 
Grey matter volume -0.95 (-2.19, 0.30) -0.99 (-2.84, 0.87) 
White matter volume -0.71 (-1.90, 0.48) -1.41 (-3.17, 0.35) 
per SD decrease in Parietal  lobe   
Grey+White matter volume -1.12 (-2.30, 0.06) -1.18 (-2.94, 0.58) 
Grey matter volume -1.23 (-2.39, 0.08) -1.19 (-2.91, 0.53) 
White matter volume -0.73 (-1.91, 0.44) -0.90 (-2.65, 0.85) 
per SD decrease in Central  lobe   
Grey+White matter volume -1.17 (-2.43, 0.09) -1.76 (-3.63, 0.11) 
Grey matter volume -1.50 (-2.74, -0.27) -1.94 (-3.78, -0.10) 
White matter volume -0.51 (-1.70, 0.67) -1.03 (-2.79, 0.73) 




Table X-3: Multivariable-adjusted estimated mean change in GC-IPL and RNFL thicknesses 
(95%CI) per standard deviation change in MRI marker 
 GC-IPL thickness 
(95%CI), m* 
RNFL thickness  
(95%CI), m*† 
per SD decrease in Occipital lobe   
Grey+White matter volume -1.77 (-6.55, 0.01) -1.87 (-4.44. 0.69) 
Grey matter volume -1.78 (-3.20, -0.36) -1.72 (-3.79, 0.34) 
White matter volume 0.07 (-1.68, 1.81) -0.27 (-2.79, 2.25) 
per SD decrease in Temporal  lobe   
Grey+White matter volume -3.45 (-5.40, -1.49) -2.70 (-2.61, 0.21) 
Grey matter volume -2.94 (-4.46, -1.41) -2.56 (-4.85, -0.27) 
White matter volume -0.55 (-2.57, 1.46) 0.14 (-2.76, 3.05) 
per SD decrease in Frontal lobe   
Grey+White matter volume 0.05 (-2.67, 2.76) 1.16 (-2.72, 5.03) 
Grey matter volume -0.34 (-3.20, 1.53) 0.59 (-2.09, 3.26) 
White matter volume 0.81 (-1.51, 3.14) 0.56 (-2.69, 3.82) 
per SD decrease in Parietal  lobe   
Grey+White matter volume -0.24 (-2.72, 2.23) 2.83 (-0.75, 6.43) 
Grey matter volume -0.88 (-2.79, 1.03) 0.93 (-1.85, 3.71) 
White matter volume 0.67 (-1.27, 2.61) 2.18 (-0.56, 4.93) 
per SD decrease in Central  lobe   
Grey+White matter volume -0.06 (-2.56, 2.44) -0.57 (-4.16, 3.03) 
Grey matter volume -1.10 (-2.80, 0.60) -1.28 (-3.73, 1.16) 
White matter volume 1.02 (-0.80, 2.83) 0.77 (-1.85, 3.39) 
*Adjusted for age, sex, age, gender, mean arterial blood pressure, plasma blood 
glucose, serum cholesterol, smoking, axial length, OCT signal strength and total 
intracranial volume. 







CHAPTER XI:  
SUMMARY AND FUTURE DIRECTIONS 




1. SUMMARY OF KEY FINDINGS  
With the growing interest in using the retina to study cerebrovascular disease and cognitive 
decline, a range of novel retinal parameters aimed at qualifying and quantifying changes in 
the retinal microvasculature and neuronal layers have been developed. Using these retinal 
vascular and neuronal parameters, this thesis explored the relationships of retinal 
microvascular changes and neuronal loss in cerebrovascular disease and dementia. The main 
findings, summarized in Table XI-1, are discussed in the following sections.  
1.1 Retinal microvascular changes are related to cerebrovascular disease (Chapters 
IV-V) 
Previous large population-based studies have extensively shown that the presence of 
retinopathy is indicative of increased risk of incident stroke.[1-5] Moving on from classical 
signs of retinal microvascular damage to using advanced image analysis techniques to better 
quantify subtle changes in retinal microvasculature, we employed a range of novel retinal 
parameters that includes vessel caliber, fractal dimensions, and tortuosity. From the Multi-
Center Retinal Stroke (MCRS) study, we found that acute ischemic stroke was associated 
with retinal arteriolar narrowing, venular widening, reduced arteriolar and venular fractal 
dimensions and increased arteriolar and venular tortuosity. Similar pattern of associations 
with retinal vascular parameters across major subtypes of ischemic stroke suggests that 
microvascular pathology is a common factor in atherosclerotic, thromboembolic and lacnuar 
stroke.  
When examining the relationship of retinal vascular parameters with cerebral small vessel 
disease in the Epidemiology of Dementia in Singapore (EDIS) study, retinal venular widening, 
reduced arteriolar fractal dimensions, and increased arteriolar tortuosity was found to be 
associated with cerebral microbleeds. Combined with previous longitudinal data from the 





white matter lesions and incidence of lacunar infarcts,[8] this suggests that retinal vascular 
parameters are potential markers of early cerebrovascular disease. 
In conclusion, both studies showed that the retinal microvasculature is affected in 
cerebrovascular disease that affects both the large vessels and the small vessels, independent 
of vascular risk factors.  
1.2 Retinal microvascular changes are related to cognitive impairment (Chapters 
VI-VII) 
In the Retinal Imaging in Dementia (RD) study, clinical dementia belonging to three major 
subtypes: Alzheimer’s disease (AD) without cerebrovascular disease (CeVD), AD with CeVD, 
and vascular dementia were associated with retinal venular narrowing, reduced vascular 
(arteriolar and venular) fractal dimensions and increased vascular tortuosity. Despite having 
separate etiologies, having all three dementia subtypes similarly associated with retinal 
vascular parameters suggest that similar microvascular pathology is present in both AD and 
cerebrovascular disease-related cognitive decline. This is consistent with how neuroimaging 
markers of cerebral small vessel disease such as microbleeds and white matter lesions are 
common in both vascular dementia and AD.[7]  
A striking finding was that although stroke and small vessel disease was associated with 
venular widening,[6, 8] dementia even in the presence of CeVD was still robustly associated 
with venular narrowing. Although stroke and dementia are both associated with reduced 
fractal dimensions and increased tortuosity, we also found that tortuosity was significantly 
higher in the dementia subtypes compared to stroke even in patients with AD without CeVD. 
This provides additional support that microvascular pathology plays an important role in not 
only cerebrovascular disease, but also AD. 
Using a formal neuropsychological assessment battery to assess participants from the 
community-based EDIS study for cognitive performance, we found that mild and moderate 
cognitive impairment not dementia (CIND) was associated with reduced retinal arteriolar and 




venular fractal dimensions. Additionally, we showed that global cognitive performance, and 
performance in the specific domains of verbal memory, visuoconstruction, and visuomotor 
speed was correlated with both arteriolar and venular fractal dimensions. 
In conclusion, these studies showed that retinal microvascular changes were associated with 
dementia attributed to AD and cerebrovascular disease, and that these microvascular changes 
are present early in cognitive impairment before the onset of dementia.  
1.3 Retinal neuronal layer changes are related to cognitive impairment (Chapters 
VIII-X) 
Spectral domain-optical coherence tomography (SD-OCT) was used to examine neuronal loss 
in the retinal nerve fiber layer (RNFL) and ganglion cell-inner plexiform layer (GC-IPL) in 
relation to cognitive impairment and cerebral neuronal loss. Although we did not find 
evidence of RNFL thinning in MCI as suggested previously by clinical studies using time 
domain-OCT, [9, 10] we found that GC-IPL thinning was strongly associated with MCI, and 
GC-IPL thickness in MCI was not different from AD. This supports conjecture that the GC-
IPL is more sensitive to neurodegenerative changes, and likely to be an earlier marker of 
neurodegenerative damage compared to the RNFL. 
We also found that GC-IPL thinning is consistently associated with AD without CeVD, AD 
with CeVD and vascular dementia, while RNFL thinning in the superior and inferior 
quadrants around the optic nerve head was associated with vascular dementia and AD with 
CeVD, but not AD without CeVD. This findings show that neuronal damage in the form of 
retinal neuronal loss as reflected by GC-IPL and RNFL thinning is not only associated with 
AD, but also strongly correlated with neurodegenerative processes associated with CeVD.  
Finally, within the EDIS study we found that GC-IPL thinning was also independently 
associated with grey matter volume loss in the occipital and temporal lobes, further enforcing 





retinal neuronal damage was associated with AD, vascular dementia, preclinical dementia, 
and even regional cerebral atrophy.  
2. IMPLICATIONS OF STUDY FINDINGS 
2.1 Retinal imaging as a tool for studying microvascular pathology and 
neurodegenerative changes in cerebral disease  
This thesis demonstrates that retinal imaging is a simple, feasible and accessible in vivo tool 
to study microvascular and neurodegenerative damage in cerebrovascular disease and 
dementia. Using retinal digital photography combined with semi-automated image analysis 
software, subtle changes in the vessel caliber, and structural changes in the retinal 
microvasculature can be easily summarized and quantified. These quantitative parameters are 
particularly attractive as they are not subject to pulse period variation, unlike vessel calibers.  
Quantifiable changes in vessel caliber, fractal dimensions and tortuosity in retinal arterioles 
and venules were observed in clinical disease such as ischemic stroke, AD and vascular 
dementia. Additionally, a subset of these microvascular changes, such as reduced fractal 
dimensions, is also associated with subclinical disease, such as cerebral microbleeds, and 
preclinical cognitive impairment. Hence, retinal vascular parameters are potentially early and 
sensitive markers of cerebral microvascular damage.  
Optical coherence tomography was used to segment and measure two key retinal neuronal 
parameters, the RNFL and the GC-IPL. By separating AD cases by presence of CeVD, RNFL 
thinning was found to be not strongly associated with AD, contrary to postulations made by 
smaller clinical studies.[11, 12] Instead, thinning of the RNFL was only evident in AD with 
CeVD and vascular dementia. GC-IPL thinning was strongly associated AD with and without 
CeVD, vascular dementia, and even MCI. Thinning of the GC-IPL was also correlated to grey 
matter atrophy, particularly in the occipital and temporal regions of the brain. Hence, GC-IPL 
is potentially an early and sensitive marker of neurodegenerative damage in the brain, and 




reflects cerebral neuronal damage resulting from either AD-related pathology or CBVD-
related pathology.  
Significant differences in retinal vascular parameters were not found between dementia 
subtypes or types of cerebrovascular disease, suggesting that microvascular pathology plays 
an important role in the pathogenesis of a range of age-related cerebral diseases. Although 
this limits the potential of retinal parameters as a diagnostic tool, these findings suggest that 
current understanding of stroke and dementia subtypes may need to be reconsidered. 
Nevertheless, retinal imaging remains highly useful as an accessible and objective tool to 
track and monitor disease progression in both clinical trials and large-scale research studies. 
Both retinal vascular and neuronal parameters show potential in providing additional insight 
into microvascular pathology and neurodegenerative mechanisms in cerebrovascular disease 
and dementia.  
2.2 Microvascular damage is a common theme in both cerebrovascular disease and 
cognitive impairment 
Retinal venular widening, reduced fractal dimensions and increased vascular tortuosity were 
associated with the major etiological subtypes of ischemic stroke and cerebral microbleeds. 
These retinal vascular changes mirror similar pathological changes in the cerebral 
microvasculature, suggesting that impaired vascular perfusion, vessel wall dysfunction and 
blood-retinal barrier damage are important contributors to ischemic stroke and small vessel 
disease.[13] As the same patterns of retinal microvasculature changes are associated with not 
only lacunar stroke but also large artery atherosclerotic and thromboembolic stroke, this 
suggests that the different subtypes are multifactorial in cause and that microvascular 
pathology is a common factor in the chain of events leading to each of these strokes. 
Common patterns of retinal microvascular changes found across the major subtypes of 
dementia, AD (without and with concomitant CeVD) and VaD suggest that that 





overt cerebrovascular disease. Reduced vascular fractal dimensions and increased vascular 
tortuosity found in ischemic stroke and cerebral microbleeds were also associated with both 
VaD and AD. As suggested by overlapping cerebrovascular pathological lesions on 
neuroimaging, clinical symptomatology, and vascular risk factor profiles in both AD and 
vascular dementia,[7] retinal microvascular changes provide additional evidence that 
overlapping microvascular pathology underlies cerebrovascular disease and AD.  
One particular group of retinal vascular parameters stood out in our studies - arteriolar and 
venular fractal dimensions. Other than showing strong associations with clinical disease 
which includes stroke, AD and vascular dementia, reduction in vascular fractal dimensions 
was also consistently associated with preclinical disease, such as early cognitive impairment 
and cerebral small vessel disease. Signs of reduction in retinal vascular network density or 
loss of perfusion in early cerebrovascular disease and cognitive decline suggests that 
pathological mechanisms leading to cerebral hypoperfusion may occur relatively early in the 
course of stroke and dementia.  
However, differences in retinal vascular parameters also hint at competing mechanisms 
leading to dementia. While retinal venular widening is predominantly associated with 
cerebrovascular disease, such as stroke, white matter lesions, lacunes, and cerebral 
microbleeds,[6, 8, 14-16] AD and VaD are associated with venular narrowing, even in cases 
with concomitant CeVD. This is possibly due to an alternate mechanism affecting perfusion 
in dementia, such as periventricular venous collagenosis.[17, 18] Collagen thickening of the 
venular walls causes venular stenosis, impeding perivascular clearance of metabolites and 
worsening blood-brain barrier damage, making brain tissue more susceptible to ischemic 
damage and neurotoxicity from amyloid deposition.[17, 19]  
2.3 Vascular pathology is an important contributor to neurodegenerative damage.  
Proponents of the vascular hypothesis of AD propose that cerebral microvascular 
abnormalities, such as blood-brain barrier dysfunction and hypoperfusion, precede or trigger a 




cascade of events leading to neurodegeneration.[20] By showing that retinal microvascular 
changes in network density, vessel tortuosity, and vessel narrowing is linked to AD, we 
provide additional evidence in support of this hypothesis. These associations remained even 
in AD cases without cerebrovascular disease, showing that microvascular pathology is indeed 
involved in the development of AD even in the absence of cerebrovascular lesions. Hence, 
modification of vascular risk factors, particularly those contributing to microvascular damage, 
may be crucial to preventing or delaying dementia. 
The presence of cerebrovascular lesions such as infarcts, white matter lesions and 
microbleeds make it difficult to directly assess cerebral atrophy using automated 
segmentation methods on MRI scans. By using OCT, we show that retinal neuronal damage 
in the form of GC-IPL and RNFL thinning was associated with dementia with 
cerebrovascular etiology, VaD and AD with CeVD. In addition to AD-related pathology, 
cerebrovascular causes of cognitive impairment appear to also affect the retinal neuronal 
layers. However, due to the limited numbers and cross-sectional design of the study, it is still 
premature to conclude that the retinal neuronal layers could be more sensitive to vascular 
assault compared to AD-related neurodegenerative pathology.   
Despite mounting evidence showing that vascular pathology is an important contributor to 
cognitive decline and dementia, even in “pure” AD, a vast majority of studies have neglected 
the impact of cerebrovascular disease. Our studies strongly highlight that cerebrovascular 
disease and vascular disease must be studied in tandem or accounted for in all studies 
focusing on cognitive impairment, AD and related dementias.  
3.  STRENGTHS AND LIMITATIONS  
3.1 Strengths 
The main strengths of the studies include the use of large population-based samples such as 
the community-based EDIS study, and the selection of population-based controls for the 





studies. All studies had standardized protocols for the quantitative assessment of retinal 
changes – retinal vascular parameters from retinal fundus photographs using a semi-
automated computer software SIVA, while RNFL and GC-IPL thickness measurements were 
obtained using an automated segmentation algorithm within a widely available SD-OCT 
machine for clinic use. This ensured that retinal changes assessed in the different studies 
could be directly compared to each other. 
3.2 Limitations 
Although strengths and limitations pertaining to each individual study have been discussed in 
the previous chapters, I would like to further discuss some of the common issues relevant to 
all the studies in this thesis. These common limitations can contribute to three main types of 
error – selection bias, information bias, and confounding. 
Selection bias 
There are a few potential sources of selection bias in our studies, although efforts have been 
made to minimize this potential source of bias by making case recruitment for the MCRS and 
RD studies as inclusive as possible, and through the inclusion of population-based studies 
such as the SEED and EDIS studies. However, as the exposure of interest heavily relies on 
retinal imaging, the ability to complete and provide retinal images of sufficient quality for 
grading was a possible source of selection bias. Both digital fundus photography and optical 
coherence tomography required participants to sit upright and follow a fixation light during 
the imaging process. Hence, subjects from the MCRS study with relatively mild strokes, and 
subjects from the RD study in milder stages of dementia with better compliance to 
instructions were more likely to complete retinal imaging successfully. Elderly participants 
with ocular opacities, such as dense cataract, were more likely excluded from analysis due to 
poor image quality. Furthermore, only a subset of SEED participants completed OCT imaging, 
reducing the pool from which non-cognitively impaired controls with gradable quality OCT 
scans could be drawn from. Unlike the studies in Chapters IV-VII comparing retinal vascular 




parameters from SIVA, controls in Chapters VIII-IX could not be fully matched to cases by 
age, sex and ethnicity, leading to a control population that was relatively younger. Hence, this 
source of selection bias in an important consideration in evaluating the results from each 
study. 
Participation rate was an issue for the EDIS study. Nearly 50% of screen-positive subjects 
eligible for the EDIS study did not participate in the second phase of the EDIS study.[21] As 
the non-participants were relatively older, it is likely that they could have had poorer 
cognitive function, or higher prevalence of MRI markers of cerebral small vessel disease 
leading to an underestimation of effect sizes in our studies. 
Information bias 
Misclassification of the outcome related to the determinant or vice versa leads to information 
bias and possibly a distortion of the findings. As measurements from both eyes are highly 
correlated to each other, only measurements from one eye (usually randomly selected) were 
included for analysis to avoid multicollinearity in our regression models. However, if the eye 
presenting with more severe changes was not selected, this may have led to misclassification 
resulting in bias towards the null. The same holds for the classification of dementia subtypes. 
As we did not have amyloid imaging or CSF biomarkers available, the diagnosis of AD was 
based on clinical criteria corroborated with findings on structural neuroimaging without 
confirmation of amyloid plaque deposition. Also, we could not eliminate the possibility that a 
portion of VaD patients may have inherent AD pathology. However, measurements from 
retinal images and OCT scans, and assessment of outcomes such as clinical diagnoses and 
MRI gradings were independently performed masked to each other. Hence, any potential 
misclassification would not have been differential and would have resulted in random error. 
Confounding 
Ideally, assessment and definition of risk factors should be standardized for all subjects in a 





the RD study benefited from being comprehensively assessed for cardiovascular risk factors 
as part of standard clinical care, the definition of cardiovascular risk factors for controls 
selected from SEED studies was based on research study definitions which relied on self-
reported history and single-visit measurement of blood pressure or blood serum markers. As 
the definitions of these confounders were not completely similar in cases and controls, this 
could have resulted in residual confounding. Other possible sources of residual confounders 
include insufficient adjustment by using categorical variables in place of continuous variables 
(such as hypertension status instead of blood pressure), and the presence of unknown 
confounders unaccounted for. 
4. FUTURE DIRECTIONS  
Throughout this thesis, we have consistently demonstrated that retinal imaging has enormous 
potential in providing insights into unraveling microvascular pathology and 
neurodegenerative mechanisms involved in cerebrovascular disease and dementia. However, 
findings from the studies presented in this thesis have raised several important questions: 
4.1 Retinal microvascular and neuronal changes and AD-related pathology 
We have demonstrated that retinal microvascular changes and GC-IPL thinning are associated 
with clinical AD and early cognitive impairment. Frost et al [22] have recently presented data 
showing that non-impaired persons with neocortical amyloid plaque burden assessed using 
PiB-PET imaging have alterations in the retinal vascular parameters. However, the retinal 
vascular parameters associated with high plaque burden are not consistent with vascular 
changes found in AD. Further studies examining retinal vascular parameters and GC-IPL 
thinning in relation with abnormal amyloid deposition using PiB-PET imaging or CSF 
biomarkers in cognitively normal or impaired persons are required to clarify if retinal 
microvascular changes are directly related to amyloid pathology. A positive outcome 
correlating retinal vascular changes with amyloid pathology will provide stronger evidence in 
support of microvascular pathology in AD. A positive outcome correlating GC-IPL thinning 




with amyloid deposition will help establish the GC-IPL as a sensitive and early marker of 
neuronal damage in relation to AD.  
Thinning of the GC-IPL was more found to be more closely correlated with grey matter 
atrophy than white matter loss. The RNFL which contains the axonal processes of the retinal 
ganglion cells may be more correlated with white matter changes rather than grey matter 
changes. As white matter integrity is better assessed using diffusion tensor imaging (DTI), 
RNFL and GC-IPL thinning could be examined in association to fractional anisotropy, mean 
diffusivity, axial diffusivity and radial diffusivity measures. Further studies can also examine 
if the retinal neuronal layers are correlated to deficits in the functional or anatomical 
connectome in persons at risk of developing dementia.[23]  
4.2 Retinal neurodegenerative changes in stroke and cerebral small vessel disease  
As we currently do not have OCT data on a group of persons with CeVD but no cognitive 
impairment, we could not draw any conclusions on whether retinal neuronal loss observed in 
VaD was due to cerebrovascular disease or neurodegenerative mechanisms specific to 
cognitive impairment. Although small clinical studies using OCT suggest that RNFL thinning 
may be associated with cerebral infarction, they have been focused on patients with 
hemianopia or visual field defects.[24-26] Certainly, more detailed OCT studies examining 
GC-IPL and RNFL changes in patients with acute and chronic infarcts, and persons with 
markers of cerebral small vessel disease are definitely needed to clarify the associations 
between retinal neuronal loss and cerebrovascular disease. This will provide additional 
information on vascular pathological mechanisms leading to neuronal loss, which may direct 
development of interventions for not only dementia but also glaucoma. 
4.3 Translating novel markers into predictive markers of disease onset 
This thesis has demonstrated that quantitative retinal vascular and neuronal parameters have 
potential in the study of cerebrovascular disease and dementia. Although we have also shown 





longitudinal studies are required to evaluate if these parameters can provide additional value 
in predicting who may be at risk of developing stroke or dementia. For example, the RD study 
is currently being extended to follow-up MCI patients for up to 2 years, with retinal imaging 
and clinical assessments. Furthermore, additional analysis examining both retinal vascular 
parameters and neuronal parameters in the same populations will allow us to evaluate whether 
combined changes in retinal vascular and neuronal parameters confer additional risk of 
developing dementia. These studies will allow us to better evaluate the value of both retinal 
vascular and neuronal changes in predicting or tracking disease progression to dementia. The 
potential usefulness of retinal imaging markers in providing additional information for stroke 
and dementia risk stratification beyond current risk assessment tools need to be evaluated in 
both high-risk and population-based cohorts. 
4.4 Static parameters to dynamic parameters: from studying structural changes to 
functional damage  
Our studies found that a particular pattern that combines reduced fractal dimensions and 
increased tortuosity in both arterioles and venules, as well as venular caliber changes are 
associated with both stroke and dementia, and appear unique to cerebral disease.  Rather than 
depending on a individual parameters, retinal vascular parameters utilized as a combination 
may be better at providing specificity for disease or a class of diseases. As our retinal image 
analysis program is increasingly being adopted in various studies locally and internationally 
to examine other vascular diseases such as ischemic heart disease, heart failure, chronic 
kidney disease, etc., different patterns of retinal vascular parameter changes can better 
evaluated if they are indeed related to different disease etiologies. 
The retinal vascular and neuronal parameters studied in this thesis are static parameters 
designed to capture structural changes in the retinal microvasculature and neuronal layers. As 
structural changes usually indicate irreversible damage, the key to uncovering early 
pathological mechanisms may be in functional or dynamic biomarkers. Latest advances in 




retinal vascular imaging such as the dynamic vessel analyzer,[27] retinal oximeter,[28] and 
scanning laser Doppler flowmetry,[29] have been developed to assess retinal vascular 
function and such as retinal neural and vascular activity, retinal oxygen saturation, and blood 
flow in the retinal blood vessels, the foveal capillary network, and the choroidal vasculature. 
These new techniques may be able to act as a surrogate to study cerebral hemodynamics in 
cerebrovascular disease and dementia. 
Adaptive optics (AO) used in combination with OCT is able to provide highly detailed 
images of the retinal structures including the retinal nerve fiber bundles, retinal capillaries, 
photoreceptors and microstructures in the ganglion cell layer and the lamina cribosa.[30, 31] 
Used in conjunction with emerging imaging technology that allows direct in vivo amyloid 
plaque imaging in the retina,[32, 33] AO will allow us to directly monitor retinal neuronal 
changes in response to amyloid plaque dynamics. Insights into vascular and 
neurodegenerative mechanisms in the retina by these new technologies will help inspire 
development of therapeutics better targeted for the prevention and treatment of 
cerebrovascular disease and dementia.  
5. CONCLUSION 
Retinal microvascular changes are strongly related to stroke, cerebral small vessel disease, 
mild cognitive impairment, and dementia, providing evidence that microvascular pathology 
plays an important role in both cerebrovascular disease and dementia. Retinal neuronal loss is 
also related to neurodegenerative changes in mild cognitive impairment, AD and vascular 
dementia. As cerebral microvascular and neurodegenerative changes are reflected in the retina, 
retinal imaging is a promising tool in aiding our understanding of the intricate mechanisms 
underlying cerebrovascular and neurodegenerative disease. The potential of retinal imaging 
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APPENDIX 1:  GLOSSARY OF ACRONYMS 
Acronym Term 
3MSE Modified Mini-Mental State Examination 
AD Alzheimer's disease 
AGES-Reykjavik Age, Gene/Environment Susceptibility-Reykjavik 
AIBL Australian Imaging, Biomarker & Lifestyle  
AMT Abbreviated Mental Test 
ANCOVA Analysis of covariance 
ANOVA Analysis of variance 
AO Adaptive optics 
ARIC Atherosclerosis Risk in Communities  
ARWMC Age-related white matter changes 
AUC Area under curve 
AV nicking Arteriovenous nicking 
AVR Arteriovenous ratio 
BDES Beaver Dam Eye Study 
BMES Blue Mountains Eye Study 
BMI Body mass index 
CADASIL Cerebral autosomal-dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy 
CASI-S Cognitive Abilities Screening Instrument-Short 
CDR Clinical Dementia Rating 
CeVD Cerebrovascular disease 
CHS Cardiovascular Health Study 
CI Confidence interval 
CIND Cognitive Impairment No Dementia 
CMB Cerebral microbleed 
CNS Central nervous system 
CRAE Central retinal arteriolar equivalent 
CRVE Central retinal venular equivalent 
CSF Cerebrospinal fluid 
CSVD Cerebral small vessel disease 
CT Computed tomography 






DSST Digit Symbol Substitution Test 
DST Digit Symbol Test 
EDIS  Epidemiology of Dementia in Singapore 
FAN  Focal arteriolar narrowing 
FLAIR Fluid-attenuated inversion recovery 
GC-IPL Ganglion cell-inner plexiform layer  
GRE Gradient-recalled echo 
HD-OCT High definition-optical coherence tomography 
HERNS Hereditary endotheliopathy with retinopathy, nephropathy and 
stroke 
HR Hazard ratio 
LALES Los Angeles Latino Eye Study 
LBD Lewy body dementia 
MA Microaneuryms 
MABP Mean arteriolar blood pressure 
MCI Mild cognitive impairment 
MCRS  Multi-Center Retinal Stroke  
MMSE  Mini Mental State Examination 
MoCA Montreal Cognitive Assessment 
MRA Magnetic resonance angiography 
MRI  Magnetic resonance imaging 
NINDS-ADRDA National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders 
Association 
NINDS-AIREN National Institute for Neurological Disorders and Stroke-
Association Internationale pour la Recherche et l'Enseignement en 
Neurosciences 
OCT Optical coherence tomography 
OR  Odds ratio 
PDD Parkinson's disease dementia 
PET Positron emission tomography 
PiB Pittsburgh compound 
RD Retinal imaging in Dementia 
RGC Retinal ganglion cell 
RNFL Retinal nerve fiber layer  
SCES Singapore Chinese Eye Study 






SD  Standard deviation 
SD-OCT Spectral domain-optical coherence tomography 
SE Standard error 
SEED Singapore Epidemiology of Eye Disease 
SiMES Singapore Malay Eye Study 
SIVA Singapore I Vessel Analysis 
SLO Scanning laser ophthalmoloscopy 
STRIVE Standards for ReportIng Vascular changes on nEuroimaging 
SWI Susceptibility-weighted imaging 
TD-OCT  Time domain-optical coherence tomography 
TMTB Trail Making Test-Part B 
TOAST Trial of Org 10172 in Acute Stroke Treatment 
VaD  Vascular dementia 
VDB Vascular Dementia Battery 
VFT Verbal Fluency Test 
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 Retinal image analysis (SIVA assessment)  
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Retinal imaging in Dementia (RD) Study  
 Subject recruitment, interview and data collection  
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 OCT scan grading and analysis 
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